genetics essay intro

• $ 0.00 0 items

Introduction to genetics

Genetics is a field of biology that studies how traits are passed from parents to their offspring. The passing of traits from parents to offspring is known as heredity, therefore, genetics is the study of heredity. This introduction to genetics takes you through the basic components of genetics such as DNA, genes, chromosomes and genetic inheritance.

Genetics is built around molecules called DNA. DNA molecules hold all the genetic information for an organism. It provides cells with the information they need to perform tasks that allow an organism to grow, survive and reproduce. A gene is one particular section of a DNA molecule that tells a cell to perform one specific task.

Heredity is what makes children look like their parents. During reproduction, DNA is replicated and passed from a parent to their offspring. This inheritance of genetic material by offspring influences the appearance and behavior of the offspring. The environment that an organism lives in can also influence how genes are expressed.

A DNA molecule is a nucleic acid, one of the four molecules of life . It comes in the form of a long, linear molecule referred to as a strand. Each strand of DNA is bonded to a second strand of DNA to form a DNA double helix. In eukaryotic cells , DNA is found in the nucleus as a tightly coiled double helix.

DNA molecules are replicated during cell division. When a cell divides, the two new cells contain all the same DNA that the original cell had.

In sexual reproduction with two parents, half of the DNA of the offspring is provided by each of the parents. The genetic material of a child is made from 50% of their mother’s DNA and 50% their father’s DNA.

A gene is a specific segment of a DNA molecule that holds the information for one specific protein. DNA molecules have a unique code for each gene which codes for their specific protein. Some organisms can have more than 100,000 different genes so they will have 100,000 unique sequences of DNA ‘code’.

Genes are the basic unit of heredity. The genes of an individual are determined by their parent or parents. A bacteria that is born by one parent cell splitting into two cells and has the exact same genes as their one parent cell.

Physical traits such as eye color or height are often determined by the combination of multiple genes. The environment an individual lives in also impacts how genes are expressed.

Chromosomes

A chromosome is a structure made from tightly packed strands of DNA and proteins called histones. Strands of DNA are tightly wrapped around the histone proteins and form into long worm-shaped structures called ‘chromatids’. Two chromatids join together to form a chromosome.

Chromosomes are formed in the nucleus of a cell when a cell is dividing. It is possible to see chromosomes under an ordinary light microscope if the cell is in the right stage of cell division.

The number of chromosomes varies between species. Humans have 46 chromosomes. Some species can have many more than 100 chromosomes while others can have as little as two.

Genetic inheritance

Inheritance is the backbone of genetics and is an important topic to cover in an introduction to genetics. Long before DNA had been discovered and the word ‘genetics’ had been invented, people were studying the inheritance of traits from one generation to the next.

Genetic inheritance occurs both in sexual reproduction and asexual reproduction . In sexual reproduction, two organisms contribute DNA to produce a new organism. In asexual reproduction, one organism provides all the DNA and produces a clone of themselves. In either, genetic material is passed from one generation to the next.

Experiments performed by a monk named Gregor Mendel provided the foundations of our current understanding of how genetic material is passed from parents to their offspring.

Last edited: 31 August 2020

Want to learn more?

Visit these pages on our website: Genetics |  DNA replication | Genetic Inheritance | Transcription & translation

This is world’s #1 textbook for beginning biologists and has been hugely valuable to me over the years. This is the resource that I recommend above anything else for aspiring biologists.

eBook - $2.95

Also available from Amazon , Book Depository and all other good bookstores.

What does DNA stand for?

Know the answer? Why not test yourself with our quick 20 question quiz

Want to create or adapt books like this? Learn more about how Pressbooks supports open publishing practices.

2 Genetics Introduction

Session Learning Objectives and a quick synopsis (see main text for explanations):

The goal of this chapter is to provide a brief overview of genetic concepts.

SLO 1 Explain the different ways genetics contributes to disease risk

Distinguish single-gene Mendelian inheritance (autosomal dominant, autosomal recessive, or sex-linked recessive) from complex polygenic inheritance (which contributes to most common diseases). Differentiate germline versus somatic mutation.

SLO 2 Record and interpret a human pedigree using standard symbols

Learn to draw and read the genetic shorthand for a family tree with squares (males) and circles (females), filled (affected) and open, and so forth, to trace the inheritance of genotypes and phenotypes.

SLO 3 Define the relationship between a gene and its phenotype

Define gene, locus, genotype, phenotype, allele, and distinguish homozygosity from heterozygosity.

SLO 4 Apply probabilities to independent vs. dependent genetic events

For simple genetic outcomes, learn when to multiply (independent events) and when to add (mutually exclusive events) probabilities.

The human genome is comprised of DNA, organized into genes, and carried on 46 chromosomes. Molecular biology encompasses how the DNA is transcribed into RNA and how RNA is translated into proteins. Human genetics is the study of how our genome and its variants give rise to our human form and its variation and how the genomes and variations of one generation are recombined and passed on to the next generation—inheritance.

Our genes and chromosomes are constantly subject to change. Genetic variations that are due to changes in the “germline” genome will be passed from one generation to the next. They are called hereditary variations. They contrast with genetic variations acquired post-zygotically in any of the vast number of cells not contributing to gametes. Such mutations are called somatic mutations. They cannot be passed between generations. Most diseases are not primarily hereditary. Nevertheless, genetics is hugely important in human disease, and for almost any disorder, inherited risk factors, acting in isolation or in concert with the environment, can be identified.

N ormal genetic variation versus disease. Most genetic variation is responsible for differences in traits distinguishing one person from the next but can also influence vulnerability to disease. Moreover, genetic factors likely have played different biological roles in different places and times throughout history as our environment has changed. Genetic variation that at one time may have conferred reproductive advantages may be harmful for modern life.

Single-gene Mendelian disorders. “Single gene” or “Mendelian” disorders are ones in which mutations in just one gene can be passed down with a predictable pattern of disease from one generation to the next. Such disorders often have dramatic clinical consequences. About 2-5% of the population has a Mendelian disorder. Many, such as cystic fibrosis, can be apparent at birth whereas others, such as Huntington Disease, are more likely to appear with aging. We will be distinguishing between single-gene Mendelian disorders and complex disorders, arising from common genetic variation of smaller effect size distributed throughout the genome and working in concert with the environment.

To understand inheritance, we need to remember that each gene lies on a specific chromosome, either on a sex chromosome or on one of the 22 pairs of autosomes (non-sex chromosomes). Normally, there are two similar copies (alleles) of each autosomal gene. For an autosomal dominant disorder, only one of the two copies need sustain a pathogenic mutation in order to cause disease, whereas, for an autosomal recessive disorder, mutations in both copies are required to cause disease. During the formation of a gamete, one of the two alleles is randomly included in each egg or sperm. Since the distribution is random, we have to think about probability theory to calculate the risk of transmitting a disorder. The risk of transmitting an autosomal dominant disorder from affected parent to child is 1/2 and is independent of the sex of the parent. The risk of transmitting an autosomal recessive disorder when each parent is a carrier is 1/4. Sex-linked recessive disorders arise from mutations on the X chromosome. Females have two X chromosomes and are seldomly affected. However, for female carriers, the risk of conceiving an affected male (XY chromosome composition) or a carrier female (XX chromosome composition) is 1/2. (This is just a brief introduction. We will be talking about each of these forms of Mendelian inheritance in greater detail later.)

In general, for Mendelian disorders, there is a diversity of mutations within the causative gene across the affected population. The mutation responsible for the disorder in one family may not be the same as one causing disease in a different family.

Exceptions are ancestral “founder” mutations that may be over-represented among certain populations. The autosomal recessive beta-chain hemoglobin mutation that causes sickle cell anemia is one example. In the carrier state, it confers relative resistance to malaria that bestows a selective advantage throughout regions of the world where malaria is prevalent. Another example involves three Ashkenazi Jewish founder mutations in the BRCA1 and BRCA2 DNA repair factors, which are frequent in contemporary populations simply because in an early population bottleneck for this community there were only a few founding ancestors. Apparently, by chance they happened to possess these three mutations.

Overall, disease alleles for Mendelian disorders are rare although they may be more prevalent for certain diseases in certain populations. This is in contrast to complex disorders, where the disease-associated alleles are common, albeit of much weaker effect.

By and large for Mendelian disorders, most pathogenic mutations alter the amino acid sequence of the polypeptide encoded by the gene or lead to its loss of production. For complex disorders, mutations often have less dramatic effects on gene function, are better tolerated and therefore prevalent across the population, and consequently exert their effects more subtly, often by influencing gene regulatory regions.

Complex disease. In contrast to Mendelian disorders, most common diseases are the result of additive effects of common genetic variants conferring variable degrees of risk interacting with lifestyle and environment—so called “complex” disorders. (“Multifactorial” and “polygenic” are synonyms for “complex.”) Examples include hypertension, diabetes mellitus, atherosclerotic vascular disease, autoimmune disorders, etc. For any disease, there are typically dozens of variant alleles for any of multiple associated genes, some of which increase risk and some of which decrease risk. Each variant may interact with environmental factors, such as diet and tobacco smoking, in different ways. Common diseases often cluster in families because these variants, along with environmental factors and the behaviors associated with them, are shared between relatives, although in less predictable ways than the clear-cut patterns apparent for Mendelian disorders. Some disorders, for example hypercholesterolemia, can result from either rare single-gene disorders inherited from just one parent or, more commonly, due to inheritance as a complex trait involving multiple genetic variants inherited from both parents and influenced non-genetic factors, such as diet.

Chromosomal and other genomic disorders. Chromosomes can undergo physical alterations. These changes can be microscopically visible or molecularly detectable duplications, deletions, insertions, inversions, translocations of segments between chromosomes, or other sorts of structural rearrangements that can disrupt the protein-coding and/or regulation of multiple genes at once. Copy number variation is a type of structural variation in which a stretch of DNA is duplicated or deleted. Autosomal chromosomal abnormalities and copy number variants can produce dramatic physical phenotypes. Abnormalities of sex chromosomes typically have less severe consequences. About half of all first-trimester spontaneous abortions (miscarriages) contain chromosomal abnormalities.

Somatic genetic variation. Mutations and chromosomal abnormalities can occur in the “germline” and will typically be present in all the cells of the body. Or they can be “acquired” (“somatic”) such that they arise post-zygotically and are restricted to a subpopulation of cells. Somatic genetic variation is re

sponsible for cancer but contributes to other disorders, as well as aging. Some inherited cancer predisposition syndromes depend upon an inherited gene for cancer risk, with the actual onset and tissue distribution of the resulting cancer determined by the occurrence of somatic mutations in the same or other genes.

Genetic testing d epend s on the type of genetic variation . Mendelian disorders exhibit predictable patterns of inheritance and can often be directly tested for by gene sequencing tests. Evaluating the genetic underpinnings of common disease is more challenging and requires genome-wide based approaches. Although not typically used in a clinical setting, such testing has become popular among consumers, where considerable confusion by patients and providers surrounds their use. Chromosomal and copy number variant disorders use a unique collection of technologies for their diagnosis. The identification and the role of acquired mutations in diagnosis and treatment of cancer continues to evolve and is increasingly relied on to personalize molecular therapies. Historical routes to the discovery of the molecular genetic basis of these different sorts of disorders has varied. Genetics is one of the most rapidly changing fields, contributes to the practice of multiple areas of medicine, and makes increasingly greater contributions to improving and individualizing the care of patients.

SLO 2 Record and interpret a human pedigree using standard symbo ls

To simplify recording family history, we make use of symbols. Males are squares. Females are circles. Death is noted with a slash. Horizontal lines connect reproductive partners. Vertical lines indicate parent-child relationships. Diamonds are used when sex is unspecified. Putting a number in the middle of the symbol can denote multiple individuals. The notation for a fetus or pending pregnancy is a diamond with a “P” in the middle. Spontaneous abortion and termination of pregnancy are often shown with a small triangle, without and with a slash, respectively. The “proband” (usually the patient) is the individual who brought the family to attention and is highlighted with an arrow. Dizygotic (fraternal) twins have a forked line connecting them, while monozygotic (identical) twins are joined with an additional horizontal line. The symbols are shaded to indicate a disease. When more than one disease is present, the symbols may be sectored like pieces of pie. We will employ these symbols in this course. For a typical family history, recorded in a medical record, pedigrees of this sort had been considered overkill; however, readily available modules for the electronic health record can automatically construct a detailed pedigree from a short questionnaire completed by patients.

IMPORTANT DEFINITIONS:

Gene – The basic hereditary unit, initially defined by phenotype. By molecular definition, a DNA sequence required for production of a functional product, usually a protein, but rarely an untranslated RNA.

Locus – Literally a “place” on a chromosome or DNA molecule, used fairly interchangeably with “gene” and sometimes used to refer to a collection of closely spaced genes.

Genotype – An individual’s genetic constitution, either collectively at all loci or more typically at a single locus or even at a particular position within a gene.

Phenotype – Observable expression of genotype as a trait or disease.

Allele – One of the alternate versions of a gene present in a population. An over-simplification is that there are just two, “normal” (wild type) and mutant. Of course, for any gene there are typically multiple different wild type alleles, distinguishable by clinically inconsequential “polymorphisms,” and many different potential mutant alleles.

Homozygosity vs. Heterozygosity – For all autosomal (non sex chromosome) genes, there are two alleles, one inherited from the mother and one inherited from the father. If both versions are the same (both wild type or both mutant), we use the term “ homozygous ,” whereas if each allele is different (one wild type and one mutant) we use the term “ heterozygous .”

Mendelian inheritance involves three simple statistical rules:

• Multiply probabilities for independent events.
• Add probabilities for mutually exclusive events.
• The total probability for all possible outcomes must sum to one.

One example is a coin toss. The probability of heads or tails is one-half and is independent of any prior tosses. “Chance has no memory.” Even if there had been a run of heads, the next toss is no more or less likely to be a tails than if there had been a run of tails—unless something is wrong with the coin! The likelihood of having two consecutive heads is 1/2 × 1/2 = (1/2) 2 = 1/4; the probability of having three tails in a row is just 1/2 × 1/2 × 1/2 = (1/2) 3 = 1/8. When you toss a coin, the two possible outcomes are heads or tails; therefore, the sum of the probabilities of each outcome must add up to a total probability of one. So, for a coin tossed three times consecutively, each of the eight possible outcomes occurs with an equal probability of 1/8.

What’s the chance that a pregnant XX female will bear an XY male conception? That’s an easy one; it’s about 1/2. Same question but for an XX female conception? Same answer (1/2). Since these are mutually exclusive probabilities, we know that the probability of conceiving either an XY male or an XX female must be one. Reassuringly, that also happens to be the sum of 1/2 plus 1/2. (For the sake of this exercise to illustrate simple probability concepts we consider only binary, chromosomally defined sex and exclude other chromosomal and non-chromosomal sex variation.)

What’s the probability that a pregnant XX female will conceive two consecutive XY males? Since these are independent events, we know that it must be 1/2 times 1/2, which equals 1/4. What about two XX females in a row? Same thing. How about one XY male and one XX female? For two children you can only have either two XY males, two XX females, or one of each, so the probability of an XY male and an XX female must equal the probability of not having two males or two females (since these are mutually exclusive events summing to one), and that is merely 1 – 1/4 – 1/4 = 1/2. But why is it twice as likely to have an XY male and an XX female as having two XY males or two XX females? That’s because there’s two different sequences in which to have an XY male and an XX female. The XY male could come first, followed by an XX female, and the chance of that sequence happening is also 1/2 × 1/2 = 1/4. Or, the XX female could arrive first, followed by an XY male, and the chance of that sequence happening is the same.

Genetics Copyright © by horwitz. All Rights Reserved.

Share This Book

Introduction to Genetics

Natasha Ramroop Singh, Kamloops, British Columbia

Copyright Year: 2009

Publisher: Thompson Rivers University

Language: English

Formats Available

Conditions of use.

Learn more about reviews.

Reviewed by James Langeland, Professor, Kalamazoo College on 1/30/23

This text does what it claims to do. It provides an introductory overview of a broad swath of genetics. read more

Comprehensiveness rating: 4 see less

This text does what it claims to do. It provides an introductory overview of a broad swath of genetics.

Content Accuracy rating: 4

No glaring errors. One could always nitpick any text book.

Relevance/Longevity rating: 3

The text is relevant, but not particularly unique in any sense. One could find virtually the same information in any number of genetics textbooks, presented in largely the same way. A major problem here is that the filed is presented more or less historically with many of the experiments and concepts being described having little to no relevance to genetics today. This is a problem with many texts so I do not single this one out.

Clarity rating: 4

As with many open source texts, this one suffers from substandard figures, which directly influences clarity. The words on the age are fine, but the adage is true-a picture can be worth a thousand words. The mainstream publishers spent a lot of money on figures and it shows--they can be really good.

Consistency rating: 4

No comments here.

Modularity rating: 4

There seem to be appropriate and logical chapter and section breaks.

Organization/Structure/Flow rating: 3

The flow is the same as nearly any other genetics textbook. It suffers from a rigid historical framework. Better than most at Muller's morphs however!

Interface rating: 5

No problems here. I do really like the integrated you tube links. I did not dive into the content of those videos (beyond the scope of my review), but the fact that they are there in abundance is a good use of the open source approach.

Grammatical Errors rating: 5

No problems here.

Cultural Relevance rating: 3

No comment.

A very timely section on SARS-Cov-2 at the end! Rich with study questions and answers. Genetics is and should be very problem based, so this is good. I appreciate what is being offered here and I understand the market. There is nothing "wrong" with this textbook. There is also no wow factor that would cause me to adopt it at this time.

Table of Contents

• Chapter 1- Mendel's First Law and Meiosis
• Chapter 2- Mendel's Second Law: Independent Assortment
• Chapter 3- The Cell Cycle and Mitosis
• Chapter 4- Pedigree Analysis
• Chapter 5- The Complementation Test
• Chapter 6- Alleles at a Single Locus
• Chapter 7- The Central Dogma- Mutations and Biochemical Pathways
• Chapter 8- Gene Interactions 
• Chapter 9- Linkage and Recombination Frequency
• Chapter 10- Sex Chromosomes & Sex Linkage
• Chapter 11- Recombination Mapping of Gene Loci
• Chapter 12- Physical Mapping of Chromosomes and Genomes
• Chapter 13- Genes and COVID-19 Susceptibility in Humans 

Ancillary Material

About the book.

Genetics, otherwise known as the Science of Heredity, is the study of biological information, and how this information is stored, replicated, transmitted and used by subsequent generations. The study of genetics can be sub-divided into three main areas: Transmission Genetics, Molecular Genetics, and Population Genetics. In this Introductory text, the focus is on Transmission or Classical Genetics, which deals with the basic principles of heredity and the mechanisms by which traits are passed from one generation to the next. The work of Gregor Mendel is central to Transmission Genetics; as such, there is a discussion about the pioneering work performed by him along with Mendel’s Laws, as they pertain to inheritance. Other aspects of Classical Genetics are covered, including the relationship between chromosomes and heredity, the arrangement of genes on chromosomes, and the physical mapping of genes.

About the Contributors

Natasha Ramroop Singh , Thompson Rivers University

Contribute to this Page

This page has been archived and is no longer updated

"Half of your DNA is determined by your mother's side, and half is by your father. So, if you seem to look exactly like your mother, perhaps some DNA that codes for your body and how your organs run was copied from your father's genes ."

So close, yet so far. This quote, taken from a high school student's submission in a national essay contest, represents just one of countless misconceptions many people have about the basic nature of heredity and how our bodies read the instructions stored in our genetic material (Shaw et al . 2008). Although it is true that half of our genome is inherited from our mother and half from our father, it is certainly not the case that only some of our cells receive instructions from only some of our DNA. Rather, every diploid, nucleated cell in our body contains a full complement of chromosomes, and our specific cellular phenotypes are the result of complex patterns of gene expression and regulation . In fact, it is through this dynamic regulation of gene expression that organismal complexity is determined. For example, when the first draft of the human genome was published in 2003, scientists were surprised to find that sequence analysis revealed only around 25,000 genes, instead of the 50,000 to 100,000 genes originally hypothesized. Clues from studies examining the genomic structure of a variety of organisms suggest that much of human uniqueness lies not in our number of genes, but instead in our regulatory control over when and where certain genes are expressed. Additional examination of different organisms has revealed that all genomes are more complex and dynamic than previously thought. Thus, the central dogma proposed by Francis Crick as early as 1958 — that DNA encodes RNA, which is translated into protein — is now considered overly simplistic. Today, scientists know that beyond the three types of RNA that make the central dogma possible (mRNA, tRNA, and rRNA), there are many additional varieties of functional RNA within cells, many of which serve a number of known (and unknown) functions, including regulation of gene expression. Understanding how the structure of these and other nucleic acids belies their function at both the macroscopic and microscopic levels, and discovering how that understanding can be manipulated, is the essence of where genetics and molecular biology converge. Detailed comparative analysis of different organisms' genomes has also shed light on the genetics of evolutionary history . Using molecular approaches, information about mutation rates, and other tools, scientists continue to add more detail to phylogenetic trees, which tell us about the relationships between the marvelous variety of organisms that have existed throughout the planet's history. Examining how different processes shape populations through the culling or maintenance of deleterious or beneficial alleles lies at the heart of the field of population genetics . Within a population, beneficial alleles are typically maintained through positive natural selection, while alleles that compromise fitness are often removed via negative selection. Some detrimental alleles may remain, however, and a number of these alleles are associated with disease. Many common human diseases , such as asthma, cardiovascular disease, and various forms of cancer, are complex-in other words, they arise from the interaction between multiple alleles at different genetic loci with cues from the environment. Other diseases, which are significantly less prevalent, are inherited. For instance, phenylketonuria (PKU) was the first disease shown to have a recessive pattern of inheritance. Other conditions, like Huntington's disease, are associated with dominant alleles, while still other disorders are sex-linked-a concept that was first identified through studies involving mutations in the common fruit fly. Still other diseases, like Down syndrome, are linked to chromosomal aberrations that can be identified through cytogenetic techniques that examine chromosome structure and number . Our understanding in all these fields has blossomed in recent years. Thanks to the merger of molecular biology techniques with improved knowledge of genetics, scientists are now able to create transgenic organisms that have specific characters, test embryos for a variety of traits in vitro , and develop all manner of diagnostic tests capable of identifying individuals at risk for particular disorders. This interplay between genetics and society makes it crucial for all of us to grasp the science behind these techniques in order to better inform our decisions at the doctor, at the grocery store, and at home. As we seek to cultivate this understanding of modern genetics, it is critical to remember that the misconceptions expressed in the aforementioned essay are the same ones that many individuals carry with them. Thus, when working together, faculty and students need to explore not only what we know about genetics, but also what data and evidence support these claims. Only when we are equipped with the ability to reach our own conclusions will our misconceptions be altered.

-Kenna Shaw, Ph.D

Image: Mehau Kulyk/Science Photo Library/Getty Images.

Shaw, K. (2008) Genetics. Nature Education 2(10):1

© 2014 Nature Education

• Press Room |
• Terms of Use |
• Privacy Notice |

An official website of the United States government

The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings
• Browse Titles

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Genetic Alliance; The New York-Mid-Atlantic Consortium for Genetic and Newborn Screening Services. Understanding Genetics: A New York, Mid-Atlantic Guide for Patients and Health Professionals. Washington (DC): Genetic Alliance; 2009 Jul 8.

Understanding Genetics: A New York, Mid-Atlantic Guide for Patients and Health Professionals.

Chapter 1 genetics 101.

Almost every human trait and disease has a genetic component, whether inherited or influenced by behavioral factors such as exercise. Genetic components can also modify the body’s response to environmental factors such as toxins. Understanding the underlying concepts of human genetics and the role of genes, behavior, and the environment is important for appropriately collecting and applying genetic and genomic information and technologies during clinical care. It is important in improving disease diagnosis and treatment as well. This chapter provides fundamental information about basic genetics concepts, including cell structure, the molecular and biochemical basis of disease, major types of genetic disease, laws of inheritance, and the impact of genetic variation.

• 1.1 Cells, Genomes, DNA, and Genes

Cells are the fundamental structural and functional units of every known living organism. Instructions needed to direct activities are contained within a DNA (deoxyribonucleic acid) sequence. DNA from all organisms is made up of the same chemical units (bases) called adenine, thymine, guanine, and cytosine, abbreviated as A, T, G, and C. In complementary DNA strands, A matches with T, and C with G, to form base pairs. The human genome (total composition of genetic material within a cell) is packaged into larger units known as chromosomes—physically separate molecules that range in length from about 50 to 250 million base pairs. Human cells contain two sets of chromosomes, one set inherited from each parent. Each cell normally contains 23 pairs of chromosomes, which consist of 22 autosomes (numbered 1 through 22) and one pair of sex chromosomes (XX or XY). However, sperm and ova normally contain half as much genetic material: only one copy of each chromosome.

Each chromosome contains many genes, the basic physical and functional units of heredity. Genes are specific sequences of bases that encode instructions for how to make proteins. The DNA sequence is the particular side-by-side arrangement of bases along the DNA strand (e.g., ATTCCGGA). Each gene has a unique DNA sequence. Genes comprise only about 29 percent of the human genome; the remainder consists of non-coding regions, whose functions may include providing chromosomal structural integrity and regulating where, when, and in what quantity proteins are made. The human genome is estimated to contain 20,000 to 25,000 genes.

Although each cell contains a full complement of DNA, cells use genes selectively. For example, the genes active in a liver cell differ from the genes active in a brain cell because each cell performs different functions and, therefore, requires different proteins. Different genes can also be activated during development or in response to environmental stimuli such as an infection or stress.

• 1.2 Types of Genetic Disease

Many, if not most, diseases are caused or influenced by genetics. Genes, through the proteins they encode, determine how efficiently foods and chemicals are metabolized, how effectively toxins are detoxified, and how vigorously infections are targeted. Genetic diseases can be categorized into three major groups: single-gene, chromosomal, and multifactorial.

Changes in the DNA sequence of single genes, also known as mutations, cause thousands of diseases. A gene can mutate in many ways, resulting in an altered protein product that is unable to perform its normal function. The most common gene mutation involves a change or “misspelling” in a single base in the DNA. Other mutations include the loss (deletion) or gain (duplication or insertion) of a single or multiple base(s). The altered protein product may still retain some normal function, but at a reduced capacity. In other cases, the protein may be totally disabled by the mutation or gain an entirely new, but damaging, function. The outcome of a particular mutation depends not only on how it alters a protein’s function, but also on how vital that particular protein is to survival. Other mutations, called polymorphisms, are natural variations in DNA sequence that have no adverse effects and are simply differences among individuals.

In addition to mutations in single genes, genetic diseases can be caused by larger mutations in chromosomes. Chromosomal abnormalities may result from either the total number of chromosomes differing from the usual amount or the physical structure of a chromosome differing from the usual structure. The most common type of chromosomal abnormality is known as aneuploidy, an abnormal number of chromosomes due to an extra or missing chromosome. A usual karyotype (complete chromosome set) contains 46 chromosomes including an XX (female) or an XY (male) sex chromosome pair. Structural chromosomal abnormalities include deletions, duplications, insertions, inversions, or translocations of a chromosome segment. (See Appendix F for more information about chromosomal abnormalities.)

Multifactorial diseases are caused by a complex combination of genetic, behavioral, and environmental factors. Examples of these conditions include spina bifida, diabetes, and heart disease. Although multifactorial diseases can recur in families, some mutations such as cancer can be acquired throughout an individual’s lifetime. All genes work in the context of environment and behavior. Alterations in behavior or the environment such as diet, exercise, exposure to toxic agents, or medications can all influence genetic traits.

• 1.3 Laws of Inheritance

The basic laws of inheritance are useful in understanding patterns of disease transmission. Single-gene diseases are usually inherited in one of several patterns, depending on the location of the gene (e.g., chromosomes 1-22 or X and Y) and whether one or two normal copies of the gene are needed for normal protein activity. Five basic modes of inheritance for single-gene diseases exist: autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, and mitochondria. (See diagram on following page.)

• 1.4 Genetic Variation

All individuals are 99.9 percent the same genetically. The differences in the sequence of DNA among individuals, or genetic variation, explain some of the differences among people such as physical traits and higher or lower risk for certain diseases. Mutations and polymorphisms are forms of genetic variation. While mutations are generally associated with disease and are relatively rare, polymorphisms are more frequent and their clinical significance is not as straightforward. Single nucleotide polymorphisms (SNPs, pronounced “snips”) are DNA sequence variations that occur when a single nucleotide is altered. SNPs occur every 100 to 300 bases along the 3 billion-base human genome. A single individual may carry millions of SNPs.

Although some genetic variations may cause or modify disease risk, other changes may result in no increased risk or a neutral presentation. For example, genetic variants in a single gene account for the different blood types: A, B, AB, and O. Understanding the clinical significance of genetic variation is a complicated process because of our limited knowledge of which genes are involved in a disease or condition and the multiple gene-gene and gene-behavior-environment interactions likely to be involved in complex, chronic diseases. New technologies are enabling faster and more accurate detection of genetic variants in hundreds or thousands of genes in a single process.

• Selected References

Department of Energy, Human Genome Project Education Resources www.ornl.gov/sci/techresources/Human_Genome/education/education.shtml

Genetics Home Reference http://www.ghr.nlm.nih.gov

National Human Genome Research Institute www.genome.gov/health

Online Mendelian Inheritance in Man www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=omim

All Genetic Alliance content, except where otherwise noted, is licensed under a Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

• Cite this Page Genetic Alliance; The New York-Mid-Atlantic Consortium for Genetic and Newborn Screening Services. Understanding Genetics: A New York, Mid-Atlantic Guide for Patients and Health Professionals. Washington (DC): Genetic Alliance; 2009 Jul 8. CHAPTER 1, GENETICS 101.
• PDF version of this title (22M)

In this Page

Other titles in this collection.

• Genetic Alliance Monographs and Guides

Recent Activity

• GENETICS 101 - Understanding Genetics GENETICS 101 - Understanding Genetics

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Connect with NLM

National Library of Medicine 8600 Rockville Pike Bethesda, MD 20894

Web Policies FOIA HHS Vulnerability Disclosure

Help Accessibility Careers

Want to create or adapt books like this? Learn more about how Pressbooks supports open publishing practices.

4 Introduction to Molecular Genetics

The three letters “DNA” have now become associated with crime solving, paternity testing, human identification, and genetic testing. DNA can be retrieved from hair, blood, or saliva. With the exception of identical twins, each person’s DNA is unique and it is possible to detect differences between human beings on the basis of their unique DNA sequence.

DNA analysis has many practical applications beyond forensics and paternity testing. DNA testing is used for tracing genealogy and identifying pathogens. In the medical field, DNA is used in diagnostics, new vaccine development, and cancer therapy. It is now possible to determine predisposition to many diseases by analyzing genes.

DNA is the genetic material passed from parent to offspring for all life on Earth. The technology of molecular genetics developed in the last half century has enabled us to see deep into the history of life to deduce the relationships between living things in ways never thought possible. It also allows us to understand the workings of evolution in populations of organisms. Over a thousand species have had their entire genome sequenced, and there have been thousands of individual human genome sequences completed. These sequences will allow us to understand human disease and the relationship of humans to the rest of the tree of life. Finally, molecular genetics techniques have revolutionized plant and animal breeding for human agricultural needs. All of these advances in biotechnology depended on basic research leading to the discovery of the structure of DNA in 1953, and the research since then has uncovered the details of DNA replication and the complex process leading to the expression of DNA in the form of proteins in the cell.

Introductory Biology: Evolutionary and Ecological Perspectives Copyright © by Various Authors - See Each Chapter Attribution is licensed under a Creative Commons Attribution 4.0 International License , except where otherwise noted.

Share This Book

• Biology Article

Genetics is the branch of biology that deals with the study of heredity and its biological process. It also involves the study of genes, genomes and the cell cycle.

What is Genetics?

Genetics is termed as the study to understand the functioning of inheritance of traits from parents to offspring. The groundwork on which heredity stands is known as inheritance. It is defined as the procedure by which characteristics are handed down from one generation to the other. Gregor Johann Mendel is known as the “Father of Modern Genetics” for his discoveries on the basic principles of heredity .

Variation, as the name suggests is the amount of dissimilarity that exists between children and their parentages. It can be determined to keep in view the behaviouristic, cytological, physiological, and morphological characters of individuals fitting into similar species.

Some of the major reasons that variation are

• Genetic/Chromosomal rearrangement.
• Mutated genes due to the influence of the ecosystem.
• Crossing over.

Let us have a detailed look at genetics notes to learn about genes and the principle of inheritance.

Law of Inheritance by Gregor Mendel

Garden Pea (Pisum Sativum) was the plant that Mendel experimented on for 7 years to get to the point to propose the laws of inheritance in live creatures. Mendel carefully chose seven distinct characteristics of Pisum Sativum for the investigation concerning hybridization. Mendel used true-breeding lines i.e. those that go through constant self-pollination and display steady characteristic inheritance.

Also Read:    Mendel’s Laws of Inheritance

Principles of Inheritance

When Mendel observed the monohybrid cross he proposed two laws of inheritance-

Law of Dominance – Distinct elements termed as factors control the characteristics. These factors at all times exist as a couple. One of the constituent genes of the couple dominates over the former.

Law of Segregation – Alleles don’t blend and the two characteristics are recuperated all through the gamete formation (in the F2 generation). The characters are apart from each other and pass on to diverse gametes. Comparable types of gametes are produced by Homozygous and Heterozygous produces diverse sorts of a gamete with varied characteristics.

Also Refer:  Principles of Heredity

Incomplete Dominance

It is the discovery that was done after Mendel’s work. Incomplete dominance is the situation in which both the alleles do not display a dominant trait resulting in a fine combination or a midway amid the characteristics of the alleles.

Explore more:  Incomplete dominance

Codominance

When two alleles lack the dominant-recessive association and thus the duo affects the creature together.

Law of Independent Assortment

The separation of one set of characteristics is autonomous of the other set of characters when they are pooled in a hybrid.

The Chromosomal Theory of Inheritance

Both genes and chromosomes exist in sets of two. The homologous chromosome contains the two alleles of a gene pair in the homologous sites. The coupling and split of a set of chromosomes will cause a split in the set of genes (factor) they carry. This united knowledge is termed the Chromosomal Theory of Inheritance.

Sex Determination

A particular nuclear arrangement was perceived by Henking. He perceived that this particular nuclear arrangement was found in only fifty per cent of sperms. He termed this body as x. Later, it was observed that the ova which only obtained the X chromosome matured and were born as females and those that didn’t receive only X chromosomes were born as males. Thus, the X- chromosome was termed a sex chromosome and the remaining ones were termed autosomes.

The occurrence due to which a modification in DNA happens and causes a variation in the phenotype and genotype of a creature is termed a Mutation .

Explore more:  Determination Of Sex

Genetic Disorders

Disorders of a Mendelian nature include:

• Haemophilia.
• Sickle Cell Anaemia.
• Phenylketonuria.

Disorders of a chromosomal nature include:

• Down’s syndrome.
• Klinefelter’s Syndrome.
• Turners Syndrome.

Explore more:  Chromosomal Abnormalities

Learn more in detail about Genetics, its importance, applications and other related topics at BYJU’S Biology

Put your understanding of this concept to test by answering a few MCQs. Click ‘Start Quiz’ to begin!

Select the correct answer and click on the “Finish” button Check your score and answers at the end of the quiz

Visit BYJU’S for all Biology related queries and study materials

Your result is as below

Request OTP on Voice Call

Leave a Comment Cancel reply

Your Mobile number and Email id will not be published. Required fields are marked *

Post My Comment

• Share Share

Register with BYJU'S & Download Free PDFs

Register with byju's & watch live videos.

• school Campus Bookshelves
• menu_book Bookshelves
• perm_media Learning Objects
• login Login
• how_to_reg Request Instructor Account
• hub Instructor Commons

Margin Size

• Download Page (PDF)
• Download Full Book (PDF)
• Periodic Table
• Physics Constants
• Scientific Calculator
• Reference & Cite
• Tools expand_more
• Readability

selected template will load here

This action is not available.

1.8: Introduction to heredity review

• Last updated
• Save as PDF
• Page ID 73825

\( \newcommand{\vecs}[1]{\overset { \scriptstyle \rightharpoonup} {\mathbf{#1}} } \)

\( \newcommand{\vecd}[1]{\overset{-\!-\!\rightharpoonup}{\vphantom{a}\smash {#1}}} \)

\( \newcommand{\id}{\mathrm{id}}\) \( \newcommand{\Span}{\mathrm{span}}\)

( \newcommand{\kernel}{\mathrm{null}\,}\) \( \newcommand{\range}{\mathrm{range}\,}\)

\( \newcommand{\RealPart}{\mathrm{Re}}\) \( \newcommand{\ImaginaryPart}{\mathrm{Im}}\)

\( \newcommand{\Argument}{\mathrm{Arg}}\) \( \newcommand{\norm}[1]{\| #1 \|}\)

\( \newcommand{\inner}[2]{\langle #1, #2 \rangle}\)

\( \newcommand{\Span}{\mathrm{span}}\)

\( \newcommand{\id}{\mathrm{id}}\)

\( \newcommand{\kernel}{\mathrm{null}\,}\)

\( \newcommand{\range}{\mathrm{range}\,}\)

\( \newcommand{\RealPart}{\mathrm{Re}}\)

\( \newcommand{\ImaginaryPart}{\mathrm{Im}}\)

\( \newcommand{\Argument}{\mathrm{Arg}}\)

\( \newcommand{\norm}[1]{\| #1 \|}\)

\( \newcommand{\Span}{\mathrm{span}}\) \( \newcommand{\AA}{\unicode[.8,0]{x212B}}\)

\( \newcommand{\vectorA}[1]{\vec{#1}}      % arrow\)

\( \newcommand{\vectorAt}[1]{\vec{\text{#1}}}      % arrow\)

\( \newcommand{\vectorB}[1]{\overset { \scriptstyle \rightharpoonup} {\mathbf{#1}} } \)

\( \newcommand{\vectorC}[1]{\textbf{#1}} \)

\( \newcommand{\vectorD}[1]{\overrightarrow{#1}} \)

\( \newcommand{\vectorDt}[1]{\overrightarrow{\text{#1}}} \)

\( \newcommand{\vectE}[1]{\overset{-\!-\!\rightharpoonup}{\vphantom{a}\smash{\mathbf {#1}}}} \)

Mendelian inheritance

Gregor Mendel's principles of heredity, observed through patterns of inheritance in pea plants, form the basis of modern genetics .

Mendel proposed that traits were specified by "heritable elements" called genes . Genes come in different versions, or alleles , with dominant alleles being expressed over recessive alleles . Recessive alleles are only expressed when no dominant allele is present.

In most sexually reproducing organisms, each individual has two alleles for each gene (one from each parent). This pair of alleles is called a genotype and determines the organism's appearance, or phenotype .

Mendel's laws

When an organism makes gametes, each gamete receives just one gene copy, which is selected randomly. This is known as the law of segregation .

Mendel's second law is the law of independent assortment , which states that the alleles for one gene sort into gametes independently of the alleles of another gene.

Punnett squares and probability

A Punnett square can be used to predict genotype and phenotypes of offspring from genetic crosses. A single-gene, or monohybrid cross is pictured below.

A test cross can be used to determine whether an organism with a dominant phenotype is homozygous or heterozygous.

Punnett squares can be used for two-gene crosses, or dihybrid crosses by following the same basic rules as for a monohybrid cross. However, since there are now more gamete types, there must also be more squares in the table.

Probabilities in genetics

The two probability rules that are most relevant to Punnett squares are the product rule and the sum rule .

The product rule states that the probability of two (or more) independent events occurring together can be calculated by multiplying the individual probabilities of the events.

In some genetics problems, you may need to calculate the probability that any one of several events will occur. In this case, you’ll need to apply another rule of probability, the sum rule. According to the sum rule, the probability that any of several mutually exclusive events will occur is equal to the sum of the events’ individual probabilities.

Common mistakes and misconceptions

• Dominant traits are not always the most common. Some people may think that dominant trait is the most likely to be found in the population, but the term "dominant" only refers to the fact that the allele is expressed over another allele. An example of this is Huntington's disease. Even though Huntington's is caused by a dominant allele, it only affects about 30,000 people in the United States 1 .
• Traits are not always the product of a single gene. For example, there are at least 3 different genes that are associated with eye color in humans. In addition, there are sometimes more than two alleles for each gene. For example, there are 3 different alleles of one gene that determine coat color of cats.

Contributors and Attributions

Khan Academy (CC BY-NC-SA 3.0; All Khan Academy content is available for free at www.khanacademy.org )

• Search Menu
• Browse content in Arts and Humanities
• Browse content in Archaeology
• Anglo-Saxon and Medieval Archaeology
• Archaeological Methodology and Techniques
• Archaeology by Region
• Archaeology of Religion
• Archaeology of Trade and Exchange
• Biblical Archaeology
• Contemporary and Public Archaeology
• Environmental Archaeology
• Historical Archaeology
• History and Theory of Archaeology
• Industrial Archaeology
• Landscape Archaeology
• Mortuary Archaeology
• Prehistoric Archaeology
• Underwater Archaeology
• Urban Archaeology
• Zooarchaeology
• Browse content in Architecture
• Architectural Structure and Design
• History of Architecture
• Residential and Domestic Buildings
• Theory of Architecture
• Browse content in Art
• Art Subjects and Themes
• History of Art
• Industrial and Commercial Art
• Theory of Art
• Biographical Studies
• Byzantine Studies
• Browse content in Classical Studies
• Classical History
• Classical Philosophy
• Classical Mythology
• Classical Literature
• Classical Reception
• Classical Art and Architecture
• Classical Oratory and Rhetoric
• Greek and Roman Epigraphy
• Greek and Roman Law
• Greek and Roman Archaeology
• Greek and Roman Papyrology
• Late Antiquity
• Religion in the Ancient World
• Digital Humanities
• Browse content in History
• Colonialism and Imperialism
• Diplomatic History
• Environmental History
• Genealogy, Heraldry, Names, and Honours
• Genocide and Ethnic Cleansing
• Historical Geography
• History by Period
• History of Agriculture
• History of Education
• History of Emotions
• History of Gender and Sexuality
• Industrial History
• Intellectual History
• International History
• Labour History
• Legal and Constitutional History
• Local and Family History
• Maritime History
• Military History
• National Liberation and Post-Colonialism
• Oral History
• Political History
• Public History
• Regional and National History
• Revolutions and Rebellions
• Slavery and Abolition of Slavery
• Social and Cultural History
• Theory, Methods, and Historiography
• Urban History
• World History
• Browse content in Language Teaching and Learning
• Language Learning (Specific Skills)
• Language Teaching Theory and Methods
• Browse content in Linguistics
• Applied Linguistics
• Cognitive Linguistics
• Computational Linguistics
• Forensic Linguistics
• Grammar, Syntax and Morphology
• Historical and Diachronic Linguistics
• History of English
• Language Acquisition
• Language Variation
• Language Families
• Language Evolution
• Language Reference
• Lexicography
• Linguistic Theories
• Linguistic Typology
• Linguistic Anthropology
• Phonetics and Phonology
• Psycholinguistics
• Sociolinguistics
• Translation and Interpretation
• Writing Systems
• Browse content in Literature
• Bibliography
• Children's Literature Studies
• Literary Studies (Asian)
• Literary Studies (European)
• Literary Studies (Eco-criticism)
• Literary Studies (Modernism)
• Literary Studies (Romanticism)
• Literary Studies (American)
• Literary Studies - World
• Literary Studies (1500 to 1800)
• Literary Studies (19th Century)
• Literary Studies (20th Century onwards)
• Literary Studies (African American Literature)
• Literary Studies (British and Irish)
• Literary Studies (Early and Medieval)
• Literary Studies (Fiction, Novelists, and Prose Writers)
• Literary Studies (Gender Studies)
• Literary Studies (Graphic Novels)
• Literary Studies (History of the Book)
• Literary Studies (Plays and Playwrights)
• Literary Studies (Poetry and Poets)
• Literary Studies (Postcolonial Literature)
• Literary Studies (Queer Studies)
• Literary Studies (Science Fiction)
• Literary Studies (Travel Literature)
• Literary Studies (War Literature)
• Literary Studies (Women's Writing)
• Literary Theory and Cultural Studies
• Mythology and Folklore
• Shakespeare Studies and Criticism
• Browse content in Media Studies
• Browse content in Music
• Applied Music
• Dance and Music
• Ethics in Music
• Ethnomusicology
• Gender and Sexuality in Music
• Medicine and Music
• Music Cultures
• Music and Religion
• Music and Culture
• Music and Media
• Music Education and Pedagogy
• Music Theory and Analysis
• Musical Scores, Lyrics, and Libretti
• Musical Structures, Styles, and Techniques
• Musicology and Music History
• Performance Practice and Studies
• Race and Ethnicity in Music
• Sound Studies
• Browse content in Performing Arts
• Browse content in Philosophy
• Aesthetics and Philosophy of Art
• Epistemology
• Feminist Philosophy
• History of Western Philosophy
• Metaphysics
• Moral Philosophy
• Non-Western Philosophy
• Philosophy of Science
• Philosophy of Action
• Philosophy of Law
• Philosophy of Religion
• Philosophy of Language
• Philosophy of Mind
• Philosophy of Perception
• Philosophy of Mathematics and Logic
• Practical Ethics
• Social and Political Philosophy
• Browse content in Religion
• Biblical Studies
• Christianity
• East Asian Religions
• History of Religion
• Judaism and Jewish Studies
• Qumran Studies
• Religion and Education
• Religion and Health
• Religion and Politics
• Religion and Science
• Religion and Law
• Religion and Art, Literature, and Music
• Religious Studies
• Browse content in Society and Culture
• Cookery, Food, and Drink
• Cultural Studies
• Customs and Traditions
• Ethical Issues and Debates
• Hobbies, Games, Arts and Crafts
• Lifestyle, Home, and Garden
• Natural world, Country Life, and Pets
• Popular Beliefs and Controversial Knowledge
• Sports and Outdoor Recreation
• Technology and Society
• Travel and Holiday
• Visual Culture
• Browse content in Law
• Arbitration
• Browse content in Company and Commercial Law
• Commercial Law
• Company Law
• Browse content in Comparative Law
• Systems of Law
• Competition Law
• Browse content in Constitutional and Administrative Law
• Government Powers
• Judicial Review
• Local Government Law
• Military and Defence Law
• Parliamentary and Legislative Practice
• Construction Law
• Contract Law
• Browse content in Criminal Law
• Criminal Procedure
• Criminal Evidence Law
• Sentencing and Punishment
• Employment and Labour Law
• Environment and Energy Law
• Browse content in Financial Law
• Banking Law
• Insolvency Law
• History of Law
• Human Rights and Immigration
• Intellectual Property Law
• Browse content in International Law
• Private International Law and Conflict of Laws
• Public International Law
• IT and Communications Law
• Jurisprudence and Philosophy of Law
• Law and Politics
• Law and Society
• Browse content in Legal System and Practice
• Courts and Procedure
• Legal Skills and Practice
• Primary Sources of Law
• Regulation of Legal Profession
• Medical and Healthcare Law
• Browse content in Policing
• Criminal Investigation and Detection
• Police and Security Services
• Police Procedure and Law
• Police Regional Planning
• Browse content in Property Law
• Personal Property Law
• Study and Revision
• Terrorism and National Security Law
• Browse content in Trusts Law
• Wills and Probate or Succession
• Browse content in Medicine and Health
• Browse content in Allied Health Professions
• Arts Therapies
• Clinical Science
• Dietetics and Nutrition
• Occupational Therapy
• Operating Department Practice
• Physiotherapy
• Radiography
• Speech and Language Therapy
• Browse content in Anaesthetics
• General Anaesthesia
• Neuroanaesthesia
• Browse content in Clinical Medicine
• Acute Medicine
• Cardiovascular Medicine
• Clinical Genetics
• Clinical Pharmacology and Therapeutics
• Dermatology
• Endocrinology and Diabetes
• Gastroenterology
• Genito-urinary Medicine
• Geriatric Medicine
• Infectious Diseases
• Medical Oncology
• Medical Toxicology
• Pain Medicine
• Palliative Medicine
• Rehabilitation Medicine
• Respiratory Medicine and Pulmonology
• Rheumatology
• Sleep Medicine
• Sports and Exercise Medicine
• Clinical Neuroscience
• Community Medical Services
• Critical Care
• Emergency Medicine
• Forensic Medicine
• Haematology
• History of Medicine
• Browse content in Medical Dentistry
• Oral and Maxillofacial Surgery
• Paediatric Dentistry
• Restorative Dentistry and Orthodontics
• Surgical Dentistry
• Medical Ethics
• Browse content in Medical Skills
• Clinical Skills
• Communication Skills
• Nursing Skills
• Surgical Skills
• Medical Statistics and Methodology
• Browse content in Neurology
• Clinical Neurophysiology
• Neuropathology
• Nursing Studies
• Browse content in Obstetrics and Gynaecology
• Gynaecology
• Occupational Medicine
• Ophthalmology
• Otolaryngology (ENT)
• Browse content in Paediatrics
• Neonatology
• Browse content in Pathology
• Chemical Pathology
• Clinical Cytogenetics and Molecular Genetics
• Histopathology
• Medical Microbiology and Virology
• Patient Education and Information
• Browse content in Pharmacology
• Psychopharmacology
• Browse content in Popular Health
• Caring for Others
• Complementary and Alternative Medicine
• Self-help and Personal Development
• Browse content in Preclinical Medicine
• Cell Biology
• Molecular Biology and Genetics
• Reproduction, Growth and Development
• Primary Care
• Professional Development in Medicine
• Browse content in Psychiatry
• Addiction Medicine
• Child and Adolescent Psychiatry
• Forensic Psychiatry
• Learning Disabilities
• Old Age Psychiatry
• Psychotherapy
• Browse content in Public Health and Epidemiology
• Epidemiology
• Public Health
• Browse content in Radiology
• Clinical Radiology
• Interventional Radiology
• Nuclear Medicine
• Radiation Oncology
• Reproductive Medicine
• Browse content in Surgery
• Cardiothoracic Surgery
• Gastro-intestinal and Colorectal Surgery
• General Surgery
• Neurosurgery
• Paediatric Surgery
• Peri-operative Care
• Plastic and Reconstructive Surgery
• Surgical Oncology
• Transplant Surgery
• Trauma and Orthopaedic Surgery
• Vascular Surgery
• Browse content in Science and Mathematics
• Browse content in Biological Sciences
• Aquatic Biology
• Biochemistry
• Bioinformatics and Computational Biology
• Developmental Biology
• Ecology and Conservation
• Evolutionary Biology
• Genetics and Genomics
• Microbiology
• Molecular and Cell Biology
• Natural History
• Plant Sciences and Forestry
• Research Methods in Life Sciences
• Structural Biology
• Systems Biology
• Zoology and Animal Sciences
• Browse content in Chemistry
• Analytical Chemistry
• Computational Chemistry
• Crystallography
• Environmental Chemistry
• Industrial Chemistry
• Inorganic Chemistry
• Materials Chemistry
• Medicinal Chemistry
• Mineralogy and Gems
• Organic Chemistry
• Physical Chemistry
• Polymer Chemistry
• Study and Communication Skills in Chemistry
• Theoretical Chemistry
• Browse content in Computer Science
• Artificial Intelligence
• Computer Architecture and Logic Design
• Game Studies
• Human-Computer Interaction
• Mathematical Theory of Computation
• Programming Languages
• Software Engineering
• Systems Analysis and Design
• Virtual Reality
• Browse content in Computing
• Business Applications
• Computer Security
• Computer Games
• Computer Networking and Communications
• Digital Lifestyle
• Graphical and Digital Media Applications
• Operating Systems
• Browse content in Earth Sciences and Geography
• Atmospheric Sciences
• Environmental Geography
• Geology and the Lithosphere
• Maps and Map-making
• Meteorology and Climatology
• Oceanography and Hydrology
• Palaeontology
• Physical Geography and Topography
• Regional Geography
• Soil Science
• Urban Geography
• Browse content in Engineering and Technology
• Agriculture and Farming
• Biological Engineering
• Civil Engineering, Surveying, and Building
• Electronics and Communications Engineering
• Energy Technology
• Engineering (General)
• Environmental Science, Engineering, and Technology
• History of Engineering and Technology
• Mechanical Engineering and Materials
• Technology of Industrial Chemistry
• Transport Technology and Trades
• Browse content in Environmental Science
• Applied Ecology (Environmental Science)
• Conservation of the Environment (Environmental Science)
• Environmental Sustainability
• Environmentalist Thought and Ideology (Environmental Science)
• Management of Land and Natural Resources (Environmental Science)
• Natural Disasters (Environmental Science)
• Nuclear Issues (Environmental Science)
• Pollution and Threats to the Environment (Environmental Science)
• Social Impact of Environmental Issues (Environmental Science)
• History of Science and Technology
• Browse content in Materials Science
• Ceramics and Glasses
• Composite Materials
• Metals, Alloying, and Corrosion
• Nanotechnology
• Browse content in Mathematics
• Applied Mathematics
• Biomathematics and Statistics
• History of Mathematics
• Mathematical Education
• Mathematical Finance
• Mathematical Analysis
• Numerical and Computational Mathematics
• Probability and Statistics
• Pure Mathematics
• Browse content in Neuroscience
• Cognition and Behavioural Neuroscience
• Development of the Nervous System
• Disorders of the Nervous System
• History of Neuroscience
• Invertebrate Neurobiology
• Molecular and Cellular Systems
• Neuroendocrinology and Autonomic Nervous System
• Neuroscientific Techniques
• Sensory and Motor Systems
• Browse content in Physics
• Astronomy and Astrophysics
• Atomic, Molecular, and Optical Physics
• Biological and Medical Physics
• Classical Mechanics
• Computational Physics
• Condensed Matter Physics
• Electromagnetism, Optics, and Acoustics
• History of Physics
• Mathematical and Statistical Physics
• Measurement Science
• Nuclear Physics
• Particles and Fields
• Plasma Physics
• Quantum Physics
• Relativity and Gravitation
• Semiconductor and Mesoscopic Physics
• Browse content in Psychology
• Affective Sciences
• Clinical Psychology
• Cognitive Neuroscience
• Cognitive Psychology
• Criminal and Forensic Psychology
• Developmental Psychology
• Educational Psychology
• Evolutionary Psychology
• Health Psychology
• History and Systems in Psychology
• Music Psychology
• Neuropsychology
• Organizational Psychology
• Psychological Assessment and Testing
• Psychology of Human-Technology Interaction
• Psychology Professional Development and Training
• Research Methods in Psychology
• Social Psychology
• Browse content in Social Sciences
• Browse content in Anthropology
• Anthropology of Religion
• Human Evolution
• Medical Anthropology
• Physical Anthropology
• Regional Anthropology
• Social and Cultural Anthropology
• Theory and Practice of Anthropology
• Browse content in Business and Management
• Business Strategy
• Business History
• Business Ethics
• Business and Government
• Business and Technology
• Business and the Environment
• Comparative Management
• Corporate Governance
• Corporate Social Responsibility
• Entrepreneurship
• Health Management
• Human Resource Management
• Industrial and Employment Relations
• Industry Studies
• Information and Communication Technologies
• International Business
• Knowledge Management
• Management and Management Techniques
• Operations Management
• Organizational Theory and Behaviour
• Pensions and Pension Management
• Public and Nonprofit Management
• Strategic Management
• Supply Chain Management
• Browse content in Criminology and Criminal Justice
• Criminal Justice
• Criminology
• Forms of Crime
• International and Comparative Criminology
• Youth Violence and Juvenile Justice
• Development Studies
• Browse content in Economics
• Agricultural, Environmental, and Natural Resource Economics
• Asian Economics
• Behavioural Finance
• Behavioural Economics and Neuroeconomics
• Econometrics and Mathematical Economics
• Economic Systems
• Economic Methodology
• Economic History
• Economic Development and Growth
• Financial Markets
• Financial Institutions and Services
• General Economics and Teaching
• Health, Education, and Welfare
• History of Economic Thought
• International Economics
• Labour and Demographic Economics
• Law and Economics
• Macroeconomics and Monetary Economics
• Microeconomics
• Public Economics
• Urban, Rural, and Regional Economics
• Welfare Economics
• Browse content in Education
• Adult Education and Continuous Learning
• Care and Counselling of Students
• Early Childhood and Elementary Education
• Educational Equipment and Technology
• Educational Strategies and Policy
• Higher and Further Education
• Organization and Management of Education
• Philosophy and Theory of Education
• Schools Studies
• Secondary Education
• Teaching of a Specific Subject
• Teaching of Specific Groups and Special Educational Needs
• Teaching Skills and Techniques
• Browse content in Environment
• Applied Ecology (Social Science)
• Climate Change
• Conservation of the Environment (Social Science)
• Environmentalist Thought and Ideology (Social Science)
• Natural Disasters (Environment)
• Social Impact of Environmental Issues (Social Science)
• Browse content in Human Geography
• Cultural Geography
• Economic Geography
• Political Geography
• Browse content in Interdisciplinary Studies
• Communication Studies
• Museums, Libraries, and Information Sciences
• Browse content in Politics
• African Politics
• Asian Politics
• Chinese Politics
• Comparative Politics
• Conflict Politics
• Elections and Electoral Studies
• Environmental Politics
• European Union
• Foreign Policy
• Gender and Politics
• Human Rights and Politics
• Indian Politics
• International Relations
• International Organization (Politics)
• International Political Economy
• Irish Politics
• Latin American Politics
• Middle Eastern Politics
• Political Methodology
• Political Communication
• Political Philosophy
• Political Sociology
• Political Theory
• Political Behaviour
• Political Economy
• Political Institutions
• Politics and Law
• Public Administration
• Public Policy
• Quantitative Political Methodology
• Regional Political Studies
• Russian Politics
• Security Studies
• State and Local Government
• UK Politics
• US Politics
• Browse content in Regional and Area Studies
• African Studies
• Asian Studies
• East Asian Studies
• Japanese Studies
• Latin American Studies
• Middle Eastern Studies
• Native American Studies
• Scottish Studies
• Browse content in Research and Information
• Research Methods
• Browse content in Social Work
• Addictions and Substance Misuse
• Adoption and Fostering
• Care of the Elderly
• Child and Adolescent Social Work
• Couple and Family Social Work
• Developmental and Physical Disabilities Social Work
• Direct Practice and Clinical Social Work
• Emergency Services
• Human Behaviour and the Social Environment
• International and Global Issues in Social Work
• Mental and Behavioural Health
• Social Justice and Human Rights
• Social Policy and Advocacy
• Social Work and Crime and Justice
• Social Work Macro Practice
• Social Work Practice Settings
• Social Work Research and Evidence-based Practice
• Welfare and Benefit Systems
• Browse content in Sociology
• Childhood Studies
• Community Development
• Comparative and Historical Sociology
• Economic Sociology
• Gender and Sexuality
• Gerontology and Ageing
• Health, Illness, and Medicine
• Marriage and the Family
• Migration Studies
• Occupations, Professions, and Work
• Organizations
• Population and Demography
• Race and Ethnicity
• Social Theory
• Social Movements and Social Change
• Social Research and Statistics
• Social Stratification, Inequality, and Mobility
• Sociology of Religion
• Sociology of Education
• Sport and Leisure
• Urban and Rural Studies
• Browse content in Warfare and Defence
• Defence Strategy, Planning, and Research
• Land Forces and Warfare
• Military Administration
• Military Life and Institutions
• Naval Forces and Warfare
• Other Warfare and Defence Issues
• Peace Studies and Conflict Resolution
• Weapons and Equipment

Genes: A Very Short Introduction (1st edn)

Author webpage

A newer edition of this book is available.

• Cite Icon Cite
• Permissions Icon Permissions

What are genes? What do they say about us? Genes: A Very Short Introduction explores the concept of the gene and looks at the discovery, nature, and role of genes in both evolution and development. Explaining the nature of genetic variation in the human population, how hereditary factors were identified as molecules of DNA, and how certain specific mutations can lead to disease, it highlights how DNA variants are used to trace human ancestry and migration, and can also be used by forensic scientists to identify individuals in crime. It also explores issues such as genetic heritability and IQ.

Signed in as

Institutional accounts.

• GoogleCrawler [DO NOT DELETE]
• Google Scholar Indexing

Personal account

• Sign in with email/username & password
• Get email alerts
• Save searches
• Purchase content
• Activate your purchase/trial code
• Add your ORCID iD

Institutional access

Sign in with a library card.

• Sign in with username/password
• Recommend to your librarian
• Institutional account management
• Get help with access

Access to content on Oxford Academic is often provided through institutional subscriptions and purchases. If you are a member of an institution with an active account, you may be able to access content in one of the following ways:

IP based access

Typically, access is provided across an institutional network to a range of IP addresses. This authentication occurs automatically, and it is not possible to sign out of an IP authenticated account.

Sign in through your institution

Choose this option to get remote access when outside your institution. Shibboleth/Open Athens technology is used to provide single sign-on between your institution’s website and Oxford Academic.

• Click Sign in through your institution.
• Select your institution from the list provided, which will take you to your institution's website to sign in.
• When on the institution site, please use the credentials provided by your institution. Do not use an Oxford Academic personal account.
• Following successful sign in, you will be returned to Oxford Academic.

If your institution is not listed or you cannot sign in to your institution’s website, please contact your librarian or administrator.

Enter your library card number to sign in. If you cannot sign in, please contact your librarian.

Society Members

Society member access to a journal is achieved in one of the following ways:

Sign in through society site

Many societies offer single sign-on between the society website and Oxford Academic. If you see ‘Sign in through society site’ in the sign in pane within a journal:

• Click Sign in through society site.
• When on the society site, please use the credentials provided by that society. Do not use an Oxford Academic personal account.

If you do not have a society account or have forgotten your username or password, please contact your society.

Sign in using a personal account

Some societies use Oxford Academic personal accounts to provide access to their members. See below.

A personal account can be used to get email alerts, save searches, purchase content, and activate subscriptions.

Some societies use Oxford Academic personal accounts to provide access to their members.

Viewing your signed in accounts

Click the account icon in the top right to:

• View your signed in personal account and access account management features.
• View the institutional accounts that are providing access.

Signed in but can't access content

Oxford Academic is home to a wide variety of products. The institutional subscription may not cover the content that you are trying to access. If you believe you should have access to that content, please contact your librarian.

For librarians and administrators, your personal account also provides access to institutional account management. Here you will find options to view and activate subscriptions, manage institutional settings and access options, access usage statistics, and more.

Our books are available by subscription or purchase to libraries and institutions.

Blog article

• The King’s genes

External resource

• In the OUP print catalogue
• About Oxford Academic
• Publish journals with us
• University press partners
• What we publish
• New features  
• Open access
• Rights and permissions
• Accessibility
• Advertising
• Media enquiries
• Oxford University Press
• Oxford Languages
• University of Oxford

Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide

• Copyright © 2024 Oxford University Press
• Cookie settings
• Cookie policy
• Privacy policy
• Legal notice

This Feature Is Available To Subscribers Only

Sign In or Create an Account

This PDF is available to Subscribers Only

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

If you're seeing this message, it means we're having trouble loading external resources on our website.

If you're behind a web filter, please make sure that the domains *.kastatic.org and *.kasandbox.org are unblocked.

To log in and use all the features of Khan Academy, please enable JavaScript in your browser.

AP®︎/College Biology

Course: ap®︎/college biology   >   unit 6.

• Introduction to genetic engineering

Intro to biotechnology

• DNA cloning and recombinant DNA
• Overview: DNA cloning
• Polymerase chain reaction (PCR)
• Gel electrophoresis
• DNA sequencing
• Applications of DNA technologies
• Biotechnology

Key points:

• Biotechnology is the use of an organism, or a component of an organism or other biological system, to make a product or process.
• Many forms of modern biotechnology rely on DNA technology.
• DNA technology is the sequencing, analysis, and cutting-and-pasting of DNA.
• Common forms of DNA technology include DNA sequencing , polymerase chain reaction , DNA cloning , and gel electrophoresis .
• Biotechnology inventions can raise new practical concerns and ethical questions that must be addressed with informed input from all of society.

Introduction

What is biotechnology.

• Beer brewing . In beer brewing, tiny fungi (yeasts) are introduced into a solution of malted barley sugar, which they busily metabolize through a process called fermentation. The by-product of the fermentation is the alcohol that’s found in beer. Here, we see an organism – the yeast – being used to make a product for human consumption.
• Penicillin. The antibiotic penicillin is generated by certain molds. To make small amounts of penicillin for use in early clinical trials, researchers had to grow up to 500 ‍   liters of “mold juice” a week 1 ‍   . The process has since been improved for industrial production, with use of higher-producing mold strains and better culture conditions to increase yield 2 ‍   . Here, we see an organism (mold) being used to make a product for human use – in this case, an antibiotic to treat bacterial infections.
• Gene therapy. Gene therapy is an emerging technique used to treat genetic disorders that are caused by a nonfunctional gene. It works by delivering the “missing” gene’s DNA to the cells of the body. For instance, in the genetic disorder cystic fibrosis, people lack function of a gene for a chloride channel produced in the lungs. In a recent gene therapy clinical trial, a copy of the functional gene was inserted into a circular DNA molecule called a plasmid and delivered to patients’ lung cells in spheres of membrane (in the form of a spray) 3 ‍   . In this example, biological components from different sources (a gene from humans, a plasmid originally from bacteria) were combined to make a new product that helped preserve lung function in cystic fibrosis patients.

What is DNA technology?

Examples of dna technologies.

• DNA cloning. In DNA cloning , researchers “clone” – make many copies of – a DNA fragment of interest, such as a gene. In many cases, DNA cloning involves inserting a target gene into a circular DNA molecule called a plasmid. The plasmid can be replicated in bacteria, making many copies of the gene of interest. In some cases, the gene is also expressed in the bacteria, making a protein (such as the insulin used by diabetics). Insertion of a gene into a plasmid.
• Polymerase chain reaction (PCR). Polymerase chain reaction is another widely used DNA manipulation technique, one with applications in almost every area of modern biology. PCR reactions produce many copies of a target DNA sequence starting from a piece of template DNA. This technique can be used to make many copies of DNA that is present in trace amounts (e.g., in a droplet of blood at a crime scene).
• Gel electrophoresis. Gel electrophoresis is a technique used to visualize (directly see) DNA fragments. For instance, researchers can analyze the results of a PCR reaction by examining the DNA fragments it produces on a gel. Gel electrophoresis separates DNA fragments based on their size, and the fragments are stained with a dye so the researcher can see them. DNA fragments migrate through the gel from the negative to the positive electrode. After the gel has run, the fragments are separated by size, with the smallest ones near the bottom (positive electrode) and the largest ones near the top (negative electrode). Based on similar diagram in Reece et al. 5 ‍  
• DNA sequencing. DNA sequencing involves determining the sequence of nucleotide bases (As, Ts, Cs, and Gs) in a DNA molecule. In some cases, just one piece of DNA is sequenced at a time, while in other cases, a large collection of DNA fragments (such as those from an entire genome) may be sequenced as a group. What is a genome? A genome refers to all of an organism's DNA. In eukaryotes, which have a nucleus in their cells to hold their DNA, the word genome is usually used for the nuclear genome (DNA found in the nucleus), excluding the DNA found in organelles such as chloroplasts or mitochondria.

Biotechnology raises new ethical questions

• Some of these relate to privacy and non-discrimination. For instance should your health insurance company be able to charge you more if you have a gene variant that makes you likely to develop a disease? How would you feel if your school or employer had access to your genome?
• Other questions relate to the safety, health effects, or ecological impacts of biotechnologies. For example, crops genetically engineered to make their own insecticide reduce the need for chemical spraying, but also raise concerns about plants escaping into the wild or interbreeding with local populations (potentially causing unintended ecological consequences).
• Biotechnology may provide knowledge that creates hard dilemmas for individuals. For example, a couple may learn via prenatal testing that their fetus has a genetic disorder. Similarly, a person who has her genome sequenced for the sake of curiosity may learn that she is going to develop an incurable, late-onset genetic disease, such as Huntington's.

Educate yourself and share your perspective

Works cited:.

• American Chemical Society. (2016). Discovery and development of penicillin. In Chemical landmarks . Retrieved from http://www.acs.org/content/acs/en/education/whatischemistry/landmarks/flemingpenicillin.html .
• Meštrović, T. and Chow, S. (2015, April 29). Penicillin production. In News medical . Retrieved from http://www.news-medical.net/health/Penicillin-Production.aspx .
• Alton, E. W. F. W., Armstrong, D. K., Ashby, D., Bayfield, K. J., Bilton, Diana, Bloomfield, E. V., ... Wolstenholme-Hogg, P. (2015). Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: A randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respiratory Medicine , 3 (9), 684-691. http://dx.doi.org/10.1016/S2213-2600(15)00245-3 .
• Reece, J. B., Urry, L. A., Cain, M. L., Wasserman, S. A., Minorsky, P. V., and Jackson, R. B. (2011). The DNA toolbox. In Campbell biology (10th ed., pp. 408-409). San Francisco, CA: Pearson.
• Reece, J. B., Taylor, M. R., Simon, E. J., and Dickey, J. L. (2012). Figure 12.13. Gel electrophoresis of DNA. In Campbell biology: Concepts & connections (7th ed., p. 243).

Additional references:

Want to join the conversation.

• Upvote Button navigates to signup page
• Downvote Button navigates to signup page
• Flag Button navigates to signup page

341 Genetics Essay Topic Ideas & Examples

🏆 best genetics topic ideas & essay examples, 💡 most interesting genetics topics to write about, ✅ good research topics about genetics, ⭐ interesting topics to write about genetics, 🔎 genetics writing prompts, ✍️ genetics essay topics for college, 📌 simple & easy genetics essay titles, 👍 good essay topics on genetics, ❓ genetics essay questions.

• Genetically Modified Food Essay In spite of the perceived benefits of genetic engineering technology in the agricultural sector, the production and use of genetically modified foods has triggered a number of issues pertaining to safety and consequences of consumption.
• The role of genetics in development In this case, the dominant gene will win over the recessive gene, and the child may exhibit the characteristics of a parent who produced dominant genes.
• Criminal Behavior: Role of Environment and Genetics In the Information age where a person has access to more knowledge about the folly of being involved in criminal activities and the negative impact of having a prison record, it is a mystery why […]
• Mendelian Corn Genetics: An Experiment Seeds are then sorted out on the basis of their color and shape and the obtained data recorded adjacent to the respective phenotypes. Determine the 2 value for each experiment, and use the table of […]
• Genetic Disorders: Causes and Treatment The individual inherits some of the characteristics from the mother and the rest is inherited from the father. Genetic disorders may be passed from the parents to the offspring’s during the process of fertilization.
• The Study of Genetics: Importance for Society A key advantage of genetics for the clinical environment is the real possibility of manipulating the genetic code of a patient’s DNA in order to edit it.
• The Genetic Algorithm: Automatic Examination Timetable Scheduling Phenotype, on the other hand, represents the population in the search space corresponding to reality or a representation of the solutions through corresponding absolute values.
• Genetic Counseling, Its Role, and Candidates In such cases, the benefits of such testing can be better explained to enable other family members to be tested and determine any other possible genetic problems.
• Should All Genetically Modified Foods Be Labeled? According to this scholar, members of the public are always comfortable with the idea of not labeling the genetically modified food.
• Genetics as a Field and Its Practical Use Even in newborn screening, an area where genetic testing is excelling, parents opt to terminate the pregnancy for lack of a better solution to their condition.
• Achondroplasia Genetic Disorder: Pedigree The pedigree problem is generally featured with the necessity to provide the correct connections among the family members in a genetic history chart.
• Yeast Genetics and Complementation Lab Report In this study, the crossing of two mutants led to the development of phenotypic traits which are nothing but the colors, red or cream.
• Marfan Syndrome in Genetic Counseling The two generation hierarchies above and one generation hierarchy below the Anne’s generation was pooled and presented in the chart as below: Firstly, the typical clinical symptoms attributed to MFS were sorted from the description […]
• Religious vs Scientific Views on Genetic Engineering With the need to increase the global economy, the field of agriculture is one among the many that have been used to improve the commercial production to take care of the global needs for food […]
• Bisexuality: Genetics and Effects of the Sexual Behavior A homosexual is a person who is attracted to people of the same gender either physically, emotionally or sexually. Heterosexuals are people who are attracted physically, emotionally, and sexually to people of the opposite sex.
• Genetics’ Role in Healthcare of Patents This paper focuses on genetics role in healthcare of patents and defines the language of genetic manipulation, its safety, legal and ethical issues, as well as mandatory screening and the role of the healthcare providers […]
• Genetic Mutation and Noonan Syndrome In general, the more nucleotide sequences that are impacted by a change, the more significant the impact of the conversion and the greater the likelihood that the mutation would be harmful.
• Genetic and Genomic Technology Positive results mean that a patient has been diagnosed with the disease, and so treatment is essential to ensure the patient’s good health.
• Biological and Genetic Influences on Criminality Men are twice as likely to be the victim of an assault or a robbery and 50 percent more likely to experience some crime of theft.
• Genetic Manipulation of Human Embryos: Bioethical Issues Nonetheless, although the modification of human genotype may help in achieving a perfect genetic composition and eliminate a number of genetically transmitted diseases, there is a looming risk. The assembling of genetic makeup to enhance […]
• Genetically Modified Foods and Pesticides for Health There is fear that insects such as bees could bring about the emergence of insects that are resistant to insecticides due to coming in contact with the genetically modified pollen.
• Privacy in Genetic Testing and Restriction of Access to Own Personal Information In a workplace context, genetic testing is associated with the most obvious intrusion of privacy within the aspects of job insurance coverage and promotion.
• Comparison of Theories of Addiction: The Biological Model and the Genetic Model Genetic and biological models aim at disclosing the essence of addiction as something natural and irreversible and the methods which are supported by neurobiology and physiology and become more appropriate for using and controlling human […]
• The Genetic Basis of Human Cancer This is one of the most difficult in curing, as it may affect any part of the body, and seriously damage the body tissues.
• Human Genetic Engineering: Key Principles and Issues There are many options for the development of events in the field of genetic engineering, and not all of them have been studied. To conclude, human genetic engineering is one of the major medical breakthroughs, […]
• Influence of Genetic Factors on Personality Heritability of personality is one of the most contentious issues in the field of modern psychology. Overall, the use of general personality characteristics in the analysis of twins compromises the reliability of evidence.
• Mitochondrial Diseases Treatment Through Genetic Engineering Any disorders and abnormalities in the development of mitochondrial genetic information can lead to the dysfunction of these organelles, which in turn affects the efficiency of intracellular ATP production during the process of cellular respiration.
• Preimplantation Genetic Diagnosis and Manipulation The promise of such disease reduction measures may inspire propositions from minorities in ECOSOC to advocate for PGD’s accessibility and investment in research.
• Aspects of the Genetic Enhancement Genetic enhancement means using genetic editing technologies to introduce changes into the genome of the fetus to achieve improvements in the physical or mental health of the future child.
• Patenting of Genetic Information Completing the sequencing of the nucleic acid sequence of the human genome led to the mass patenting of genes in the United States.
• Genetic Engineering: Is It Ethical to Manipulate Life? In the case of more complex operations, genetic engineering can edit existing genes to turn on or off the synthesis of a particular protein in the organism from which the gene was taken.
• Cystic Fibrosis: A Comprehensive Overview of the Genetic Causes and Pathophysiology In the development of cystic fibrosis, three main points are leading: lesions of the external secretion glands, changes in the connective tissue, and water and electrolyte disorders.
• Genetic and Environmental Impact of the Chornobyl Disaster The ecological impact of the explosion on the lands surrounding Chornobyl comes first. Chornobyl remains the worst in human history due to radioactive contamination.
• Genetics and Antipsychotics: Usefulness of Pharmacogenetic Analysis The response to antipsychotics can be observed as complex phenotypes, a combination of genetic and clinical elements, and symptoms that vary in severity as well as in adherence level.
• Crop Genetic Erosion: Understanding and Responding to Loss of Crop Diversity The recombining and shuffling of genes are expected to create more complexity and increase the capacity of the species to survive in the changing world.
• Can the Human Race Survive Without Genetically Modified Food? Although genetically modified food is a recent invention, the humankind will be unable to survive without it due to the rise in the global population.
• Children’s Temperament and Personality: Genetic Basis Biology is seen to play a major role in influencing children’s temperaments and personality traits, with outcomes being a result of genetic determination.
• The Morality of Prenatal Genetic Screening Most of the time, “genetic screening has been more associated with this option in the collective mental, rather than the possibility to better address a specific condition, leading to the complex discussion of an ethical […]
• Genetic Technology Integrated in Modern Society​ The recombinant DNA technique has a variety of uses and has enabled the development of novel enzymes that are well-suited for usage in particular food processing settings.
• Genetically Modified Organisms: Benefit or Harm? In other words, scientists may choose the DNA of the foods that some individuals may be allergic to, which can be harmful if they eat GMO crops.
• Experimentation in Inheritance and Genetics Eventually, a solution to the problem of development not referring to the cytoplasm was reached. In this regard, it is evident that experimentation plays a central part in the history of inheritance and genetics.
• Breast Cancer as a Genetic Red Flag It is important to note that the genetic red flags in Figure 1 depicted above include heart disease, hypertension, and breast cancer.
• T. Dobzhansky’s Input to Synthesis in Genetics One of the chapters titled “Dobzhansky, Waddington, and Schmalhausen: Embryology and the Modern Synthesis” discusses his views on the evolutionary theories of Schmalhausen and Waddington.
• Role of Nutritional Genetics in Health In the recent past, there has been a heightened interest in applying genomic technologies to comprehend the role of diet in disease development and health.
• Historical Development of Embryology and Epigenetics The theory of preformationism was widely recognized from the late 17th to the end of the 18th century. This concept proposed the occurrence of the generation of offspring due to the unfolding and development of […]
• Genetic Screening: Advantages and Disadvantages The results of screening can be used for monitoring a patient, the prevention of occurrence of certain diseases, and the treatment of diseases after diagnosis.
• Ethical Analysis: Preimplantation Genetic Diagnosis Furthermore, it is imperative to ascertain the goals of the therapy and the probability of achieving success. The last step in this model of decision-making is acting.
• Epigenetics: How Twin Mice Can Look Different In contrast to genetic changes, epigenetic shifts can be reversed because they have no impact on the DNA sequence; however, they can impact the way in which one’s organism reads the sequence.
• Genetically Modified Organisms (GMOs) in Food Production Thus, in case of GMOs, it is necessary to acknowledge the internal motivations and character in people that adhere to this type of food production.
• Aspects and Characteristics of Epigenetics In addition, the value of this source is that it shows the relationship between epigenetics and the occurrence of abnormalities such as diabetes and obesity.
• International Bioethics and Genetics Genetic discrimination is a problem of bioethical significance in which a patient’s confidential rights are violated to create favorable conditions on the part of the person or company who is the subject of the discriminatory […]
• The Ethical Dimensions of Genetic Testing If there is a hereditary condition that runs in the family, a DNA test can detect the presence of such conditions.
• Breast Cancer: Genetics and Malignancy In the presence of such conditions, the formation of atypical cells is possible in the mammary gland. In the described case, this aspect is the most significant since it includes various details of the patient’s […]
• Genetically Modified Organisms: Ethical Perspective Of course, some use the deontological approach and state that it is simply wrong to interfere with genetic codes as it is the divine domain.
• The Ethics of Genetic Modification In particular, the discussion of genetic modifications circulates around the possibilities of human embryo modifications and ethical considerations of the consequences of such experiments.
• Researching the Concept of Epigenetics When it comes to the considerations of epigenetics in terms of a disease for which an individual is at high risk, it is necessary to consider family history as well as environmental factors that add […]
• Genetics and Genomics in Healthcare Development The fourth dwells on the global utilization of genetics and genomics research while the fifth is an analysis of the influence of various factors on the utilization of genomics and genetics in healthcare.
• Genetic Disease in a Pregnant Woman and Fetus The patient should consider the relationship between oncogenesis and pregnancy and consider folic acid to maintain birth defects. Folic acid is a common supplement during pregnancy to make new cells and prevent the development of […]
• Triplet Nature of the Genetic Code One of the assumptions of molecular biology from an evolutionary perspective is that the triplet nature of the genetic code is a traditional form of two-nucleotide coding.
• Epigenetics: Analysis of Article Based on the completed family history assessment, I would not wholly link my risk metric to the outcome of the investigation and infer that I am vulnerable to the above-identified conditions. The outcome could be […]
• Idea of “Designer Babies” and Genetic Manipulations To date, the idea of “designer babies,” which claims that it is possible to alter the genes of the embryo, carrying out specific genetic manipulations, is becoming pretty popular but needs to be explored more.
• The Role of Genetics and Diet of Acne in Teenagers It is significant that the number of relapses, the duration of the course of therapy, and the increase in the number of patients with moderate and severe forms of acne directly depend on the adherence […]
• Examination of Albinism Genetic Disease In the majority of albinos, the lack of melanin leads to such symptoms as the absence of pigmentation in skin and hair.
• Gene Therapy and Genetic Enhancement On the other hand, genetic enhancement targets modifying the genes to augment the aptitudes of an organism outside the ordinary. Somatic gene editing impacts the cells of an individual under treatment and it is inherited […]
• The Reasons for Genetic Counseling According to Abacan, “genetic counseling is the process of helping people understand and adapt to the medical, psychological and familial implications of genetic contributions to disease”.
• Kidney Stones and Patient’s Genetics and Epigenetics Citrate inhibits the development of kidney stones through the formation of calcium citrate complexes thereby preventing the formation of insoluble crystals.
• Cloning: Genetically Identical Copy The clone develops in the womb and eventually, the adult female gives birth, with the new clone having an identical genetic makeup to the organism from which the somatic cell originated.
• Epigenetics: Subject and Example of Study Epigenetics refers to the study of how behaviors and the environment can cause changes that affect the way genes work. They are not static in the human body and are dynamically altered by changes in […]
• Down Syndrome Genetics and Behaviors Using current research literature on behavioral issues and novel treatments for Down syndrome, this paper explores and discusses behavioral inflexibility, restrictive and repetitive behaviors, and Down syndrome’s neurogenetic nature.
• Genetics: Only Girls Born in Miejsce Odrzanskie, Poland However, it may also be necessary to understand the limitations of such a study and consider the possibility of a coincidence.
• Genetic Testing: Advantages and Disadvantages At the same time, I acknowledge all the benefits that genetic testing can bring in terms of diagnosing a wide range of diseases and conditions.
• Mitosis and Genetic Makeup of Different Species As the centromeres of a cell align among the spindle equator, the genetic material of the maternal cell is duplicated, which allows for the two daughter cells to emerge.
• ZIP Code Prevails Over Genetic Code One of the health determinants is diet, which depends directly on the climate a person lives in and the scope of food products they can afford.
• Genetic Modification and Cloning Even though it is hard to predict all the outcomes of genetic modification and cloning, I would suggest using CRISPR Cas9 in treating retinal diseases such as the one described in the case study.
• Color Blindness and Its Genetic Nature Nevertheless, color blindness genes may be carried by the non-color-blind female and transferred to future generations. Depending on the mutation, inherited color blindness may be congenital or may reveal itself in childhood or adulthood.
• Genetic Modifications of Human and Animal Species As for the genetic modification of animals and insects, it can also be beneficial. In the case of humans, there must also be clear boundaries for modification.
• Environmental and Genetic Factors That Influence Health The factors of inaccessibility of proper treatment, poor lifestyle, and environmental agents’ exposure combined with the costs of addressing the CKD challenge lead to disparities in populations.
• SCN8A-Related Epilepsy – Genetic Seizure Disorder The paper contains the discussion of the standardized procedure for this diagnosis, suggests how the present experience would affect the medical practice concerning this kind of epilepsy.
• Molecular Genetics: Gene Sequence Homology The emergence of the Mendelian genetics in the 19th century and the discovery of DNA structure by James Watson and Francis Crick in the 20th century have paved the way for the development of molecular […]
• Genetic Testing: Screening for Colon Cancer This disorder is characterized by the development of hundreds of thousands of adenomatous polyps in the colon and rectum early in life.
• DNA Profiling and Required Genetic Testing The reliable tests for conducting genetic testing should be more than one in order to remove the element of doubt on matching DNA bands.
• The Relationship Between Epigenetics and the Effects of the Holocaust Tests are most likely to identify existing changes of DNA and the proteins related to DNA, which are responsible for the structure of the DNA and the availability of other elements related to the DNA.
• Acute Myeloid Leukemia: Genetic Features of Black Patients According to the researcher, the differences in the biological impact of disease and the socioeconomic factors play a crucial role in the disparity between the Blacks and the Whites in the recovery process.
• Resolving Genetic Issues or Playing With Mother Nature? Because mother nature is essential in sustaining human life, it is not right to play with mother nature. It is not right to play with mother nature because of the consequences of playing with her.
• Genetically Modified Food: Health Risks The main research question of the future study for me as a person with 1st Degree in Food and Nutrition will be the question of the harm of eating genetically modified foods and the possible […]
• Barlow’s Syndrome: Genetics of Mitral Valve Prolapse and Its Clinical Impact For the patients with mitral valve prolapse experiencing the episodes of tachycardia and rapid heartbeats the use of beta-blockers is allowed. The patient should be allowed to share their concerns and feelings about the mitral […]
• The Development of the Neural System and Genetic Program In the process of determining the connections worth keeping, a person’s brain takes into account their lived experiences and daily life, which in turn shape the direction of a person’s neural growth.
• Genetic Disorder: “A Genetic Link to Anorexia” The author effectively proves that the development of anorexia nervosa may occur not only due to the exposure to the social pressure of beauty standards, but also the presence of a genetic predisposition.
• Genetic Enhancement: Ethical Aspect In addition, it can take the shape of cosmetic modifications, which change the overall basis of human uniqueness and the unalterable aspect of the human body.
• Genetic Modification and Implicit Bias Against People With Disabilities There is also a factor of disabilities that are life-threatening to a child, or illnesses that may be able to be fatal within the first few years of life.
• Biotechnology and Genetic Engineering Apart from that, there are some experiments that cannot be ethically justified, at least in my opinion, for example, the cloning of human being or the attempts to find the gene for genius.
• Genetics and Genomics in Healthcare The first phase was used to determine the suitability of the survey tool while the main survey led to the collection of the desired data.
• Genetics, Reproductive and Cloning Technology in “Frankenstein” If Mary Shelley was for the idea of cloning technology, I think her novel would have ended up with Frankenstein creating a female companion for the monster to compliment the theme of love in the […]
• Genetic Mapping in the United States Genetic mapping is allowed and regulated by the Genetic Information Non-discrimination Act in the United States. On the contrary, genetic mapping of children in the United States can be conducted with the consent of a […]
• Knowing One’s DNA Genetic Makeup: Pros and Cons In addition, the knowledge that one might not get a job or insurance because of their genetic makeup is stressful and depressive.
• Genetics of Human Social Behavior Twin study method addresses questions such as what effects do environmental factors have on the twin similarities and twin differences.study which stands for Genome wide association is a method that seeks to establish the components […]
• The Factors That Cause Instances of Genetic Diversity Genetic diversity is a term that is used to refer to the difference in characteristics that occurs among members of the same species.
• Genetic Testing: Should You Bother to Exercise? However, some people are of the view that the effect of genetic variation on exercise-mediated body responses is dismal. This argument is usually based on the idea that several other factors such as diet, lifestyle, […]
• Genetic Screening for Mandatory Obesity Screening of Children The progress in behavioral genetics points to the significance of biological heredity in character traits, as well as in medical conditions. A good example is in the case of cancer where the affected genetic condition […]
• Genetically Modified Food: Analysis and Implications A section of scientists are opposed to the idea with claims that it brings about irreversible damage to biodiversity by changing the natural setting of the environment. Genetic engineering involves alteration of the cell which […]
• Epigenetics of High Fructose Corn Syrup at a Molecular Level Increasing or decreasing the amount of glucose concentration level in the blood, directly affects the concentration of fructose in blood, since they all act as determinants of the overall blood concentration In this case, high […]
• Genetic Engineering in the Movie “Gattaca” by Niccol This would not be right at all since a person should be responsible for their own life and not have it dictated to them as a result of a societal construct created on the basis […]
• Modern East Asians and Denisovans Share Genetic Material The researchers did not explain the specific mode of delivery of the genetic material through hybridization thus it must be assumed that the Denisovans in Siberia were able to travel to Southeast Asia and intermarry […]
• Genetic Counseling – Tay Sachs Disease In this case, there is a 25% likelihood of passing the gene to their children. This would be effective in preventing further passing down of the disease to their offspring.
• Psychiatric Genetics. Epigenetics and Disease Pathology The switching on and off of the imprinted genes is the same regardless of the parental origin. The genome-wide DNA analysis revealed that there was a difference in DNA methylation of the glucocorticoid receptor gene […]
• The Genetics of Crime: ‘Criminal Gene’ The idea that criminal and offending behavior stands in the correlation with the genetic features of the offender is not a novelty of our time.
• Genetic Family Historical Analysis In the family, Andrew is the only member who thinks that his disease is caused by a genetic predisposition. The above implies that Andrew should work closely with his physicians to ensure his therapy is […]
• Genetic Counseling Analysis To take a detailed family history, I would start with gathering the information about the consumers. Finally, I would ask about the members of the family who have already passed away and clarify the cause […]
• Genetics and the Asthma Case The allergies she complains of are some of the symptoms associated with asthma. Asthma is also known to attack children below the age of 15 years.
• Genetic Engineering Using a Pglo Plasmid The objective of this experiment is to understand the process and importance of the genetic transformation of bacteria in real time with the aid of extrachromosomal DNA, alternatively referred to as plasmids.
• A Genetic Clue to How Limbs Evolved From Fins The purpose of the study is to unveil the mechanisms of the evolution and change of fin to limb. The researchers used a morphological analysis of fossils and skeletons of modern animals, which supports the […]
• Genetic Inheritance and Its Role in Obesity This essay therefore analysis the different formations of obesity, the causes and in particular the significance of inheritance in the occurrence of obesity.
• Managing Diabetes Through Genetic Engineering Genetic engineering refers to the alteration of genetic make-up of an organism through the use of techniques to introduce a new DNA or eliminate a given hereditable material. What is the role of genetic engineering […]
• Genetic Diseases: Sickle Cell Anemia This genetic disorder research paper aims to elucidate the underlying molecular causes of SCA as well as its symptoms, inheritance, treatment, diagnosis, and prevalence in certain populations.
• Genetically Identical Twins and Different Disease Risk The study of MZ twins offers fascinating insights that help researchers explore the link between the sequence of the genotype and the phenotype.
• Genetic Disorders That Can Be Treated With Gene Therapy It is in this context that the application of gene therapy has increased the hope of medical professionals in overcoming and controlling such failures in the treatment of genetic disorders.
• Using Genetically-Modified Bacteria to Fight Cancer at Johns Hopkins To do so, a concise summary of the article will be provided, followed by a review of its relevance to the course.
• Diabetes Mellitus Type 2: The Family Genetic History This paper aims at analyzing family genetic history of a family, evaluating the impact of the family history on an adult participant’s health and planning a future wellness change to promote the wellness of the […]
• Forecast of Genetic Technology Therefore, this essay forecasts the advancement of genetic technology in the 22nd century in aspects of gene therapy and eugenics with the view of assessing its potential benefits and dangers.
• Genetic Male Pattern Baldness Vertex hair loss: Vertex hair loss can be observed on the top of the head which is crown area and does not touch the hairline of the forehead.
• Watching Television: Genetic Influence This can be testified by the manner the research question correlates to the dynamics of examining why watching TV has such a huge influence on genetics.
• Museum Genetic Presentation When this condition is violated, the population is opened allowing individuals to move from one population to another hence creating a net flow of genes which results to genetic variations and consequently, to evolution.
• Genetic Information in the Trosack Case The purpose of this essay is to integrate genetic information in the Trosack case to ensure that the patients can deal with the genetic basis of the disease in their child.
• Advanced Pathophysiology: Genetic Technology In accordance to Tay-Sachs disorder, the specialist is likely to provide the following information: the origin of the disorder, what factors contribute to the occurrence of the disorder, characteristics of the disorder, treatment if available […]
• Effects of the Interaction Genetic Diversity This study though is trying to show the synergism between the UV-B and low genetic diversity as possible proof of the hypothesis that the UV-B could be the possible cause of declining amphibian populations.
• Genetics of Prostate Cancer and Physical Features However, even though observations attest to the highly hereditary nature of the disease, research in the field so far has proved to be inconclusive, with most scientists failing to isolate the gene or genes which […]
• Criminal Justice and DNA: “Genetic Fingerprinting” DNA is one of the popular methods used by criminologists today, DNA technique is also known as “genetic fingerprinting”.the name given the procedure by Cellmark Diagnostics, a Maryland company that certified the technique used in […]
• Genetic Basis of Fitness Differences in Natural Populations In the article to summarize, the authors recognized that one way genomics affect biology is the possibility of identifying and studying how the characteristics affecting fitness, a key issue in natural selection, are genetically based.
• Computational Modelling and Genetic Regulatory Networks Analysis in Development The studies also include the control of transcription and the mechanisms of RNA maturation. The key determinants of cell fate are the transcription factors.
• Biotechnology and Animal Welfare: How Genetically Modified Chicken Serves the Demand in Fast Food Chains Beef was the most often used meat for the restaurants due to its containing in burgers, however, in 2020, the tendency started to move in the direction of chicken consumption.
• Breast Cancer Risk Factors: Genetic and Nutritional Influences However, the problems of genetics contribute to the identification of this disease, since the essence of the problem requires constant monitoring of the state of the mammary glands to detect cancer at an early stage.
• Breast Cancer Genetics & Chromosomal Analysis In this paper, the chromosomal analysis of breast cancer will be assessed, and the causes of the disorder will be detailed.
• The Role Genetics Information Plays in Treating Cancer Another process that also causes the disease to develop is called gene amplification and refers to the situation of the emergence of multiple copies of the same gene.
• Ethical Issues on Genetic Modified Baby: CRISPR-Ca9 Genetic Modification The discussion presented below gives a detailed analysis of the subject of genetically modified babies and the ethical values associated with the entire scientific process.
• Biotechnology, Genetics and Reproduction On the one hand, this is an opportunity to become parents for infertile couples, on the other hand, the ART industry acts as a new type of business and, therefore, we can talk about the […]
• Leukemia Types: Characteristics, Genetics, and Symptoms Leukemia is widely referred to as a group of blood cancers and is classified by the type of white blood cells and by the rate of disease progression over time.
• Evolutionary Biology: Program Model at Genetic Level The constant development of new technologies, natural sciences, and ideological factors causes a change in perceptions of the human body’s model and the impact of social processes on the behavior of the individual.
• Genetics of Sexual Orientation: Privacy, Discrimination, and Social Engineering The study tested the DNA of 400 gays and established a section of the X chromosome called Xq28. The outcome of the research is not limited to the research team only.
• Clinical and Genetic Aspects of Neurofibromatosis Neurofibromatosis is an autosomal dominant genetic disorder that is caused by a mutation of a gene and characterized by a growth of tumors in nerves which may affect the structure of bones and skin conditions.
• Genome: Bioethics and Genetic Engineering Additionally, towards the end of the documentary, the narrator and some of the interviewed individuals explain the problem of anonymity that is also related to genetic manipulations.
• Researching the Genetic Enhancement: Unethical Practice and Social Norms One of the challenges that have emerged with the advent of genetic enhancement is the inability to ensure that all people have access to the technology.
• Genetic Test’s Availability to Employers and Insurers The introduction of genetics has gone a long way in sparking a heated debate as to why such companies are finding it necessary to introduce it to the list of information that the assured must […]
• Genetically Modified Foods: Substantial Equivalence Main principle of this concept is that genetically modified foods should be considered safe and reliable as conventional foods if the nutritional quality and compositions of GM foods are same as conventional foods.
• The Interrelationships and Implications of Genetic Discoveries In addition to this, the new sub-discipline comes with the ability to illuminate controversial topics within the field of medical sociology such as stem cell research and analysis of the interrelationships in human embryo and […]
• The Debate Pertaining to Genetic Modification This article looks at the setting up of a body, Royal Commission on Genetic Modification or the acronym RCGM on May 2000 to collect views from both the members of the public and scientific experts […]
• Genetic Predisposition to Alcohol: The Appreciation and Therapy for Alcoholism Through family studies it has been established that the likelihood of alcohol dependence and similar complications happening is more in the families of the individuals who have been affected as compared to in the people […]
• Epigenetics Influence on Adopted Embryos The exciting news is the role of epigenetics or influence of the adoptive mother’s body has on the DNA of the embryo as it grows using the mother’s nourishment, energy, and systems.
• Mental Illness Around the World: Socio-Cultural and Genetic Aspects Discussing the relationship between socio-political concept of people’s cultural identity and the degree of their susceptibility to mental illnesses represents a certain challenge, especially given the fact that the etiology of such illnesses has not […]
• Genetically Modified Organisms: For and Against The fact is that, genetic modification is the changing of the DNA code by the means of the genetic engineering, thus, the genes of the organisms are deviating from the normal genes of similar organisms, […]
• Ethical Problem of Genetic Testing and Chromosomal Abnormalities The testing can also be done to diagnose the genetic disorder, detecting future risks of contracting diseases as a result of genetic disorders, how these disorders respond to drugs, and detecting the extent of risks […]
• Unlocking Human Genome: Genetic Testing and Screening In the case of 64 year old Joe Miller, I recognize and understand that the patient has the right to die with dignity and that that includes dying on his own terms.
• Genetics of Parkinson Disease-Associated PARK2 Gene The following description highlights various aspects of the Human Genome Project that are thought to be connected in a series of events in influencing the cloning of the PARK2 gene.
• Genetic Research and Related Promises & Concerns More than 4000 diseases are thought to result from the defective functioning of a gene or a set of genes and if it were possible to identify the location or site of each gene on […]
• Genetic Difference in Explaining Athletic Performance Thus, St Louis argues that science on race and sports is not viable as it limits the explanation to physiological factors ignoring the importance of social and economic variables.
• The Various Aspects of Genetic Research Even a slight change in the pairing of the nucleotides will completely change the behavior of the human in question. Also, the genetic engineering helps the scientist to find out what is the function of […]
• Anderson and Genetic Research, Evolutionism & Creationism Creationists, for their part, have went on challenging and debating the essential standards of evolutionary biology, by rejecting the notion that progress is the only believable elucidation of the origin of life and modification in […]
• Genes and Environment: Genetic Factors and Issues Analysis Even at the very beginning when the egg combines with the sperm the organism is more then merely the genetic information contained in those parts, the egg contains important nutrients that will interact with the […]
• Genetic Engineering Is Ethically Unacceptable However, the current application of genetic engineering is in the field of medicine particularly to treat various genetic conditions. However, this method of treatment has various consequences to the individual and the society in general.
• Genetic Analysis: Term Definition and Molecular Genetics Experiments A 2 l of the DNA was pipetted from the tube labelled “DNA” to a new tube labeled ” Diluted” to which a 38 l of TE buffer was added and mixed gently.
• Issues of Sharing a Patient’s Genetic Information
• Ethical Issues Involving Genetic Test Accounts
• Creating a Genetically Modified Organism
• Genetics: State of Otter Conservation
• Genetic Basis for Alcoholism
• Genetically Modified Potato as Hepatitis B Vaccine
• Genetic Predisposition to Breast Cancer: Genetic Testing
• Genetic Testing Under Americans With Disabilities Act
• Genetic Counseling Preventing Pulmonary Arterial Hypertension
• Genetic Screening of Newborns and Its Benefits
• Evolution of Limbs: Fossil and Genetic Information
• Understanding Genetically Modified Foods by Howard et al.
• Next Generation Sequencing in Genetics
• Cystic Fibrosis: Genetics and Gender Factor
• 23andMe, a Genetics and Health Company
• Crispr/Cas9 Impact on Medical Genetics
• Growing GMO Seeds: Monsanto Corporation
• Genetic Disorders: The Turner and Down Syndromes
• Genetically Modified Foods: Pros or Cons
• Why Human Genetics Is Important
• Plasmids, Their Characteristics and Role in Genetics
• Type 2 Diabetes From Cultural and Genetic Aspects
• Genetic Testing in the Neonatal Realm: Technique of Assessing a Predisposition
• Genetic Testing and Related Health Issues
• Genetics: the Eugenics Movement
• Genetics: “Bad Blood” Educational Series by BBC
• Genetically Engineered Food Against World Hunger
• Genetic Mapping and Its Social, Ethical, and Legal Implications
• Genetic Factors of Huntington’s Disease Progression
• “Intelligence, Race, and Genetics” by Sternberg et al.
• Genetic and Social Bond Theories in Criminology
• Epigenetics and Its Role in Cancer Detection and Prevention
• The Role of Epigenetics in Cancer: Contributors to the Formation of Cancer Tumors
• Genetics: the Erroneous Concept of Blending Inheritance
• Genetically Modified Foods: Pros and Cons
• Genetic Factors of Speech Coding at the Subcortical Level
• Reproductive and Genetic Technology in Infertility Treatment
• Genetically Modified Seeds in Environmental Context
• Genetically Modified Foods: Scientific Resources
• Genetically Modified Organisms in Canadian Agriculture
• What Concepts Create Misconception in Genetics?
• Genetic Testing Limitation: Ethical Perspective as a Framework
• Genetically Modified Salmon Labeling Issues: Biotechnology, Religious Beliefs, and Eating Preferences
• Molecular Genetics and Biological Inheritance
• Thalassemia as a Genetic Disorder and Its Management
• Huge Ethical Concerns: Human Genetic Creation and the Bible
• Down Syndrome as the Most Common Genetic Condition in the US
• Danville Airlines’ Genetic Testing and Screening
• Concept of Genetic Cross Among Drosophila Melanogaster
• Prostate Cancer, Its Genetics and Prevention Methods
• Biodiversity, Its Evolutionary and Genetic Reasons
• Genetic Testing & Counseling and Their Value
• Abortion: Quality of Life and Genetic Abnormalities
• Ethics of Genetic Testing: Screening and Monitoring
• Advanced Diagnostic Procedures: Genetic Screening Pros and Cons
• Evolutionary Theory and Genetics
• Froma Harrop Views on Genetically Modified Food
• Genetics and Sociological Theories
• Genetically Modified Organisms in Farming
• Nutrition: Is Genetically Modified Food Bad or Good?
• Natural Sciences: Genetics Processes
• GMO Production: Reasons and Potential Effects
• Genetically Modified Foods: Should They Be Consumed?
• Do Our Genes Determine Learning Ability?
• Benefits and Concerns Regarding Genetically Modified Crops
• The Genetics of Alcohol Dependence
• Genetic Experimentation and Development
• Genetic Modification and Testing: Ethical Considerations
• Should Parents Be Allowed to Choose the Characteristics of Their Children Through Genetic Manipulation?
• Schizophrenia Genetic and Environmental Factors
• Ecological Effects of the Release of Genetically Engineered Organisms
• In Vitro Fertilization and Pre-implantation Genetic Diagnosis
• Epidemiology: Genetics-Related Programs
• Advanced Diagnostic Procedures: The Individual Impact of Genetic Diagnosis
• Possible Benefits of New Genetics
• The Effect of Genetically Modified Food on Society and Environment
• Proposition 37 and Genetically Engineered Foods
• Genetically Modified Food of Monsanto Company
• How Do Genetic and Environmental Factors Contribute To The Expression of Depression?
• Genetically Modified Corn in the United States of America
• Genetic and Cultural Differences Are Not Two Opposites
• The Human Genome Project and Its Revolutionary Insight into the Genetic Blue Print of the Human Body
• The Underpinnings of Genetic Diversity – Contribution of Darwin and Vavilov
• Genetically Modified Food and European Consumer Behavior
• Genetically Modified Foods Projects
• The Extent of Genetic Experimentation and Developments
• Genetically Modified Organisms and Controversial Discussions in Australia
• Overview on the Effects of Genetically Modified Food
• Is It Ethical to Abort Based On Genetic Disability?
• The Biotechnology Importance in Genetic Modification
• Can Genetically Modified Food Feed the World: Agricultural and Biotechnological Perspective
• Agriculture and Genetics Disciplines Relationship
• Genetically Modified Foods Negative Aspects
• Analyzing the Prospects of Genetically Modified Foods
• Will Genetically Modified Foods Doom Us All?
• The Specifics of Society Genetic Constitution
• Single Nucleotide Polymorphisms Genetic Epidemiology
• The Evolutionary Genetics of Mycobacterium Tuberculosis
• Genetically Modified Foods and Environment
• The Debate Pertaining to Genetically Modified Food Products
• Is Genetically Modified Food Safe for Human Bodies and the Environment?
• Consumer Judgment on Genetically Modified Foods
• Genetic Alteration of Food Sources: A New Strategy to Improve Food Production
• Business Ethics-Labeling Genetically Modified Food
• Objection to the Production of Genetically Modified Foods
• The Importance of Facial Attractiveness on Genetic Diversity
• Ethical Implication of Human Genetics Research
• Is Genetically Engineered Food the Solution to the World’s Hunger Problems?
• Towards Understanding the Causes of Genetic Diversity
• The Correlation Between Genetics and Environmental Lifestyle
• The Roles of Genetics and Nurture on People with Dyslexia
• Tourette Syndrome: Symptoms, Causes, and Genetics
• The Relationship between Genetics and Religion
• The Theory Of Inheritance Within The Field Of Genetics
• An Analysis of the Role of Genetics and Environment in Causing Alcoholism
• Understanding the Basics of Genetics and Its Diseases
• Nature, Nurture and Egalitarian Policy: What Can We Learn from Molecular Genetics
• Significance of Discoveries in Genetics and DNA
• Winter Wheat Breeding, Genetics, And Cultivar Development
• The Issue of Genetics and Intelligence in the Article All in the Genes
• The Use of Genetics in Insurance and Impliations
• The Contribution of Family History, Age and Genetics to the Development of Alzheimer’s Disease
• Masters Program With The Department Of Molecular Genetics
• The Development Of Genetics Food Modifying Techniques: Analyzing The Effect Of Continuing Development
• Why Genetics Is Important And A Huge Part Of Our Lives
• Molecular Genetics: Catching the Criminal Using Electrophoresis
• The Importance of Genetics and Individuality in the Formation of a Personality
• How Does Genetics Affect The Achievement Of Food Security
• The Inheritance of Economic Status: Education, Class, and Genetics
• An Overview of the Principles Behind the Genetics and the Biochemical Prosprects
• The Importance Of Mendel’s Laws In Modern Genetics
• The Role of Genetics and Social Structure to the Rising Rate of Homicide in Miami
• The Effects Of Genetics And Environment On Biofilm Growth
• The Ethical Issues Surrounding the Field of Genetics Technology
• The Major Scientific Breakthroughs of Introns and Exons in Genetics
• What Part Do Genetics Play In Autoimmune Diseases
• The Genetics, Structure, Function, And Regulation Of Alpha Amylase
• Ongoing Intelligence Debate and Considerations of Environment, Culture, and Genetics
• The Genetics of Addiction Hereditary or Learned Behaviour
• The New Genetics of Mental Illness by Edmund S. Higgins
• The Importance of Family, Community and Culture Over Genetics and Individual Characteristics in Outliers, a Novel by Malcolm Gladwell
• The Cause of Our Overall Fear and Its Link to Genetics and Evolution Process in Our Fear of Immigrants, an Article by Jeremy Adam Smith
• The Life and Work of Gregor Mendel, the Father of Genetics
• The Establishment of a State Fisheries Genetics Program in Illinois
• Politically Correct Fanatics Their Denial Of Patterns And Genetics Among People
• The Significance of Selective Engineering in Genetics
• Genetics And The Possible Causation Of Autism Spectrum Disorders
• The Evolutionary Factors That Have Shaped The Genetics
• The Engineering Of Human Genetics In Dreams And Nightmares
• The Public and Private Sectors in the Process of Innovation: Theory and Evidence from the Mouse Genetics Revolution
• The Aspects of the Connection between the Environment and Genetics
• An Analysis of Scientific Knowledge About Founder Mutations in Genetics
• James Watson and his Contributions DNA and Genetics
• The Causes of Aging in Humans and the Impact of Genetics and Lifestyle on Age
• Genetics: Alcoholism and Normative Developmental Trajectory
• Is Homosexuality A Personal Choice Or Is It Genetics
• Will Genetics Destroy Sports?
• How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?
• Are Gender Roles Defined by Society or by Genetics?
• How Did the Drosophilia Melanogaster Impact Genetics?
• Does Genetics Affect Childhood Obesity?
• How Does Genetics Affect the Achievement of Food Security?
• Can Crop Models Identify Critical Gaps in Genetics, Environment, and Management Interactions?
• How Does Genetics Influence Human Behavior?
• Does Genetics Matter for Disease-Related Stigma?
• How Did Dolly Sheep Change Genetics Forever?
• Is Genetics Responsible for Allergies?
• How Does Genetics Affect Caffeine Tolerance?
• Can Genetics Cause Crime or Are We Presupposed?
• How Does Genetics Affect Child Development?
• Is Genetics Responsible for Mental Illnesses?
• How Do Genetics and Environment Affect a Child’s Behaviors?
• Can Genetics Reveal the Causes and Consequences of Educational Attainment?
• How Do Genetics and the Environment Influence One’s Self-Identity?
• What’s Genetics Engineering?
• How Do Neuroscience and Behavioral Genetics Improve Psychiatric Assessment?
• Why Will Tampering With Our Genetics Be Beneficial?
• How Does the Environment Change Genetics?
• Will Benchtop Sequencers Resolve the Sequencing Trade-off in Plant Genetics?
• Why Is Genetics Important in Real Life?
• How Does Genetics Play a Role in Aging?
• Chicago (A-D)
• Chicago (N-B)

IvyPanda. (2024, February 26). 341 Genetics Essay Topic Ideas & Examples. https://ivypanda.com/essays/topic/genetics-essay-topics/

"341 Genetics Essay Topic Ideas & Examples." IvyPanda , 26 Feb. 2024, ivypanda.com/essays/topic/genetics-essay-topics/.

IvyPanda . (2024) '341 Genetics Essay Topic Ideas & Examples'. 26 February.

IvyPanda . 2024. "341 Genetics Essay Topic Ideas & Examples." February 26, 2024. https://ivypanda.com/essays/topic/genetics-essay-topics/.

1. IvyPanda . "341 Genetics Essay Topic Ideas & Examples." February 26, 2024. https://ivypanda.com/essays/topic/genetics-essay-topics/.

Bibliography

IvyPanda . "341 Genetics Essay Topic Ideas & Examples." February 26, 2024. https://ivypanda.com/essays/topic/genetics-essay-topics/.

• Down Syndrome Topics
• Nature vs Nurture Research Topics
• Biomedicine Essay Topics
• Disorders Ideas
• Animal Ethics Research Ideas
• Discovery Ideas
• Disability Essay Topics
• Gender Inequality Research Topics

• Previous Article

Cover Image

Introduction, the human genome and variation, chromosome structure and chromosomal disorders, the sex chromosomes, x and y, single-gene disorders, mitochondrial disorders, epigenetics, complex disorders, cancer: mutation and epigenetics, genetic testing in the diagnostic laboratory, diagnosis, management and therapy of genetic disease, challenges in delivering a genetics service, competing interests, author contribution, appendix. glossary of terms, abbreviations, further reading: the human genome and variation, the genetic basis of disease.

• Split-Screen
• Article contents
• Figures & tables
• Supplementary Data
• Peer Review
• Open the PDF for in another window
• Cite Icon Cite
• Get Permissions

Maria Jackson , Leah Marks , Gerhard H.W. May , Joanna B. Wilson; The genetic basis of disease. Essays Biochem 3 December 2018; 62 (5): 643–723. doi: https://doi.org/10.1042/EBC20170053

Download citation file:

• Ris (Zotero)
• Reference Manager

Genetics plays a role, to a greater or lesser extent, in all diseases. Variations in our DNA and differences in how that DNA functions (alone or in combinations), alongside the environment (which encompasses lifestyle), contribute to disease processes. This review explores the genetic basis of human disease, including single gene disorders, chromosomal imbalances, epigenetics, cancer and complex disorders, and considers how our understanding and technological advances can be applied to provision of appropriate diagnosis, management and therapy for patients.

When most people consider the genetic basis of disease, they might think about the rare, single gene disorders, such as cystic fibrosis (CF), phenylketonuria or haemophilia, or perhaps even cancers with a clear heritable component (for example, inherited predisposition to breast cancer). However, although genetic disorders are individually rare, they account for approximately 80% of rare disorders, of which there are several thousand. The sheer number of rare disorders means that, collectively, approximately 1 in 17 individuals are affected by them. Moreover, our genetic constitution plays a role, to a greater or lesser extent, in all disease processes, including common disorders, as a consequence of the multitude of differences in our DNA. Some of these differences, alone or in combinations, might render an individual more susceptible to one disorder (for example, a type of cancer), but could render the same individual less susceptible to develop an unrelated disorder (for example, diabetes). The environment (including lifestyle) plays a significant role in many conditions (for example, diet and exercise in relation to diabetes), but our cellular and bodily responses to the environment may differ according to our DNA. The genetics of the immune system, with enormous variation across the population, determines our response to infection by pathogens. Furthermore, most cancers result from an accumulation of genetic changes that occur through the lifetime of an individual, which may be influenced by environmental factors. Clearly, understanding genetics and the genome as a whole and its variation in the human population, are integral to understanding disease processes and this understanding provides the foundation for curative therapies, beneficial treatments and preventative measures.

With so many genetic disorders, it is impossible to include more than a few examples within this review, to illustrate the principles. For further information on specific conditions, there are a number of searchable internet resources that provide a wealth of reliable detail. These include Genetics Home Reference ( https://ghr.nlm.nih.gov/ ), Gene Reviews ( https://www.ncbi.nlm.nih.gov/books/NBK1116/ ), the ‘Education’ section from the National Human Genome Research Institute ( https://www.genome.gov/education/ ) and Online Mendelian Inheritance in Man ( https://www.omim.org/ ). In this review, an understanding and knowledge of basic principles and techniques in molecular biology, such as the structure of DNA and the PCR will be assumed, but explanations and animations of PCR (and some other processes) are available from the DNA Learning Center ( https://www.dnalc.org/resources/ ). The focus here will be on human disease, although much of the research that defines our understanding comes from the study of animal models that share similar or related genes.

The human genome and the human genome reference sequence

The complete instructions for generating a human are encoded in the DNA present in our cells: the human genome, comprising roughly 3 billion bp of DNA. Scientists from across the world collaborated in the ‘Human Genome Project’ to generate the first DNA sequence of the entire human genome (published in 2001), with many additions and corrections made in the following years. Genome sequence information for humans and many other species is freely accessible through a number of portals, including the National Center for Biotechnology Information (NCBI; https://www.ncbi.nlm.nih.gov/ ) and Ensembl ( http://www.ensembl.org/ ), which also provide a wealth of related information.

The majority of our DNA is present within the nucleus as chromosomes (the nuclear DNA or nuclear genome), but there is also a small amount of DNA in the mitochondria (the mtDNA or mitochondrial genome). Most individuals possess 23 pairs of chromosomes ( Figure 2 ), therefore much of the DNA content is present in two copies, one from our mother and one from our father.

The human nuclear genome encodes roughly 20000 protein-coding genes, which typically consists of both protein-coding (exon) and non-coding (intron) sequences. Our genome also contains roughly 22000 genes that encode RNA molecules only; some of these RNAs form components of the translation machinery (rRNA, tRNA) but there are many more that perform various roles within the cell, including regulation of expression of other genes. In fact it is now believed that as much as 80% of our genome has biological activity that may influence structure and function. The human genome also contains over 14000 ‘pseudogenes’; these are imperfect copies of protein-coding genes that have lost the ability to code for protein. Although originally considered as evolutionary relics, there is now evidence that some may be involved in regulating their protein-coding relatives, and in fact dysregulation of pseudogene-encoded transcripts has been reported in cancer. Additionally, sequence similarity between a pseudogene and its normal counterpart may promote recombination events which inactivate the normal copy, as seen in some cases of perinatal lethal Gaucher disease. Furthermore, some pseudogenes have the potential to be harnessed in gene therapy to generate functional genes by gene editing approaches. The distribution of genes between chromosomes is not equal: chromosome 19 is particularly gene-dense, while the autosomes for which trisomy is viable (13, 18, 21) are relatively gene-poor ( Table 1 ).

Note that although these numbers seem very precise they should be taken as indicative only, since (i) chromosomes of each individual will vary from the reference sequence, and (ii) the human reference genome sequence is continuously updated with corrections (the data here are from GRCh38.p12, which represents a particular ‘build’ of the human genome). Note that the data for the acrocentric chromosomes 13, 14, 15, 21, 22 does not include the shared ribosomal DNA array repeats present on the p arms (see Figure 2 ). Data from Ensembl, June 2018.

From the very beginning of the Human Genome Project, it was recognised that there was a huge amount of DNA sequence variation between healthy individuals, and therefore there is no such thing as a ‘normal’ human DNA sequence. However, if we are to describe changes to the DNA sequence, we need to describe these changes with respect to some baseline; this baseline is the human reference genome sequence.

Variation versus mutation

A geneticist’s definition of mutation is ‘any heritable change to the DNA sequence’, where heritable refers to both somatic cell division (the proliferation of cells in tissues) and germline inheritance (from parent to child). Such changes to the DNA may have no consequences but sometimes lead to observable differences in the individual (the ‘phenotype’). Consequently, in the past such alterations in the human population, particularly when they were associated with a disease state, were referred to as ‘mutations’. However, for many people this terminology has negative connotations, and brings to mind the ‘mutants’ seen in science fiction and zombie films! Therefore modern practice, particularly for medical genetics within the context of a health service, is to refer to differences from the reference sequence as ‘variants’. Variants may be further classified as benign (not associated with disease) or pathogenic (associated with disease), although there are increasing numbers of human DNA variants identified for which we are still not sure of the effect; these are termed ‘variants of uncertain significance’ or VUS ( Table 2 ).

Although this system was designed for classification of variants in relation to a potential role in cancer predisposition, it can also be used to classify variants in other situations.

Where two (or more) different versions of a DNA sequence exist in the population, these are referred to as ‘alleles’: each allele represents one particular version (or variant) of that sequence. By analysing many human genomes we can calculate the frequency at which a particular variant occurs in the population, often expressed as the ‘minor allele frequency’ or MAF. Where the MAF is at least 1%, a variant can be called a ‘polymorphism’, although this is a fairly arbitrary cut-off.

Single nucleotide variants: The most frequent variants in our genome are substitutions that affect only one base pair (bp), referred to as single nucleotide variants (SNV) or as single nucleotide polymorphisms (SNP) ( Figure 1 ) depending upon the MAF. It has been estimated that there are at least 11 million SNPs in the human genome (averaging approximately 1 per 300 bp). It also seems likely that if we sequenced the genomes of everyone on the planet, for most positions in our genome we would discover at least one individual with an SNV, wherever such variation is compatible with life.

Some types of variants found in human genomes

Variation involving one or a few nucleotides are shown above the chromosome icon, and structural variants below; in each case the variants are depicted in relation to the reference sequence. For depiction of structural variants A, B, C and D represent large segments of DNA; Y and Z represent segments of DNA from a different chromosome. Note that differentiation between CNVs and deletions/insertions depends upon the size of the relevant DNA segment (see text for further details). Abbreviation: CNV, copy number variant. Chromosome ideogram from NCBI Genome Decoration Page.

Insertions and deletions (indels): Insertions or deletions of less than 1000 bp are also relatively common in the human genome, with the smallest indels being the most numerous.

Structural variants: Structural variants are defined as variants affecting segments of DNA greater than 1000 bp (1 kb). They include translocations, inversions, large deletions and copy number variants (CNV). CNVs are segments of our genome that range in size from 1000 to millions of bp, and which, in healthy individuals, may vary in copy number from zero to several copies ( Figure 1 ). By analysis of many human genomes it is apparent that CNV exists for approximately 12% of the human genome sequence. The largest CNVs may contain several entire genes. Where the population frequency of a CNV reaches 1% or more, it may be referred to as a copy number polymorphism (CNP).

Repeat variations: Human genomes contain large numbers of repetitive sequences. These include ‘interspersed repeats’ which constitute approximately 45% of our genome, and represent remnants of mobile DNA elements (transposons). There are also several classes of ‘tandem repeats’, in which the repeated units are side-by-side in a head-to-tail fashion forming arrays of repeats of the same (or very similar) sequence. The number of repeats in each array can vary, generating multiple alleles, so that these loci have high variability within the population, and can be used in identifying individuals (see below). Tandem repeats include minisatellites and microsatellites ( Figure 1 / Table 3 ). Although generally inherited stably (i.e. with the same number of repeats) from parent to child, expansions in some microsatellites are associated with disease.

Note that repeats with unit lengths of 7–9 bp may be classified as micro- or minisatellites depending on their biological behaviour.

Many (but not all) authors include mononucleotide repeats in the category of microsatellites.

Variation between healthy individuals

Given that no two individuals look exactly alike (apart from identical twins) it will come as no surprise that this is reflected in our DNA. What is surprising is the amount of variation between us. Looking at any one human genome, compared with the reference sequence, we would find approximately 3 million SNPs, and approximately 2000 structural variants. The genomes of any two unrelated individuals will differ in approximately 0.5% of their DNA (approximately 15 million bp), and most of this variation can be attributed to CNVs and large deletions. Although much of the variation in our genome lies within the non-coding DNA, we now know that, on average, each individual has several hundred variants that are either known, or predicted, to be damaging to gene function, including roughly 85 variants that lead to truncated (incomplete) protein products. Furthermore, the total number of functional genes per human genome may vary by up to 10% between individuals as a consequence of CNVs, large deletions and loss-of-function variants. Faced with this enormous level of variation you might wonder, not why some individuals are affected by disease due to inherited ‘mutations’, but rather how any of us manage to remain relatively healthy! Clearly there is no requirement for all of our genes to be functional: for many genes only one working copy is required, and in other cases there appears to be a level of redundancy or plasticity built into the system. However it is becoming increasingly apparent that some of the variations in our genomes may lead to higher susceptibility to common diseases.

Variation between populations

The greatest amount of variation is found within populations of African ancestry, which is consistent with initial migration out of Africa, with each group of migrants taking subsets of variants with them. Common variants tend to be shared between all populations, whereas rare variants are more likely to be specific to particular populations or related populations. Some of the differences will be related to environmental adaptation, for example skin pigmentation or enzymes to detoxify dietary plant toxins. These same enzymes are also responsible for the metabolism of many pharmaceutical (and recreational) drugs; genetic variants may lead to some individuals being ultrarapid metabolisers or poor metabolisers, which may translate into poor drug response or adverse side effects. For example, deficiency in dihydropyrimidine dehydrogenase, leading to a toxic response to the cancer treatment 5-fluorouracil, is two to three times more common in African-American populations than in Caucasians.

DNA profiling

In the early 1980s, with the discovery of minisatellites, which are highly variable within the population but inherited stably from parent to child, it became possible to use these in forensic analyses and paternity testing, to generate unique patterns (similar to supermarket barcodes) for each individual, a technique referred to as ‘DNA fingerprinting’. This technology needed large amounts of sample (micrograms of DNA) and tended to be time-consuming (1–2 weeks) in addition to requiring use of radioactive labels. Towards the end of the 1980s, microsatellites were first reported and since these could be analysed with simple and rapid PCR-based assays, needing only approximately 1 nanogram of sample DNA, ‘DNA profiling’ using microsatellites quickly replaced the earlier DNA fingerprinting approach. Forensic DNA profiling in the U.K. currently analyses 16 microsatellites from across the genome, together with a region from the amelogenin gene present on both X and Y chromosomes that is 4 bp different in size between them, allowing gender identification. The process is similar to QF-PCR for prenatal aneuploidy testing, which will be discussed later. Finding a perfect match between the two samples (e.g. from crime scene and suspect) strongly suggests that these came from the same individual – the likelihood of finding a perfect match between samples from two different individuals is estimated at 1 in a billion – unless of course they are identical twins. On the other hand, if the two samples do not match, it can be concluded that the crime scene sample was not from the suspect. Likewise, in paternity testing, DNA profiling can exclude a man as the father of a child, but cannot prove he is the father with absolute certainty. DNA profiling is also useful in helping to identify human remains, for example where decomposition makes physical identification difficult. The fact that certain variants (including microsatellite alleles) are more frequently found in populations of particular ancestry means that the capability already exists to make some inferences on likely ancestral origin based on only a DNA sample and research is underway to establish whether particular features (for example, eye colour, hair colour and even facial characteristics) can be predicted from DNA. Thus the DNA profiling of the future may generate an identikit image of a wanted individual.

De novo mutations and mosaicism

Most of the variants in our genome were inherited from one of our parents. However, our DNA is constantly bombarded with DNA damaging agents and furthermore every time a cell’s DNA is replicated prior to division there is opportunity for errors. Genomic sequencing of trios (child plus both parents) has demonstrated that on average each individual has 74 de novo SNVs that were not present in either parent, in addition to approximately three de novo insertions/deletions. Approximately 1–2% of children will have a de novo CNV greater than 100 kb in size. Microsatellites have a relatively high mutation frequency, with gain or loss of a repeat unit occurring in roughly 1 per 1000 microsatellites per gamete per generation. In contrast with aneuploidy, which is most often a consequence of meiotic error during oocyte generation, new mutations are almost four times more common in the male germline than the female germline, which is likely to relate to the high number of cell divisions during spermatogenesis. For both sexes the new mutation rate increases with age, though again, the increase is more marked in the male germline. Most new mutations will have little or no effect on health, particularly those outside coding sequences, but some are associated with disease.

If a new mutation occurs during embryogenesis or development this can lead to mosaicism, where some cells in the individual have that new variant while others do not. Mosaicism for a new mutation may also be present in the gonads (‘gonadal mosaicism’), such that a new variant may be transmitted to less than 50% of the offspring, depending upon the percentage of gonadal cells in which the new variant is present. New mutations occurring during embryogenesis and development also generate a few differences between the genomes of identical twins.

Very rarely fusion of two embryos will generate a chimera: an individual that has two genetically distinct cell lines present. Where the same sex chromosome constitution is present in both cell lines chimerism might only come to light with the observation of apparent non-maternity or non-paternity amongst offspring (where one cell line predominates in the gonads and the other predominates in blood cells). Fusion of two embryos of different sex can lead to characteristics of both genders being present, and chimerism is found in approximately 13% of cases of hermaphroditism.

The massive amount of variation between individual human genomes can make it very difficult to determine which variants are benign and which might be associated with a disease. Even where a disease-associated variant is present, this will be present within a genomic context of millions of other differences from the ‘reference’ sequence, some of which may impact upon the severity of that disease in the individual. Thus it will become increasingly common to investigate wider genomic influences when considering contribution of variants to disease. Note that several scientific conventions are used when referring to chromosomes, genes, proteins and variants affecting them; these ensure unambiguous communication between scientists and health professionals. International System for Human Cytogenetic Nomenclature (ISCN) is used for describing karyotypes and changes at the chromosomal level. Individual loci and genes, for which there are often multiple different historical names, have now been assigned specific unique names by the HUGO Gene Nomenclature Committee (HGCN) ( https://www.genenames.org/ ). Sequence variants are described according to Human Genome Variation Society (HGVS) guidelines ( http://varnomen.hgvs.org/ ) for both DNA and proteins. Finally, since the same names are applied to genes and the proteins they encode, italics are used to refer to the gene, with standard font used when referring to the protein.

Almost every human cell contains a full diploid genome, consisting of 2 metres of DNA arranged into 46 chromosomes: 22 homologous autosomal pairs, and the sex chromosomes comprising two X chromosomes in females and an X and a Y in males. The exceptions are anucleate cells like erythrocytes (red blood cells), cell fragments (platelets) and haploid germline cells (sperm and eggs) which contain 23 chromosomes. Although mechanisms have evolved which ensure that during cell division, daughter cells will inherit a complete genome, those mechanisms occasionally make mistakes. This can lead to cells with chromosomal abnormalities, which can be categorised as numerical abnormalities, i.e. the resulting daughter cell contains too many or too few chromosomes, or structural abnormalities, where more complex rearrangements of the genome have taken place.

The normal chromosome complement of a species (i.e. the number, size and shape of chromosomes) is called its karyotype. According to the ISCN, the ‘normal’ human karyotype is denoted by either 46,XX (female) or 46,XY (male). Human chromosomes consist of DNA which is wrapped around a core of histone proteins to form chromatin. Most of the time, chromatin exists in a diffuse form within a cell’s nucleus, however, during metaphase of the cell division cycle, the chromosomes condense. It is these condensed chromosomes which can be stained with a variety of chemicals, and which can then be observed under a light microscope, to reveal the characteristic banding patterns. The bands reflect regions of chromatin with different characteristics, and therefore different functional elements. A photographic representation of a person’s metaphase chromosomes, arranged by size, may be referred to as a karyogram or karyotype ( Figure 2 A,B) and a graphical representation is called an ideogram ( Figure 2 C). The available stains for chromosomes differ in their chemical properties and consequently in the resulting banding pattern. The most commonly used stain is called Giemsa after the chemist who developed it in 1904; the resulting banding pattern of chromosomes is referred to as G-banding. The microscopic analysis of stained chromosomes is termed cytogenetics. Depending on the quality of the chromosome preparation, trained cytogeneticists can identify abnormalities with a resolution of approximately 3–4 Mb (millions of bp), however, abnormalities below this resolution threshold cannot be identified using conventional cytogenetics and require alternative, molecular techniques (see section ‘Genetic testing in the diagnostic laboratory’).

Giemsa banding (G-banding) to form a karyogram

( A ) Metaphase spreads like this are obtained from cultured cells arrested in metaphase using colcemid, followed by Giemsa staining to create characteristic light and dark bands. Generally the dark bands represent regions which are AT-rich and gene-poor. ( B ) The chromosomes from the spread are arranged in pairs to view the karyotype, often using specialist software like Cytovision. ( C ) Diagrammatic representations of the G-banding patterns, called ideograms, are used as a reference. The ideograms have been aligned at the centromere (dotted line); blue shaded regions are highly variable – note for example the variation between p arms of chromosome 13, 14 and 15 in (B). In fact the p arms of the acrocentric chromosomes (13, 14, 15, 21, 22) all have very similar content, which includes the nucleolar organiser regions or NORs. Each NOR contains a tandem repeat of ribosomal DNA (rDNA) which encodes the rRNAs. Between all five acrocentrics there are approximately 300–400 rDNA repeats, though the actual number varies between individuals. Chromosome ideograms from NCBI Genome Decoration Page.

When viewing condensed metaphase chromosomes under a microscope, some key features can be identified ( Figure 3 ). All mammalian chromosomes have a centromere, which appears like a narrow waist, here proteins attach for separation of chromosomes during cell division. In humans, the centromere is located between the two arms of the chromosome, the shorter arm is called the ‘p’ arm (for ‘petite’), while the longer arm is called ‘q’ (‘queue’). Depending on the location of the centromere relative to the two arms, human chromosomes are classified as ‘metacentric’, where the centromere is more or less in the middle of the chromosome, ‘submetacentric’, where the centromere is somewhat offset from the centre or ‘acrocentric’, where the centromere is significantly offset from the centre, with only a very short p arm. In some species such as the mouse, the centromere is located at one end of the chromosome, termed as telocentric. In humans, chromosomes 1, 3, 16, 19 and 20 are metacentric, chromosomes 13, 14, 15, 21, 22 and Y are acrocentric, while the remainder are submetacentric. In eukaryotes, the structures at the ends of each linear chromosome are called telomeres and consist of 300–8000 repeats of the sequence TTAGGG, which forms a loop at the end. One function of telomeres is to protect the ends of chromosomes from being recognised as ‘damaged DNA’ and erroneously repaired by the cell’s DNA repair machinery. They also accommodate the loss of sequences during each round of replication, which occurs as a result of the so-called ‘end replication problem’. In cells without the enzyme telomerase (which extends existing telomeres), a short stretch of sequence is lost from the 5′ end of the newly replicated strand with each cell division, which ultimately can lead to cell senescence.

Chromosome structure and band nomenclature

This ideogram of the complete chromosome 8 illustrates the general structure of all human chromosomes: short (p) and long (q) arms, joined at the centromere. Each chromosome has a characteristic G-banding pattern, with each band annotated, for example p22 or q23. In chromosomes which are less condensed, more bands are seen as separate entities, while bands may merge together in more condensed chromosomes (for example, q21.1, q21.2 and q21.3 appear as a single band [q21] in a more condensed chromosome 8). The approved way of stating the location q21.1 is q-two-one-point-one ( not q-twenty-one-point-one). Telomeres, with a shared structure, are present at both ends of each chromosome. Each telomere is composed of arrays of TTAGGG repeats, followed by a subtelomere, which is formed of repetitive sequences which can be similar between several telomeres. Chromosome ideogram from NCBI Genome Decoration Page.

Numerical abnormalities

An abnormality where a cell contains more than two complete sets of the human haploid genome (69 chromosomes or more) is termed as polyploidy. Triploidy (three haploid sets of chromosomes) occurs in 1–3% of pregnancies and usually arises from fertilisation of a single egg with two sperms or sometimes from fertilisation involving a diploid gamete (egg or sperm). Viability of triploid foetuses is usually very low and leads to early spontaneous abortion during pregnancy while tetraploidy (four haploid sets of chromosomes) is even rarer and not compatible with life. However, a situation where the chromosome number is not an exact multiple of the haploid chromosome number is called aneuploidy.

Aneuploidy usually arises because a gamete is formed that contains more or fewer chromosomes than the normal complement. This results from a phenomenon called non-disjunction, where the replicated chromosomes do not separate properly at cell division, and can happen during either meiosis I (non-disjunction of paired chromosomes) or meiosis II (non-disjunction of sister chromatids) ( Figure 4 ). Non-disjunction generates germ cells which either contain an extra copy of one of the chromosomes or lack one chromosome. Fertilisation then leads to the formation of a zygote with an extra chromosome or a missing chromosome respectively ( Figure 5 ). Non-disjunction most commonly occurs during meiosis II of oocyte formation, and is influenced by the mother’s age and other environmental factors. The risk of delivering a trisomic foetus increases from 1.9% in women aged 25–29 years to over 19% in women aged over 39 years. There is also evidence that folic acid deficiency, smoking, obesity and low-dose irradiation with radioactive contaminants increases the risk of non-disjunction.

Principles of meiosis and non-disjunction

For simplicity, only one pair of newly replicated autosomes is shown in two different colours to distinguish the maternal from the paternal chromosome and crossover is not considered. During spermatogenesis, all four meiotic products can form the gametes (sperm), while in oogenesis, only one of the four products will actually become the ovum (egg) as one daughter cell forms a polar body at meiosis I (MI) and another forms a polar body at meiosis II (MII). For clarity, all four potential meiotic products are shown. ( A ) During normal meiosis, four haploid meiotic products are formed. ( B ) If non-disjunction occurs during MI, two daughter cells are formed which completely lack this particular chromosome (nullisomic for this chromosome), while two others contain two copies of the chromosome (disomic). ( C ) If non-disjunction occurs during MII, one nullisomic and one disomic daughter cell is formed, while the remaining two form normally.

Fertilisation outcomes

( A ) Fertilisation of a normal oocyte with a normal sperm cell leads to the formation of a diploid (2n) zygote. ( B ) If a nullisomic oocyte is fertilised, the resulting zygote will be monosomic for one chromosome. ( C , D ) Fertilisation of a disomic oocyte results in trisomic zygotes. Note that in (C), the oocyte has resulted from non-disjunction in meiosis I, and the resulting zygote contains one chromosome (ignoring crossover) from each maternal grandparent as well as the paternal contribution. In (D), the oocyte has resulted from non-disjunction in meiosis II, and the resulting zygote contains two chromosomes (aside from crossover regions) from one grandparent.

Examples of syndromes caused by aneuploidy

Most aneuploidies are lethal. However, those that are viable are listed in Table 4 , together with approximate incidence rates and common symptoms. Foetuses with trisomy 13 or 18 may survive to term, while individuals with trisomy 21 can survive beyond the age of 40. Presence of an extra autosome generally leads to severe developmental abnormalities, and only trisomies of small, gene-poor chromosomes ( Table 1 ) appear to be tolerated. Autosomal monosomies have even more severe consequences, as they invariably lead to miscarriage during the early stages of pregnancy. The developmental consequences of such trisomies and monosomies are a result of an imbalance of the levels of critical gene products encoded on the affected chromosomes. For example, the major features of Down syndrome (DS) are associated with the presence of three copies of a 1.6-Mb region at chromosome location 21q22.2, called the Down Syndrome Critical Region.

Common names are given, where available, together with estimated incidence rates and symptoms frequently associated with the condition.

Having an abnormal number of sex chromosomes generally has milder consequences than abnormal numbers of autosomes and is discussed in more detail in the section ‘The sex chromosomes, X and Y’.

Structural abnormalities

DNA damage, e.g. by radiation or mutagenic chemicals, can lead to chromosome breaks. Complex cell cycle checkpoints prevent cells with unrepaired chromosome breaks, in particular free broken ends (i.e. ends without telomeres), from entering mitosis. DNA repair mechanisms exist which recognise chromosome breaks and attempt to repair them. However, these mechanisms occasionally repair broken chromosomes incorrectly, which can then result in chromosomes with structural abnormalities. Errors during recombination, e.g. between mispaired homologues, may also result in such abnormalities.

If a single chromosome sustains breaks, incorrect repair can lead to material being lost (deletion), inverted or incorporated into a circular structure: a ring chromosome. The resulting structurally abnormal chromosomes can be stably propagated during cell division, as long as they possess a single centromere. Chromosomes without a centromere are eventually lost. Chromosomes with two centromeres are rarely found, in these cases one centromere appears to be suppressed.

If single breaks occur in two separate chromosomes, incorrect joining of the resulting fragments may lead to the exchange of material between chromosomes (translocation). In a balanced reciprocal translocation DNA from two different chromosomes is exchanged without net loss. If both resulting hybrid (or ‘derivative’) chromosomes carry one centromere, they will be replicated and segregated stably. However, during gamete formation, it can happen that only one of the hybrid chromosomes, together with one of the unaltered chromosomes, are segregated into a gamete ( Figure 6 ). Fertilisation of such gametes leads to the formation of a zygote with partial trisomy of genetic material from one of the chromosomes involved in the translocation, and partial monosomy of material from the other participating chromosome. Depending on the location of the breakpoints, and therefore on how much genetic material is present in trisomic or monosomic form, such embryos can be viable, but have a high risk of developmental abnormalities. Nevertheless, approximately 1 in 500 individuals carry a balanced reciprocal translocation. These carriers frequently appear asymptomatic, however, there is an increased miscarriage rate associated with either parent being a translocation carrier and offspring of carriers may present with congenital abnormalities.

Segregation of reciprocal translocations

( A ) A carrier of a reciprocal translocation has one unaltered copy of each chromosome that participates in the translocation, together with two hybrid chromosomes. Only the relevant chromosomes are shown, for illustration each is labelled with a circled number. ( B ) During meiosis, replicated sister chromatids pair up with their homologues. In the case of a translocation carrier, so-called ‘quadrivalents’ can form, in which four instead of two chromosomes pair up. ( C ) Three possible segregation paths are illustrated. During ‘alternate’ segregation, chromosomes 1 and 4, and chromosomes 2 and 3 are segregated into separate gametes. ‘Adjacent 1’ and ‘Adjacent 2’ segregation leads to different combinations as indicated. Note that other segregation patterns can also occur, e.g. where three chromosomes segregate into one gamete, and only one into the other. ( D ) Only alternate segregation leads to gametes which either carry the two unaltered, ‘normal’ chromosomes, or the two hybrid chromosomes. Zygotes formed from these gametes are expected to be phenotypically normal (unless there is a critical gene disruption at the translocation breakpoint). However, in the other two instances, all gametes carry one unaltered and one hybrid chromosome. Fertilisation of these gametes leads to zygotes carrying partial trisomy of one chromosomal segment, and partial monosomy of a different segment.

A second type of translocation is the Robertsonian translocation. Here, two acrocentric chromosomes both break at the centromere, lose their short p arms, and form a single chromosome, containing one centromere and the q arms of both original chromosomes. Carriers of Robertsonian translocations are usually phenotypically normal since only a small amount of genetic material, the nucleolar organiser region (NOR), is present in the short arms of all acrocentric chromosomes (see Figure 2 ). Therefore, the loss of two short arms can be compensated by the remaining acrocentric chromosomes. However, similar to reciprocal translocations, gamete formation and subsequent fertilisation can lead to the formation of zygotes with either monosomy or trisomy of one of the participating acrocentric chromosomes and therefore children with chromosomal imbalances. As is the case with meiosis in carriers of translocations, meiosis in carriers of inversions can also lead to the formation of gametes carrying an unbalanced combination of chromosomes. Therefore, such carriers may also have children with chromosomal imbalances. Carrier frequencies for Robertsonian translocations and inversions which are not considered normal variants are estimated to be 1:1000 and 1:2000 respectively.

Truly balanced translocations and inversions do not lead to the net loss of genetic material, therefore only affect the phenotype of the carrier if either a chromosome break has disrupted an important gene or a break affects the expression of a gene without disrupting its coding region, e.g. by juxtaposing the complete coding region of one gene to the control sequences of a different gene.

Microdeletions, microduplications, CNVs

Molecular genetic analysis of patients with symptoms that cannot be explained using cytogenetics can lead to the identification of the underlying causes, which in many cases are microdeletions, microduplications and other CNVs. Such variations can involve single genes or relatively few genes, which can then allow researchers to determine which particular gene is responsible for specific symptoms. Table 5 shows example of microdeletion and microduplication syndromes, together with key genes, where known, and associated symptoms. Note that in some cases, both microdeletion of a key region as well as microduplication of the same region have been identified as causative for ‘reciprocal’ syndromes. An example is a 3.6-Mb region at 17p11.2, which, when deleted, causes Smith–Magenis syndrome, but when duplicated, causes Potocki–Lupski syndrome.

Where specific genes have been identified as associated with particular features of the syndrome these are noted, but this does not exclude a role for additional genes in the region. Extent of the deletions/duplications often varies between patients but in general larger imbalances are associated with greater severity of symptoms.

Primary sex determination in mammals is chromosomal, meaning that the development of the gonads into male (testes) or female (ovary) is determined by the sex chromosomes. The female caries two X chromosomes (46,XX) and the male has one X and one Y chromosome (46,XY). In some animals, sex determination is in part, or whole, environmentally determined (for example by temperature in most turtles), but in mammals, initiation of sexual fate is entirely driven by the chromosomes. Along with the haploid set of autosomes (22 in humans), each egg of the female has a single X chromosome, while the male can generate a sperm carrying either an X or a Y chromosome. If the egg receives an X chromosome from the sperm, the resulting XX individual will form ovaries through development and be female. If the egg receives a Y chromosome from the sperm, the resulting XY individual will form testes and be male ( Figure 7 ). The Y chromosome is relatively small (57 Mb, with 171 genes and of these only approximately one-third are protein encoding (see Table 1 )), but carries a gene that is crucial for the formation of the testes, encoding a testis-determining factor (TDF), also known as the sex-determining region Y ( SRY ) ( Figure 8 ). All else being wild-type, an individual carrying a normally functioning copy of this gene will develop as a male. Thus, if the Y chromosome is missing (45,X) or if SRY is deleted, female development will ensue, although, two X chromosomes are needed for complete ovarian development. Development of primary sexual characteristics aside from the gonads, that is the reproductive structures (penis, epididymides, seminal vesicles and prostate gland in males; oviducts, vagina, cervix and uterus in females) as well as secondary sexual characteristics (mammary glands in females, along with other sex-specific features such as size, musculature, facial hair and vocal cartilage) are determined by hormones that are secreted by the gonads and this is influenced by many other genetic and environmental factors. Oestrogen, secreted by the ovaries, directs female development, while the newly formed testes secrete anti-Müllerian duct hormone and testosterone which masculinises the foetus.

The X and Y chromosomes determine male or female sexual development

Males produce haploid gametes (sperm) that are either 23,X or 23,Y. Females produce haploid gametes (eggs) that are 23,X. Daughters inherit an X chromosome from their mother and an X chromosome from their father. Sons inherit an X chromosome from their mother and a Y chromosome from their father (paternal chromosomes indicated in blue, maternal chromosomes indicated in green).

Schematic map of the X and Y chromosomes

The X and Y chromosomes are depicted, showing the short (p) and long (q) arms and centromeres (black circle). The pseudoautosomal regions (PAR) 1 and 2 are highlighted in red. The sex-determining genes SRY and DAX1 are indicated. The location of the X inactivation centre (XIC) and the XIST gene is shown. Locations of other genes specifically mentioned in the text are indicated.

The X chromosome is relatively large (156 Mb) and incorporates approximately 1500 genes more than half of which are protein encoding (see Table 1 ), the vast majority of these have nothing to do with sex determination and are needed by both males and females. As such, the imbalance between males and females with respect to the number of X chromosomes in the genome (and therefore potential gene expression levels) needs to be rectified and this is accomplished by different mechanisms in different animal species. This balancing phenomenon, referred to as ‘dosage compensation’ is achieved in mammals by a process termed X chromosome inactivation. Early in development, in every cell in the female embryo, one of the two X chromosomes becomes inactivated, such that the majority, but not all, of the genes are not expressed from the inactive chromosome (Xi). As a consequence, the levels of expression of these genes on the active X chromosome (Xa) in female cells are equivalent to levels in male cells that only have one X chromosome. With respect to which of the two X chromosomes are inactivated, this occurs randomly from one cell to another, but then persists through subsequent cell divisions. This means that as development continues, female tissues become a patchwork, an expression-mosaic, with one of the two X chromosomes activated in some patches and the other X chromosome activated in adjacent patches. The result of this process is visible in female tortoiseshell cats, which are heterozygous for X-linked black and orange coat colour genes; the consequence of X inactivation is evident as random black and orange patches of fur in the adult. As a stochastic process, the proportion of cells that have inactivated the paternally inherited X chromosome, versus the maternally inherited X chromosome, will average 50% each. However, from one individual to another and even from one tissue to another within an individual, there can be considerable skewing from the 50% mean. Think of the tortoiseshell cat, most show roughly equivalent areas of orange and black fur, but some are more black than orange, while others are more orange than black. All female mammals are effectively expression-mosaics with respect to their X chromosomes.

One consequence for geneticists of the male-specific Y chromosome and X-inactivation in females is that the terminology of recessive and dominant allele variants becomes complicated. In addition, as described below, pathogenic allele variants on the X-chromosome can show hugely variable disease penetrance in females.

The pseudoautosomal regions

During human oogenesis, the two X chromosomes synapse in meiosis I and engage in crossover, exactly as the autosomes do. In male spermatogenesis, despite the X and Y chromosomes being of very different sizes and different genetic make-up, the chromosomes do pair (and undergo recombination) in meiosis, at short regions of homology at the ends of each chromosome. These regions are termed pseudoautosomal regions (PAR) 1 and 2 ( Figure 8 ), because they are present on both the X and Y chromosomes; most of the genes in these regions are not subject to X inactivation in females and they behave like autosomal sequences in terms of inheritance patterns. All genes tested within the larger PAR1 escape inactivation in female cells, thus both alleles are expressed in both male and female cells. The smaller PAR2 region has been a recent acquisition in evolutionary terms, there is no equivalent in the mouse (and even some primates). PAR2 genes behave differently. The two most telomeric genes of PAR2, IL9R and CXYorf1 , escape inactivation and are expressed from the Xi as well as Xa in female cells. However, two other genes of PAR2, SYBL1 and HSPRY3 , do become inactivated on Xi. To compensate for this in male cells, the Y chromosome alleles of these two genes are hypermethylated and not expressed, thus in both female and male cells, only one allele is expressed.

In addition to genes within the PARs, there are several homologous gene pairs (or gametologues) present on the X and Y chromosomes, that are located in the X and Y-specific regions, that do not undergo recombination. Consequently these gene pairs have diverged from one another through evolution and often have quite different sequence from each other, although may retain a similar function. An example is the RPS4X and RPS4Y pair, which encode ribosomal proteins of essentially the same function, but differ in 19 of the 263 encoded amino acids. RPS4X escapes inactivation, therefore both alleles are expressed in female cells, while male cells express both single alleles RPS4X and RPS4Y .

SRY, DAX1 and sex determination

The SRY gene is located on the short arm of the Y chromosome, just 5 kb away from the PAR1 boundary ( Figure 8 ). It encodes a transcription factor and is a trigger for driving male sexual development. In 46,XY individuals where the gene is dysfunctional or deleted, female development ensues. Furthermore, in approximately 80% of 46,XX male cases, the SRY gene is found translocated to an X chromosome.

In the developing embryo, a long and narrow structure called the genital ridge is the precursor to gonad formation in both sexes. The somatic cells of the genital ridge differentiate into either Sertoli cells, which promote the testicular differentiation programme or into granulosa cells, which promote ovarian differentiation. Expression of SRY in the genital ridge induces the start of Sertoli cell differentiation. While expression of SRY is brief, it initiates a cascade of events that will lead to male development. The next gene in the cascade is SOX9 , an autosomal gene (located on chromosome 17) which also encodes a transcription factor and is essential for testes development. Expression of SOX9 in the genital ridge acts to induce the expression of several other genes required for testicular development, and also anti-Müllerian duct hormone which suppresses ovarian development. Thus the reverse is the case during ovarian development in XX individuals, where SOX9 is repressed. Some rare 46,XX individuals who have an extra copy of the SOX9 gene, develop as males (despite the absence of an SRY gene). Conversely, individuals who have a non-functional variant of SOX9 or gene deletion, develop a syndrome called campomelic dysplasia (which involves multiple organ systems) and 75% of 46,XY patients with this syndrome develop as phenotypic females or hermaphrodites.

It was initially thought that female development was the default state in the absence of SRY, however, this does not accurately reflect the situation that female sexual development is an active, genetically controlled process. A gene on the X chromosome, DAX1 (aka NROB1 ), which encodes a hormone receptor/transcriptional regulator, is required for female sexual development. DAX1 is expressed in the genital ridge shortly after SRY and antagonises the function of SRY by interfering with the induction of SOX9 , in a dose-dependent manner. Normally, in 46,XY genital ridge cells, DAX1 is expressed from the X chromosome and SRY from the Y chromosome, in a ratio that leads to testes development. In 46,XX genital ridge cells, one copy of DAX1 is expressed (the other is inactivated on Xi), in the absence of SRY, to produce ovaries. However, if there are two active copies of DAX1 (for example, through gene duplication on Xa), along with SRY in 46,XY individuals, this leads to poorly formed gonads that produce neither anti-Müllerian duct hormone nor testosterone and individuals appear phenotypically female.

Following initiation of the female developmental pathway, several genes play a key role in female sexual development. The WNT4A gene (chromosome 1) encodes a secreted factor that is essential for the growth of ovarian follicle cells and is down-regulated by SOX9. The gene NR5A1/SF1 (on chromosome 9) encodes another transcriptional regulator important in both male and female pathways (as well as in the adrenal glands). Along with SRY, SF1 co-regulates SOX9 expression and is therefore critical in male sex determination. However, this multifunctional protein also plays a role later in ovarian follicular development. Thus, mutations in this gene can lead to disorders of sex development (DSD), including sex reversal, in both XX and XY individuals. Thus the SRY and DAX1 genes (present on Y and X chromosomes respectively) determine sex, as they act to flip the switch between male and female sexual fates. However, in each case, there are critical downstream regulators that promote one programme and/or inhibit the other programme and variant or mutated forms of these genes can cause DSD.

The human Y chromosome has 63 protein encoding genes, and aside from genes within the PARs and the gametologues, the majority are expressed in the testis and are involved in male fertility. The Y chromosome also has a large number (392 at last count) of pseudogenes. These have resulted from the fact that the Y chromosome (outside the PARs) has no recombination partner. As a consequence, through evolution, harmful gene mutations cannot uncouple (and thereby be selected against) from necessary genes and therefore such deleterious mutations, now in the form of pseudogenes, hitchhike along with the necessary genes.

The process of X inactivation

Early in female development (the early blastocyst), one X chromosome in each 46,XX cell becomes inactivated. This is initiated from a region called the X-inactivation centre (XIC) at Xq13 and in humans occurs at random, it can be either the X chromosome inherited from the mother, or the one inherited from the father. Inactivation starts with the expression of a long, non-coding RNA located within the XIC, called the X-inactive specific transcript ( XIST ), from the chromosome that will be silenced ( Figure 9 ). XIST RNA coats the chromosome from which it is expressed, spreading from the XIC outwards in both directions along the entire length of the chromosome. This then leads to several epigenetic changes along the coated chromosome, including depletion of RNA polymerase II, loss of histone acetylation and an increase in histone ubiquitination and repressive methylation to silence gene expression on Xi. The Xi chromosome becomes condensed and can be seen microscopically as a dense area to the side of the nucleus referred to as the Barr body (as it was first described by the cytogeneticist Murray Barr). The inactivation is stable through subsequent cell divisions so that the same Xi is maintained in each cell lineage throughout development and adult life, with the exception of the germline. In germ cells X inactivation is reversed, so that all oocytes contain an active X.

A simplified view of genes located at the XIC (not to scale), which maps at Xq13.2 on the human X chromosome and spans over 1 Mb. XIST (red) is surrounded by a number of other non-coding RNA genes (blue), which have an effect upon XIST regulation, including TSIX . Additionally, there are protein encoding genes (yellow), within the XIC region and recently RLIM has been shown to regulate XIST expression. Deletions across this region affect the process of X chromosome inactivation, but the function of all the genes and sequence regions located at XIC are yet to be fully understood.

At the XIC another non-coding transcript is expressed, partially overlapping and in the opposite (antisense) direction to XIST , the TSIX transcript is specifically expressed from the active X chromosome Xa ( Figure 9 ). TSIX acts locally as a negative regulator of XIST expression and protects Xa against inactivation. In conditions of aneuploidy, with more than two X chromosomes, only one X remains activated, which reveals that there is a counting mechanism at play. For each autosome set, one X chromosome remains active, although how this occurs is currently poorly understood. Deletion of XIC sequences (including the XIST and TSIX genes) from one X chromosome still allows inactivation of the other, wild-type X chromosome, in 46,XX individuals. Furthermore, in transgenic mice, introduction of an XIC into an autosome, renders the autosome subject to silencing. These studies show that the XIC (and XIST ) is required for initiation of chromosome inactivation in cis , but that the counting mechanism must involve factors and regions outside XIST and TSIX . It is thought that X chromosome inactivation (and the counting mechanism) must be regulated by X-encoded activators and autosomally encoded suppressors which control XIST . Recently, an X-linked gene, RLIM (or RNF12 ), located 500 kb upstream of XIST , has been identified as an important regulator of XIST expression, as the RLIM protein works to degrade an inhibitor of XIST transcription. However, the complexities of this process are yet far from being fully understood.

Approximately one-fifth of the genes on the X chromosome escape inactivation on Xi. These either have a Y chromosome homologue (for example, located in a PAR, as described above), or those that do not have a Y homologue tend to lie in clusters (mostly on the short arm, Xp) and apparently the 2:1 dosage (expression in female:male cells) is not problematic. It is thought that these genes are surrounded by a DNA sequence that binds a protein factor (termed CTCF) that can insulate the genes from the actions of XIST .

Due to the low gene count of the Y chromosome and the process of X inactivation, having an abnormal number of sex chromosomes has milder consequences than abnormal numbers of autosomes. Females with Triple X syndrome (47,XXX) or males with 47,XYY tend to be taller than average, but usually show few other physical differences ( Table 4 ) and have normal fertility, thus can go undiagnosed. X inactivation in 47,XXX cells will lead to the inactivation of two X chromosomes, so despite the presence of the trisomy, the vast majority of the X-linked genes will be expressed from just the single Xa in each cell. However, overexpression of genes that escape X inactivation (as described above) gives rise to the syndrome. In 47,XYY men, there is double the Y chromosome gene dose. Therefore, there will be double the levels of Y-specific gene expression and an extra dose of products of the genes that have an X chromosome homologue (one dose from X and two doses from Y). Males with 47,XYY, as well as the above noted features, tend to have an increased risk of behavioural, emotional and social difficulties.

Men with Klinefelter syndrome (47,XXY) carry an extra X chromosome and tend to be sterile, however symptoms are frequently very subtle ( Table 4 ) and only noticed at puberty. Again, one of the two X chromosome will be inactivated (Xi) in each cell, therefore, 47,XXY cells will only show overexpression of genes (compared with 46,XY cells) that escape X inactivation (in 47,XXX individuals, this extra expression is in the context of female development, while in 47,XXY individuals it is in the context of male development, so can have different consequences). Men with 48,XXXY display a more severe syndrome, resulting from the extra overexpression of genes that escape X inactivation, as well as the expression of Y-specific genes.

Complete loss of the X chromosome, 45,Y is early embryonic lethal. However, females with monosomy of chromosome X (45,X) or partial loss of an X chromosome, develop Turner syndrome ( Table 4 ). In 45,X cases where an entire sex chromosome (X or Y) is lost, the remaining X chromosome does not undergo inactivation, however, this leads to half the normal expression levels of genes that do not undergo X chromosome inactivation. As such, the loss of dosage of several of these genes contributes to the syndrome. In cases where there is only partial loss of the X chromosome, such individuals will display some features of the syndrome. A gene that lies within PAR1, with alleles on both X and Y chromosomes, SHOX ( Figure 8 ), is responsible for approximately two-thirds of the height deficit seen in Turner syndrome individuals. With loss of this region of the X chromosome, SHOX is expressed from the other allele, therefore at only half the usual levels and this is not sufficient (haploinsufficiency) to fully achieve its required growth-related function. Heterozygous loss-of-function mutations in this gene alone in both males and females causes Leri–Weill dyschondrosteosis which is characterised by skeletal dysplasia and short stature. Loss of function in both alleles causes Langer mesomelic dysplasia, which is associated with severe limb aplasia and severe height deficit. Conversely, duplication of the SHOX gene is associated with tall stature.

Pathogenic single gene variants

Haemophilia a, an example of x-linked recessive inheritance.

Haemophilia A is a condition where blood clotting is defective, due to deficiency in the activity of one of the blood clotting factors, factor VIII. Symptoms can vary considerably, from mild cases, where patients only bleed excessively after major trauma or surgery, to severe cases, where patients suffer up to 30 annual episodes of spontaneous or excessive bleeding, even after minor trauma. Factor VIII is encoded by the F8 gene, located on chromosome Xq28 ( Figure 8 ) and the gene is subject to X inactivation. There is no Y homologue, therefore if males inherit a pathogenic variant allele on the maternal X chromosome (or in 30% cases have a de novo mutation), they will be affected and disease severity will reflect the type of mutation (ranging from expression of a dysfunctional protein to complete absence of the factor). Females who are heterozygous, carrying one copy of a pathogenic variant allele, are generally asymptomatic and thus haemophilia shows a typical X-linked recessive inheritance pattern (see section on ‘Single-gene disorders’). However, as a result of X inactivation, some cells will express the wild-type F8 allele (from Xa), while other cells will express the pathogenic variant allele and the overall expression ratio between the two alleles can be 50:50 or skewed to one or the other. No cell will express both alleles. As a consequence, most female carriers produce enough factor VIII (between 30 and 70% of normal circulating levels, the variation depending both upon the nature of the variant allele and the degree to which it is Xi silenced) to appear largely unaffected. However, a significant proportion of female carriers do show some bleeding problems (for example, heavy menstrual bleeding) and in some cases (carriers who have less than 30% of normal factor VIII levels) can show mild haemophilia symptoms. In rare cases, where females inherit two variant alleles, they are more severely affected, as in males.

Rett syndrome, an example of X-linked dominant inheritance

Rett syndrome is an X-linked, dominant, neurodevelopmental disorder seen predominantly in females and becomes apparent in babies between the age of 6 and 18 months. After an initial phase of apparently normal development, individuals develop severe mental and physical disabilities, displaying coordination problems, slower growth, repetitive movements, seizures, scoliosis and other problems. The age at which symptoms first appear and the severity, varies considerably from one individual to another. Rett syndrome affects approximately 1 in 10000 females and is a single gene disorder involving the X-linked MECP2 gene. Due to the severity of symptoms, this usually arises as a de novo mutation. Boys with a similar mutation have a more severe phenotype, for example congenital encephalopathy, and die shortly after birth. MECP2 encodes a protein that binds to methylated DNA and has an important epigenetic function as a repressor of gene expression. Although the gene is normally expressed throughout the body, its function is essential in mature nerve cells and the phenotypic consequences of loss-of-function mutations (for example, loss of expression mutations or mutations that give rise to a non-functional protein) are most profound in the brain. The nature of the mutation and the extent to which the allele has lost function dictates one variable seen in disease severity. Additionally, the MECP2 gene is subject to X chromosome inactivation, this therefore also contributes to the variation seen in disease severity. If the mutant allele shows skewed inactivation (such that this allele is more frequently inactivated on Xi than the wild-type allele), this can result in considerably milder symptoms. It has been proposed that following X inactivation during development, cells which inactivated the chromosome carrying the wild-type MECP2 allele and therefore express the mutant MECP2 allele, may be selected against, resulting in a skewed X inactivation body pattern. In addition other genetic factors may exacerbate or alleviate the disease pathogenicity to contribute to the variation observed. The levels of MECP2 are critical and both too little and too much are deleterious. Therefore, mutations that result in overexpression of this gene give rise to a different syndrome ( MECP2 duplication syndrome). In males MECP2 duplication leads to severe intellectual disability and epilepsy; similar duplications in females lead to a more variable condition depending upon the proportion of cells that inactivate the X chromosome containing the duplication.

In conclusion, the presentation and severity of syndromes and diseases resulting from variants of the sex chromosomes are not only influenced by the nature of the variant itself, but also by the sex-linked ploidy of these chromosomes and the consequences of X chromosome inactivation.

Many conditions and diseases depend on the genotype at a single locus (or gene), with inheritance following Mendel’s laws of segregation, independent assortment and dominance. Therefore, these diseases are often called ‘Mendelian’ although not all inherited disorders follow Mendel’s laws (e.g. triplet-repeat diseases and imprinting disorders). To date, over 6000 phenotypes have been identified for which the molecular basis is known, these phenotypes and the associated genes are collected in the database OMIM (‘Online Mendelian Inheritance in Man’, https://www.omim.org/ ). Some well-characterised examples are shown in Table 6 .

Diseases are shown together with their inheritance patterns, the affected gene, the most commonly found types of mutation, and estimated incidence rates. Note, some diseases, for example osteogenesis imperfecta (of which there are several forms), can be caused by pathogenic variants in one of a number of different genes.

Modes of inheritance and examples

Mendelian diseases can be recognised by their characteristic patterns of inheritance in family trees or pedigrees. Pedigrees can also reveal if the locus in question resides on an autosome or a sex chromosome and if a genetic variant is dominant or recessive. To understand the concepts of dominant and recessive variants, it is important to recall that each diploid human cell carries two copies (called alleles) of each autosomal gene, one inherited from the mother and one from the father. Frequently, these alleles are not identical. A person carrying two identical copies of the same allele on both autosomes is homozygous for this allele, while a person carrying two different alleles is heterozygous for the locus. A dominant allele is one which leads to a particular phenotype (e.g. a genetic disorder) no matter if the second allele is ‘normal’ or not. This is because the second, ‘normal’ allele cannot compensate for the effect of the dominant allele. A recessive allele, on the other hand, does not lead to a phenotype on its own, here, the ‘normal’ allele is sufficient or can compensate. However, if a person inherits recessive alleles of a gene from both parents, then the corresponding phenotype is displayed because no ‘normal’ allele is present to compensate. Consequently, five distinct types of Mendelian inheritance patterns can be distinguished.

Autosomal dominant

A person with an autosomal dominant disorder usually has at least one similarly affected parent and on average 50% of their children will have the disorder. Such conditions are revealed in pedigrees ( Figure 10 ) because the disease occurs in each generation, affects both males and females, and transmission can occur from either parent to offspring of either sex. Frequently, but not always, autosomal dominant disorders are caused by genetic variants which convey a novel function to a gene product (termed gain-of-function). In this case, the presence of a ‘normal’, non-pathogenic allele of the gene on the homologous autosome cannot compensate for the altered function of the mutated gene. Note that autosomal dominant disorders can also be caused by loss-of-function alleles, if 50% of normal gene expression from the normal allele is not sufficient, a phenomenon termed haploinsufficiency.

Autosomal dominant inheritance and pedigree

( A ) Inheritance pattern of an autosomal dominant variant (red). Only the relevant chromosomes are shown. ( B ) Pedigree of a family with an autosomal dominant condition. ( C ) Key for pedigree symbols.

Autosomal recessive

Autosomal recessive conditions are caused by loss-of-function pathogenic variants which on their own do not lead to a recognisable phenotype. Here, the presence of a second, functional allele of the gene in question on the homologous autosome is sufficient to compensate. Consequently, such conditions only manifest themselves in individuals who carry pathogenic variants at both the homologous loci (either two identical or two different recessive variants). Usually, such individuals have two unaffected parents, who are both non-symptomatic heterozygous carriers of a single pathogenic allele ( Figure 11 ). The children of two carrier parents have a 25% chance of inheriting both pathogenic variants, while the children of affected individuals are obligate carriers of a pathogenic variant. Disease incidence is frequently increased in families where parents are consanguineous (related by descent). In families with multiple affected generations, autosomal recessive diseases often skip one or more generations.

Autosomal recessive inheritance and pedigree

( A ) Inheritance pattern of an autosomal recessive variant (red). Only the relevant chromosomes are shown. ( B ) Pedigree of a family with an autosomal recessive condition. See Figure 10 C for key to symbols.

X-linked recessive

Diseases which are caused by recessive variants in loci located on the X chromosome affect females and males differently. Males have a single X chromosome, therefore, if they carry a pathogenic variant, they have no second allele to compensate for its effect, and will be affected by the disease. All their daughters will inherit their X chromosome, therefore will be carriers, while their sons will be unaffected ( Figure 12 ). Since females carry two X chromosomes, they will typically only be affected by the disease if they inherited one pathogenic variant of the relevant gene from their (affected) father and a second pathogenic variant from their mother, who could be an unaffected carrier or a homozygous, affected individual. However, due to the phenomenon of X chromosome inactivation in females, such variants are often not completely recessive and can show some aspects of the phenotype in female carriers (as explained in the section ‘The sex chromosomes, X and Y’).

X-linked recessive inheritance and pedigree

( A ) Inheritance pattern of an X-linked recessive variant (red). Only the relevant chromosomes are shown. ( B ) Pedigree of a family with an X-linked recessive condition. See Figure 10 C for key to symbols.

X-linked dominant

A dominant pathogenic variant on the X chromosome will typically affect both males and females (but this is also complicated by X-inactivation). All daughters of an affected male will inherit the condition, while all of his sons will be unaffected. In the case of an affected female, if she has a single pathogenic variant, her children will have a 50% chance of being affected. However, if she has inherited a pathogenic variant from each of her parents, both her parents will typically have been affected, and all her children will also be affected. The actual situation may be more complicated, for example in late-onset conditions if an apparently unaffected parent died before they developed the disorder or if one of the pathogenic alleles is non-penetrant due to non-random X-inactivation. X-linked dominant disorders are rare, but examples are shown in Table 6 .

Since the Y chromosome is very small and only contains comparatively few genes, Y-linked single-gene disorders are even rarer than X-linked dominant ones. As much of the Y chromosome exists in a hemizygous state (with the exception of genes with homologues on the X chromosome), recessive and dominant definitions do not apply; as such, the phenotype of Y chromosome variants will be manifest. Consequently, affected males also have affected fathers, unless a de novo mutation has occurred, and all their sons will be affected. Since daughters of affected males will inherit their father’s normal X chromosome, and not the affected Y chromosome, they will be unaffected, and their offspring will also be unaffected. An example of a Y-linked condition is nonobstructive spermatogenic failure, which leads to fertility problems in males which may be addressed by assisted reproductive methods such as in vitro fertilisation (IVF).

Types of variants and their effects

Mendelian disorders are caused by pathogenic variants at single loci (in single genes), therefore, it is relevant to briefly discuss what kinds of mutations are involved and what their consequences upon gene function are. This depends on where within the sequence of a gene the change has occurred (e.g. within the coding region, in a control region or in a region involved in post-transcriptional modification).

Mutations can be categorised into those where nucleotides are exchanged against different ones where the total number of nucleotides do not change, and those where nucleotides are deleted, inserted or a combination thereof, with a concomitant change in the overall number of nucleotides. Where only a few nucleotides are involved, this is referred to as a microlesion, if only a single nucleotide is involved, this is referred to as a point mutation.

The following section will briefly describe mutations in coding regions, but microlesions outside the coding region of a gene can still have severe consequences. Mutations that change the regulation of a gene’s expression (e.g. promoter mutations) can lead to the production of too much or too little of the resulting protein, which may lead to a noticeable phenotype. Mutations can also occur in the conserved intronic sequences directly adjacent to intron–exon boundaries. Such mutations can then lead to aberrant splicing of the resulting transcript, with subsequent consequences on the encoded protein. In addition, mutations in non-coding RNAs can have profound effects, for example in one of the numerous miRNAs, which act to control the expression of other genes.

Point mutations

A point mutation is one which changes one nucleotide by substitution (one base pair is replaced by another), deletion or addition. If a substitution point mutation occurs within the coding region of a gene, various outcomes are possible: silent or synonymous mutations lead to the exchange of one codon for a different codon which still encodes the same amino acid. For example, the codons ATT, ATC and ATA all code for the amino acid isoleucine and if a mutation changed ATT to ATC, this would not lead to a change in the encoded protein sequence, therefore, such mutations are not expected to change the function of the encoded proteins. Missense mutations lead to a change in the codon such that it encodes a different amino acid. For example, a change from GAG to GTG will lead to the incorporation of valine into the resulting protein instead of glutamic acid. Such changes could lead to the complete loss-of-function of the resulting protein, or a dramatic change in function, or may have only a small effect that can be tolerated. This depends on the context of the amino acid within the mature protein, its function and on the chemical characteristics of the amino acids that are exchanged. Nonsense mutations lead to a codon for an amino acid being exchanged for one of the three stop codons. For example, a change from TAC to TAG leads to a change from the codon for tyrosine to a stop codon. Translation of the resulting mutated coding sequence leads to the formation of a prematurely truncated polypeptide, and most such truncations lead to non-functional proteins, although if they occur towards the C-terminal end of the protein they may have less effect.

Insertions, deletions and indels

The term ‘indel’ refers to mutations that change the total number of nucleotides in a genome, by in sertion, del etion or a combination of both. Indels generally refer to small changes from a point mutation, up to 1 kb. Indels occurring in sequences which control levels of gene expression or transcript splicing will lead to aberrant gene expression or splicing, but the effect of indels in coding sequences depends on the actual number of nucleotides inserted or deleted.

Deletion of three (or a multiple of three) nucleotides from a coding sequence corresponds to the deletion of one (or more) codons and will lead to the expression of a protein where one (or more) amino acids are deleted, without changes to the remaining amino acid sequence ( Figure 13 ). Such polypeptides may still be functional. However, if a number of nucleotides which is not divisible by three is deleted from a coding region, all subsequent codons will be altered, a phenomenon called a ‘frameshift’ ( Figure 13 ). A ribosome translates mRNA molecules one triplet (codon) at a time, before moving to the next triplet. If a single nucleotide is deleted, the ribosome will still translate one triplet at a time, but from the deletion point onwards, each triplet will now differ from those originally present. This will lead to the formation of a polypeptide whose sequence will differ completely from that originally present. Frequently, such frame shifts lead to stop codons being brought into the reading frame soon after the deletion point, thereby truncating the protein.

Insertions and deletions

( 1 ) A wild-type sequence consisting of three-letter words. ( 2 ) Insertion of three letters inserts another three-letter word, and keeps the remainder of the sequence unchanged. ( 3 , 4 ) Deletion of a number of letters which is a multiple of three removes a number of words, but leaves the remainder of the sequence unchanged. Note that the resulting sentence still makes (more or less) sense. Deletion ( 5 ) or insertion ( 6 ) of a number of letters which is not a multiple of three changes all three-letter words after the point of deletion/insertion. The resulting sentence does not make sense any more. These two cases are examples of frameshift mutations.

Insertion of nucleotides follows the same principle. Insertion of three (or a multiple of three) nucleotides leads to the insertion of one (or more) amino acids into the translated protein, while insertion of a number of nucleotides not divisible by three will lead to a frameshift mutation.

Examples of single-gene disorders

A special case of insertion mutations are the nucleotide repeat expansion disorders, typically triplet-repeat disorders ( Table 7 ). Trinucleotide repeats are repetitive sequences where triplets of nucleotides are repeated in tandem multiple times; in some cases these repeats are located in coding sequences and are translated as stretches of polypeptide consisting of a repeat of the same amino acid. Other trinucleotide repeats are located in non-coding sequences. It is possible that the presence of expanded repeats within a transcript is toxic for the RNA processing machinery in the nucleus. The nucleotide sequence of trinucleotide repeats is often (CAG) n or (CTG) n , where n is the number of repeat units, but other trinucleotide repeats are also known. One unusual aspect of these repeats is that they can become unstable and expand, such that the number of repeats increases dramatically from one generation to the next, a phenomenon termed ‘anticipation’. In addition, the repeats (over a certain number) can be unstable through somatic cell division, such that cells of some tissues show hugely varying numbers of repeats in the expanded allele. In all known cases of trinucleotide repeat expansion disorders, individuals carrying a number of repeats up to a threshold do not show any clinical symptoms, while individuals carrying longer repeats show progressively severe symptoms.

Four genes subject to repeat expansions are shown, with the gene affected, repeat sequence, normal and pathogenic range of repeat, main disease features and estimated incidence.

Huntington disease

Huntington disease (HD) is one of the trinucleotide repeat expansion disorders where the CAG repeat encodes a polyglutamine tract within the coding region of the huntingtin gene HTT on chromosome 4p16. It is a progressive neurodegenerative disorder with patients suffering from progressive neural cell loss and atrophy. Symptoms start with personality and mood changes, followed by a steady deterioration of physical and mental abilities. The function of the huntingtin protein is unclear, but it is essential for development. Inheritance follows an autosomal dominant pattern, caused by a gain-of-function associated with the repeat expansion. Unaffected individuals carry between 9 and 35 CAG repeats, incomplete penetrance occurs in carriers of 36–39 repeats, while the disease is fully penetrant when 40 or more repeats are present. Alleles containing 250 and more repeats have been reported.

While repeat alleles of 9–30 are almost always transmitted without change to the next generation, larger alleles show instability, both in somatic tissues and in the germline, with a tendency towards expansion from one generation to the next. There is a correlation between the number of repeats and the severity of disease and also an inverse correlation between the number of repeats and the age of disease onset. The degree of repeat instability is also largely proportional to the number of repeats, and is also affected by the sex of the transmitting parent, with larger expansions occurring in male transmission. This leads to ‘anticipation’ where an apparently healthy individual might have a child with late onset HD and a grandchild with more severe symptoms and an earlier onset, and so on.

Achondroplasia

Achondroplasia (ACH) is the most common form of dwarfism in humans and is inherited in an autosomal dominant fashion with 100% penetrance. Individuals with ACH have shortened limbs, a large head, and a trunk of relatively normal size.

ACH is caused by specific variants in FGFR3 , the gene for fibroblast growth factor (FGF) receptor 3 (FGFR3), on chromosome 4p16. Almost all individuals with ACH are heterozygous for a variant which leads to a substitution of arginine for glycine at position 380 (p.Gly380Arg) in the mature protein. Eighty percent of ACH cases are due to spontaneous, de novo mutations, often occurring during spermatogenesis. FGFR3 is a transmembrane receptor protein which binds to FGF ligands and triggers intracellular signalling processes. One of these processes is the inhibition of chondrocyte proliferation in the growth plate of long bones. The p.Gly380Arg variant in FGFR3 generates a constitutively active version of the receptor which can be further activated by binding of FGF. Therefore, this variant acts as a gain-of-function mutation. Consequently, chondrocyte proliferation in growth plates is constitutively inhibited. While one such variant allele (in the heterozygous state) leads to ACH, homozygosity is lethal before birth or perinatally. Interestingly, loss-of-function variants in FGFR3 have also been described which cause a different condition, camptodactyly, tall stature and hearing loss (CATSHL) syndrome. This is an example where different variants of the same gene result in different phenotypes, so-called ‘allelic disorders’.

Cystic fibrosis

Cystic fibrosis (CF) mostly affects the lungs (resulting in breathing difficulty and frequent lung infections) and the pancreas (with disruption of the exocrine function), but the liver, kidney, intestines and male reproductive system are also frequently affected. It is the most common lethal genetic disease among Caucasians, and is inherited in an autosomal recessive pattern.

CF is caused by pathogenic variants in the CFTR gene, which encodes the CF transmembrane conductance regulator, a transmembrane protein which functions as a selective chloride channel. If the CFTR protein does not function properly, the chloride balance between the inside and outside of cells becomes disrupted, leading to the build-up of mucus in narrow passages in affected organs such as the lungs. Such blockages lead to damage and reduced function in these organs. The CFTR gene is located on chromosome 7q31 and encodes a protein of 1480 amino acids. The gene is approximately 250000 nts long and over 2000 pathogenic variants have been identified in its sequence. These variants fall into different classes (e.g. those where protein synthesis is defective, those where reduced amounts of normal protein is made, those where the synthesised protein is not processed properly and does not reach the membrane and others). As long as an individual carries one functional allele of CFTR , they may show no or only very mild symptoms ( Figure 14 ), but an individual carrying two pathogenic variants will display symptoms that depend on the amount of functional protein generated. The most common pathogenic variant, representing approximately 70% of Caucasian CF alleles, is a deletion of the codon for a phenylalanine at position 508 (p.Phe508del) in the mature protein. This particular variant leads to the synthesis of a protein which does not fold properly into its 3D shape, and is degraded by the cell before it can reach the membrane, therefore representing a loss of function.

CF symptoms depend on residual CFTR activity

The left-hand side shows a scale of residual CFTR protein activity, between 0 and 100%. The right-hand side shows corresponding symptoms. Note that heterozygotes, carrying one pathogenic CF allele, still retain 50% of CFTR activity, therefore may be asymptomatic or show only mild symptoms. Only patients with 5% or less residual CFTR activity show full CF symptoms. Figure adapted from Davis 2001 .

Mitochondria – structure and function

Mitochondria are cellular organelles containing a genome which is independent of the nuclear genome, and are thought to have arisen from a symbiotic relationship between a primitive bacterial cell and a precursor of a eukaryotic cell. Mitochondria are the ‘powerhouse’ of the cell and are responsible for generating energy in the form of ATP. In addition, these organelles are key structures in controlling the process of programmed cell death or apoptosis. As such, they embody the life and death of the cell. They are capsule-like in structure ( Figure 15 ) with two membranes, an outer and an inner, and an intermembrane space in between the two. The inner membrane folds on itself forming cristae which increase the overall surface area and contain a series of protein complexes and transport chains involved in the production of ATP.

Mitochondrial structure

The mitochondrion has two membranes; the inner membrane folds into series of cristae on which are the electron carriers and ATP synthase, responsible for the generation of ATP. The matrix of the mitochondrion contains multiple copies of the circular mtDNA (image by Mariana Ruiz Villarreal, reproduced from Wikimedia Commons: Public Domain).

The generation of energy by the mitochondria involves several stages which are collectively known as cellular respiration. Firstly, a sugar (usually glucose) taken in by a cell is broken down by glycolysis in the cytoplasm, to generate two molecules of pyruvate, NADH and ATP. The pyruvate produced in glycolysis is converted into acetyl CoA which then enters the Krebs cycle – both the reactions occur in the mitochondrial matrix. The product of the Krebs cycle is NADH, which undergoes oxidative phosphorylation in the last stage of cellular respiration. In oxidative phosphorylation, which occurs on the cristae of the inner membrane, electrons are transferred from NADH or FADH 2 to O 2 by a series of electron carriers ( Figure 16 ). As a result of this process, ATP is formed.

The electron transport chain

On the inner membrane of the mitochondria, electrons from NADH and FADH 2 pass through the electron transport chain to oxygen which then undergoes a reduction reaction, producing water. The chain comprises five complexes and a series of electron transporters and electrons are passed from donors to acceptors down the chain, releasing energy which is utilised to generate a proton gradient across the mitochondrial membrane (image reproduced from Wikimedia Commons: Public Domain).

Control of some aspects of apoptosis or programmed cell death (so called because the survival or death of the cell is determined by a balance of cellular components) is another important mitochondrial function. In the very early stages of apoptosis, mitochondria release cytochrome c , an essential component of the electron transport chain, which initiates a pathway of procaspase activation, central to apoptosis. Key in mediating the mitochondria to release cytochrome c are proteins from the BCL family which reside in the outer mitochondrial membrane.

The mitochondrial genome

Located in the mitochondrial matrix, the mitochondrial genome exists as a circular, dsDNA molecule ( Figure 17 ), of approximately 16500 bp encoding 37 genes, each of which is vital to the function of mitochondria. However, numerous nuclear DNA encoded proteins also contribute to the formation and function of the mitochondria. Each cell contains thousands of mitochondria and each mitochondrion contains multiple copies of the mitochondrial genome. Thirteen of the 37 mitochondrial genes encode subunits of the four respiratory complexes involved in oxidative phosphorylation, which are situated in the inner membrane, while the rest code for 22 tRNAs and 2 rRNAs. The majority of components of the respiratory complexes are expressed from the nuclear genome and transported into the mitochondria.

Circular and double stranded, with no introns, the mitochondrial genome comprises 37 genes which code for components of the respiratory complexes involved in oxidative phosphorylation as well as for tRNA and rRNA. Many of the components of the respiratory complexes are coded for by the nuclear DNA (image reproduced from Wikimedia Commons: Public Domain).

The mitochondrial genome is unique in several ways. Almost 93% of mtDNA is coding, compared with the nuclear genome of which only 3% is coding, and mtDNA is free from introns, histones and epigenetic marks. MtDNA is subject to a mutation rate 100-times higher than that of the nuclear genome, since the mtDNA repair systems are less robust (more error prone) than nuclear DNA repair systems and because the internal environment of the organelle has more reactive molecules that can damage DNA (from the products of the respiratory transport chain). Importantly, mtDNA is only inherited maternally – a female will pass on mitochondria to all her children while a male will not normally pass on any of his mitochondria ( Figure 18 ).

Mitochondrial inheritance

In the case of a mitochondrial mutation (see following section), an affected mother ( A ) will pass the mutation on to all of her children since mitochondria are maternally inherited. On the other hand paternal mitochondrial mutations ( B ) will not be transmitted to his children.

Heteroplasmy is an important feature of the mitochondrial genome – this means that not all copies of the mitochondrial genome within a cell are the same ( Figure 19 ). If a particular variant is present in all copies of the mitochondrial genome in a cell, the cell is said to be homoplasmic for the mutation. The situation where some mitochondria contain the mutation while others which do not are referred to as heteroplasmy. Obviously this is an important phenomenon when considering the inheritance of mitochondrial mutations (discussed below) as offspring may inherit a high or low proportion of mutant mitochondria from a carrier mother.

Heteroplasmy

A primordial germ cell containing a mixture of mutant and normal mtDNA may give rise to oocytes which have high, intermediate or low mutation loads, dependent on the region of cytoplasm which contributes to it.

Mitochondria and disease

A number of conditions, from age-related hearing loss to specific forms of epilepsy and diabetes, are associated with mutations in the mitochondrial genome, with the phenotypes and severity varying widely. Often affecting tissues with high energy requirements such as muscle and nerve tissue, there is significant overlap between phenotypes caused by different mutations. As an example, two phenotypically distinct conditions caused by mitochondrial mutations are described below.

Leber hereditary optic neuropathy (LHON) is a mitochondrially inherited disorder of vision, with a reported incidence of approximately 1/30000 to 1/50000 births in European populations and symptoms which typically appear in the teens or twenties. The central area of vision tends to be most severely affected, with blurring and cloudy vision progressing to loss of sharpness and colour vision in the later stages. The pathogenesis of the condition results from cell death in the optic nerve. Mutations in a number of mitochondrial genes, including those encoding several NADH dehydrogenases (MT-ND 1, 4 and 6 ), are known to cause LHON.

The precise link between these mutations and the optic nerve cell death is unknown, and further complicated by the fact that up to 85% of individuals harbouring these mutations never develop visual problems. In some families, additional complications are present, including cardiac conduction and mild neurological problems. Although many different mutations have been associated with LHON, one of three missense mutations is thought to be present in 90% of affected families. Genetic diagnosis of the mutations causing mitochondrial disease such as LHON can be carried out using PCR-based techniques, such as allele-specific PCR.

Leigh syndrome, in contrast with LHON, typically appears within the first year of life. It is a severe and progressive neurological condition, with progressive loss of both mental and motor skills. Affected children usually die within 2 or 3 years of first showing symptoms, generally because of respiratory failure. With an overall similar frequency to LHON, Leigh syndrome is found in some populations (for example in Quebec, Canada) at a much higher frequency. Lesions in the basal ganglia, cerebellum and brainstem are seen on MRI scans in affected individuals. Both nuclear and mtDNA mutations have been observed in this condition, affecting complexes II, III, IV as well as ATP synthase, also known as complex V.

Therapy for mitochondrial disease

A number of traditional approaches have been used to combat the symptoms of mitochondrial disease, mainly in the form of dietary supplements, with little success. More recently, several strategies, including gene transfer using adeno-associated viral vectors have been trialled, in an attempt to replace the mutated gene.

However, as there is currently no effective strategy for treating mitochondrial disease, the approach of preventing rather than curing the conditions seems very attractive. Women who carry a mitochondrial mutation have the option of using a donor egg or adoption in order to avoid the possibility of having an affected child, but the possibility of having their own healthy biological child is more attractive to many. Thus mitochondrial replacement therapy or the ‘three parent baby’, in which the nucleus is removed from an egg containing mutated mitochondria and is placed into an enucleated egg from a healthy donor, has gained increasing interest in recent years.

There are two main approaches to achieve this – pronuclear transfer and spindle nuclear transfer ( Figure 20 ). With pronuclear transfer, which is currently the technique approved in the U.K., the mother’s egg as well as a donor egg are both fertilised with the father’s sperm. Subsequently the nucleus from each fertilised egg is removed and the donor egg’s nucleus is then replaced with that of the mother. In the alternative technique (spindle transfer), the nucleus is removed from an unfertilised mother’s egg and this is then inserted into a donor egg which has had its nucleus removed. Fertilisation with the father’s sperm then takes place. Although the U.K. approved pronuclear transfer in 2016, the first baby to be born using this technique was a boy born to Jordanian parents at a clinic in Mexico, to avoid the transmission of a mitochondrial mutation causing Leigh syndrome. It is expected that more babies will be conceived using this technique.

Mitochondrial replacement therapy (‘three-parent baby’)

Eggs are harvested ( 1 ) from the mother-to-be, whose mitochondria are affected by a pathogenic DNA variant. The nucleus is extracted from the egg ( 2 ). Eggs are also harvested ( 3 ) from a donor female who has healthy mitochondria, and the nucleus is removed from the egg, leaving only the cytoplasm ( 4 ). Now the nucleus (2) is injected into the enucleated egg (4) to generate an egg (5) that has the nuclear DNA of the mother-to-be, and healthy mitochondria. This can now be fertilised in vitro using sperm from the father (6), and allowed to develop for a few days before implantation into the mother-to-be.

The nucleotide sequence of the human genome contains within it a vast amount of complex information that is required for a healthy human, and changes to the DNA sequence may lead to disease states as described in previous sections. However, there is another layer of information that is superimposed upon the nucleotide sequence information, and study of this additional information is referred to as ‘epigenetics’, a term derived from the Greek and literally meaning ‘above the genetics’. This epigenetic information takes the form of chemical groups (for example, methyl groups) attached to the DNA or attached to the histone proteins around which the DNA is wrapped in chromatin. A key concept is that epigenetic information can be inherited between cell generations.

DNA methylation

In humans (as well as other mammals) cytosines within the dinucleotide sequence CG may become methylated ( Figure 21 ). Note the distinction between a C–G base pair (where the C and G are on opposite DNA strands) and a CG dinucleotide, which is a CG sequence along one strand of the DNA read in the 5′ to 3′direction (consequently, this is often referred to as CpG, to indicate the phosphate linkage on the DNA backbone). However, due to the complementarity of DNA there will also be a CG sequence in the 5′ to 3′ direction on the other strand of DNA ( Figure 22 ). The methylated cytosines are recognised by specific proteins, which bind to the DNA at these locations, and often lead to the recruitment of further proteins; these protein complexes can lead to alterations in chromatin structure and thereby activity of genes, typically by affecting the modification of histones.

Methylation of cytosine and consequences of deamination of methyl-C

( A ) Cytosine can be methylated to generate 5-methylcytosine; this may undergo spontaneous deamination to generate thymine. The arrow indicates position of attachment to the deoxyribose ring. ( B ) CG dinucleotides (indicated by vertical lines) are relatively rare in the genome overall compared with the expected frequency. This is believed to be an evolutionary consequence of deamination of methylcytosine leading to conversion of many C–G base pairs within CG dinucleotides into T–A. However due to the importance of DNA methylation in transcription regulation (see Figure 25 ), CG dinucleotides are present at higher frequency around promoter regions (transcriptional start sites) of genes, generating so-called ‘CG islands’ (also known as CpG islands).

Methylation occurs on the C of the sequence CG and facilitates binding of specific regulatory proteins to the DNA

Note that the sequence CG is palindromic, in the sense that the same sequence occurs in the 5′ to 3′ direction on both strands of the DNA. Abbreviation: N, any nucleotide.

The cell has several different enzymes which are responsible for DNA methylation, the DNA methyltransferases (DNMTs). Two of these, DNMT3A and DNMT3B, appear to specialise in de novo methylation, while the major role for DNMT1 appears to be in maintenance methylation ( Figure 23 ). The importance of maintenance methylation is evident when DNA replication is considered ( Figure 24 ). When methylated DNA is replicated by the action of DNA polymerase, the new strand will be generated by incorporation of standard nucleotide triphosphates, and thus no methyl groups will be present. If this DNA is replicated again, the newly synthesised DNA would have no methylation. However, hemimethylated DNA is recognised by DNMT1, which will methylate the cytosine on the complementary strand. This ensures that DNA methylation patterns are heritable between cell generations.

Methylation and demethylation

The methylation process is initiated by addition of a methyl group to one strand of the DNA by DNMT3A or DNMT3B. The resultant hemimethylated DNA becomes fully methylated by the action of DNMT1. Removal of methyl groups from DNA may be active (involving DNA demethylases) or passive (in the absence of maintenance – see also Figure 24 ). Abbreviation: m, methyl (CH 3 ) group.

DNA methylation status is heritable but requires maintenance

( A ) The Cs within CG dinucleotides (blue) represent potential methylation sites. In this piece of DNA sites 1 and 2 are fully methylated (i.e. on both strands of the DNA), but site 3 is not methylated. ( B ) Following replication the new strands of DNA (green) are unmethylated; further rounds of replication of this hemimethylated DNA would lead to some unmethylated DNA. However, hemimethylated DNA is a substrate for the maintenance methylase, DNMT1. ( C ) The daughter DNA molecules are now fully methylated at the originally methylated positions (1 and 2), but remain unmethylated at position 3, which was unmethylated in the original DNA template. Abbreviation: m, methyl (CH 3 ) group.

Methylation patterns in DNA are dynamic and can be altered in response to stimuli or at particular stages of development. To achieve this, it is necessary to have enzymes which can remove methyl groups from DNA: the DNA demethylases.

Histone modifications

For packaging into chromatin in eukaryotes, DNA becomes wrapped around octamers of histones; each octamer includes two molecules each of H2A, H2B, H3 and H4. The histone octamer forms a disc-like shape, with the N-terminal tails of each of the individual histones protruding from this disc. The histone proteins are subject to a variety of post-translational modifications, which include acetylation, methylation, phosphorylation and ubiquitination. Like DNA methylation, these modifications may be altered in response to changing circumstances, and influence the compaction of the chromatin and its accessibility by transcription factors and other proteins ( Figure 25 ). The best understood histone modifications are those which occur on the N-terminal tails. For example, acetylation of lysine residues in the N-terminal tails renders chromatin less compact and thus facilitates transcription. Acetyl groups can be added by the histone acetyl transferase (HAT) group of enzymes, and removed by histone deacetylases (HDACs); thus the activity of HATs will facilitate transcription, while the activity of HDACs will tend to inhibit transcription.

Chromatin status is influenced by DNA methylation and histone acetylation

In active chromatin the N-terminal tails of histone proteins are acetylated (by HATs); the additional positive charges encourage a looser packing of nucleosomes that makes the DNA more accessible for other proteins and thus facilitates transcription. Addition of methyl groups to the CG dinucleotides (by DNMTs) and removal of the acetyl groups from the histones (by HDACs) provokes a more compact chromatin structure, which is not easily accessible by transcription factors, generating inactive chromatin. Reactivation of inactive chromatin is facilitated by DNA demethylases (which remove the methyl groups) and HATs.

DNA methylation status can influence histone modification and vice versa. For example, methyl-C binding proteins can recruit HDACs to sites of DNA methylation, and histone methylation may either facilitate or inhibit DNA methylation, depending upon which amino acid has been methylated within the histones. One consequence of all this modification is that, although all our cells may contain the same genome and therefore the same genes, the pattern of which genes may or may not be active in a given cell or tissue type is dependent upon the modifications present in the DNA and on the histone proteins: the epigenetics.

Chromosomal imprinting

Several regions of the human genome, involving roughly 100 genes, are rendered inactive by epigenetic mechanisms depending upon parent of origin. For some genes only the paternal allele is active, while the maternal copy is epigenetically silenced throughout the life of the individual. For other genes it is the maternal copy that is active and the paternal copy which becomes epigenetically silenced. The process of epigenetic silencing in a parent-of-origin specific manner is termed as ‘chromosomal imprinting’, and involves DNA methylation, histone modification and additional protein and RNA factors. During gametogenesis all previous imprints are removed from the DNA, and new imprints are established: female imprints during oogenesis and male imprints during spermatogenesis ( Figure 26 ), thus each embryo should receive chromosomes with a complementary set of imprints and therefore one active copy of each imprinted gene.

Imprints are erased and reset during gametogenesis

For each imprinted chromosome region, healthy adult humans ( 1 ) will have, in their somatic cells, one maternal and one paternal imprint. During gametogenesis, the imprints present ( 2 ) must first be erased ( 3 ), and then the imprints are reset ( 4 ) according to the sex of the parent. Therefore during oogenesis all relevant regions are given a female imprint, and during spermatogenesis all relevant regions are given a male imprint. Thus at fertilisation ( 5 ) the union of egg and sperm generates a baby ( 6 ) with one maternal and one paternal imprint for each imprinted region. Chromosomes are shown in green, with male and female imprints indicated by blue and pink respectively.

What is the purpose of imprinting? In general, paternal imprints lead to gene expression patterns associated with increased growth, and maternal imprints lead to gene expression patterns associated with decreased growth. Some theories regarding the origin of imprinting relate to adaptive co-evolution. Other theories are based on conflict relating to strategies for reproductive success: the mother has to make a greater investment of energy in the child than the father, and too much maternal investment in one child may be detrimental to her ability to reproduce again; however the father’s reproductive success may be facilitated by larger babies that are better equipped to survive. There is also a potential conflict between the needs of the developing foetus and the continued health of the mother. Imprinting is observed in all mammals and in some other species; there is much debate about its origins, but correct imprinting is critical for normal development.

For imprinted genes, with one copy epigenetically silenced throughout the lifetime of the individual, it is clearly vital that a functional copy of that gene is inherited from the other parent. Where this is not the case, for example due to gene mutations or errors affecting the resetting of imprints during gametogenesis, imprinting disorders will be seen.

Imprinting disorders and uniparental disomy

There are a number of genetic conditions which are related to imprinting, including Beckwith–Wiedemann syndrome, Silver–Russell syndrome, Angelman syndrome (AS) and Prader–Willi syndrome (PWS). One of the best characterised imprinted regions is located close to the centromere on the long arm of chromosome 15 (15q11.2). The genes in this region include SNRPN , two clusters of genes for small nucleolar RNAs (snoRNA), and UBE3A . The products of SNRPN and snoRNA genes appear to play roles in RNA processing within the nucleus, while the UBE3A protein functions in targeting proteins for degradation by the proteasome. Thus the products of genes in this region clearly have wide-ranging effects within the cell. SNRPN and the two snoRNA clusters are active only on the paternal chromosome 15, while UBE3A is active on the maternal copy ( Figure 27 ). Absence of the paternally expressed genes leads to PWS ( Table 8 ). In contrast, if there is no maternal copy of 15q11.2, and thus no active UBE3A gene, then the individual will be affected by AS. While the majority of PWS and AS cases are a consequence of microdeletions, there are other mechanisms ( Table 8 ), including uniparental disomy (UPD).

Imprinting on chromosome 15

A cluster of genes near the centromere of chromosome 15 (at band 15q11.2) is subject to imprinting in a parent-of-origin specific manner (indicated by blue and pink shading): a number of genes including SNRPN and many snoRNA genes are expressed exclusively from the paternal chromosome 15, and are silenced on the maternal 15. Conversely, the UBE3A gene is silenced on the paternal copy and active on the maternal copy. Thus loss of function of these genes has different consequences depending upon the parental origin: loss of UBE3A on the maternal 15 leads to Angelman syndrome ( Table 8 ) whereas loss of UBE3A on the paternal 15 is without consequence since the gene is inactive anyway on the paternal copy. The mechanism involves DNA methylation (indicated by hatching) of the SNRPN region of the maternal chromosome 15.

UPD is a rare phenomenon in which both homologues of a chromosome pair are derived from the same parent. If both chromosomes 15 are maternal in origin then the child will be affected by PWS, and if both 15s are paternal in origin the child will be affected by AS. There are essentially three mechanisms which can lead to UPD, each requiring two errors affecting meiosis/mitosis. Monosomy rescue is a rare, sporadic event which can allow a monosomic zygote to survive by duplication of the monosomic chromosome; the mechanism permitting this is not entirely clear, but it will always result in UPD. Trisomy rescue is, likewise, a rare, sporadic event, in which trisomic cells lose one chromosome, for example by anaphase lag, in which one chromosome does not get incorporated into a daughter nucleus during mitosis. Depending upon which of the three chromosomes is lost, trisomy rescue leads to UPD in one third of cases. A final possibility is for a nullisomic gamete to combine with a disomic gamete (in other words, meiotic errors in both parents), which appears statistically unlikely. UPD of some chromosomes is without consequence (for example 1, 5, 9, 10, 13, 21, 22), but for chromosomes that harbour imprinted genes (which include 6, 11, 14, 15, 20), the relevant imprinting disorder will ensue.

UPD can be in the form of heterodisomy (both homologues from one parent are present) or isodisomy (two copies of one of the parental homologues). In isodisomy, because the two chromosomes are identical there will be homozygosity for all alleles and therefore in this case UPD may also unmask a recessive disorder.

Although most cases of imprinting disorders occur as a consequence of de novo mutations, there are also cases in which mutations have been transmitted through families. For example, if a new UBE3A mutation is present in a spermatozoon that fertilises an egg, the resultant child would not show any phenotype, since the paternal copy of UBE3A is epigenetically silenced anyway. If the child is a male, he could also transmit this same mutation to offspring without consequence to their health. However, if the child is female, and she transmits this mutation to her offspring, they would be affected by AS.

Interestingly, imprinting of UBE3A appears to be maintained only in the brain; other tissues have biallelic expression. Furthermore, overexpression of UBE3A , for example as a consequence of gene duplication on the maternal chromosome 15, is associated with autism.

Epigenetic contributions to other disorders

During development, epigenetic modifications at many genetic loci change as part of the differentiation process, generating tissue types with specific patterns of gene expression. Epigenetic changes may also occur in response to environmental stimuli. Deficits affecting components of epigenetic mechanisms can lead to disease states. A well-characterised example involves the MECP2 gene which encodes a methyl-C binding protein. This protein recognises and binds to methylated cytosines in DNA, acting to recruit other complexes like HDAC which can alter the transcriptional status of the DNA. Pathogenic loss-of-function variants in MECP2 lead to Rett syndrome, as discussed earlier. Another example is the rare autosomal recessive disorder: immunodeficiency, centromeric instability and facial anomalies (ICF) syndrome. Roughly half of ICF cases are a consequence of biallelic pathogenic variants in the DNMT3B gene. From mouse studies, complete loss of function of DNMT3B appears to be incompatible with life, and thus the variants that lead to ICF are generally missense, with each patient having at least one missense variant which retains some DNMT3B function. Note that epigenetic changes can also involve non-coding RNAs, for which X-inactivation provides a good example.

It is becoming increasingly apparent that changes in epigenetic programming play a role in many conditions, including cancer, mental illness, autoimmune disease, diabetes and obesity. Identical twins have different patterns of DNA methylation and histone modification that may contribute to different disease susceptibility between them. Because epigenetic marks like DNA methylation can be faithfully copied between cell generations (in other words they are heritable), epigenetics can also help explain how the foetal or childhood environment can influence later susceptibility to disease. There is also evidence that epigenetic marks, including those on imprinted genes, may be perturbed during IVF, and that this may lead to health problems, for example imprinting disorders, in some children conceived by IVF.

The clear inheritance patterns associated with single gene (monogenic) disorders have facilitated the identification of the causative genetic changes for these conditions. However, increasing attention is now focused on genetic contributions to complex multifactorial disorders like diabetes, heart disease and schizophrenia, where disease is the outcome of a complex interplay of multiple genetic and environmental influences. The impact of an individual variant in one gene may be very small, but when present together with multiple variants in other genes, in the context of a particular environment, may lead to an increased risk of disease. The same is true for many traits (for example, height) and behaviours (for example, aggression or novelty seeking).

Type 2 diabetes (T2D) exemplifies complex disorders and is one that is increasing in incidence across the world. The major environmental contributions to T2D relate to diet and exercise: high-calorie diets in the context of a less active lifestyle, often involving long periods spent in front of a computer or television. This lifestyle presents a stark contrast with the environment that our ancestors had to survive, and traits that might once have been advantageous (like an energy-saving metabolism) have become a disadvantage. Identifying the genetic factors underlying T2D is challenging because of the small effects of individual contributions.

Whereas type 1 diabetes (T1D) is characterised by loss of insulin production as a consequence of autoimmune destruction of pancreatic islet cells, T2D is most commonly associated with insulin resistance – the body is no longer able to respond appropriately to insulin. T2D typically has a late onset (>35 years) and is associated with obesity, though onset at younger ages is increasing.

Family studies

Initial clues that genetics plays a role in complex disorders like T2D tend to come from family studies, in particular, the study of twins. If one of a pair of monozygotic (identical) twins is affected by a monogenic disorder like CF it is practically certain that the other twin also has CF, in other words, is concordant, because they have virtually identical DNA. However, for dizygotic (non-identical) twins, who share, on average, 50% of their DNA, the chance of being concordant for CF is 50%. For a disorder that is completely environmental in origin there would be expected to be little difference in concordance when comparing dizygotic with monozygotic twin pairs. For T2D concordance is approximately 70% for monozygotic twins, but only approximately 25% for dizygotic twins, therefore indicating significant genetic involvement. Furthermore, the risk of T2D is higher for any individual if a parent is also affected (higher still if both are affected). The relative contribution of genetic factors to a disease phenotype is known as ‘heritability’, and for T2D estimates of the heritability vary between 25 and 80%.

Identifying genetic loci associated with complex disorders

One way of identifying the loci involved is a ‘candidate gene’ approach. For T2D potential candidates might be genes involved in glucose metabolism or the response to insulin, or in predisposition to obesity. Investigation of the PPARG gene, based on its known role in adipocyte differentiation and glucose homoeostasis, identified a common polymorphism which was protective for T2D ( Table 9 ). However, due to the complexity of regulatory and metabolic networks in the cell, the number of potential candidate genes for T2D is immense, and fully investigating all possible candidates would require massive investment of time and money. Furthermore, by looking only at genes that are expected to play a role based on current understanding some key players might be missed.

To facilitate the identification of susceptibility loci, approaches based on genetic linkage or ‘association’ have been used ( Figure 28 ). Such approaches rely upon the observation that genetic recombination does not occur randomly across our genome, but instead tends to occur at ‘hotspots’ spread throughout chromosomes. The consequence is that particular segments of the genome tend to remain together through many generations. This means that we can use ‘genetic markers’, most often SNPs, as tags for the genome segments, and then look within populations to test whether particular markers associate with the disease. This approach is typified by the ‘genome-wide association study’ or GWAS ( Figure 29 ).

The principles of genetic association

SNP1 (with alleles C and T) and SNP2 (with alleles A and G) are two polymorphic sites present on one chromosome. Within one of the group of ancestors, a new mutation (yellow star) has occurred very close to the position of SNP1; this is a new pathogenic variant which contributes to a particular disease condition (yellow individual). Because SNP1 is so close to the pathogenic variant, there will be little or no recombination between these sites down the generations, whereas recombination is likely to occur between SNP2 and the pathogenic variant. Thus when the descendants are genotyped, SNP2 has identical allele distribution in both healthy and affected individuals (no association of SNP2 with the disease). However, for SNP1 there is an excess of the T allele (and a corresponding deficit in the C allele) in the affected population, in other words SNP1 shows association with the disease. In reality, for complex conditions where there may be many different predisposing variants in several different genes, the scale of association would be less extreme, requiring analysis of thousands of individuals.

Genome wide association study for T2D-related loci

Appropriate study groups are selected from the general population ( 1 ). For example, a group of individuals who have T2D ( 2 ) and a group of individuals who are healthy to act as controls ( 3 ). These groups must be matched as far as possible in terms of their constitution to avoid confounding effects – for example, matched for gender, ethnicity, smoking, socioeconomic status, education and so on. For each individual, thousands of SNPs across the genome are genotyped ( 4 ), and then the overall allele frequencies are compared between the two groups for SNPs across each chromosome ( 5 ). Each spot on the graph represents one SNP at a known location on a particular chromosome. The expectation is that, for the vast majority of SNPs, the MAF will be similar between the two groups. However, where there is a difference, either a significantly higher ( 6 ) or significantly lower ( 7 ) MAF in the affected group, this identifies a specific chromosome location which may play a role in T2D. Note that the actual variants which either predispose to obesity or protect from T2D may be close to the relevant SNPs (i.e. genetic linkage) rather than the SNPs themselves being causative or protective.

One problem with GWASs is that even with high statistical stringency, reproducibility is not guaranteed and results from different studies can appear contradictory, although this may reflect that there are too many other variables between the study groups. Large meta-analyses attempt to pull results from multiple GWAS together to determine significance on a large scale. It is important to note that association of a SNP with a particular trait or condition does not necessarily indicate causation, instead it is quite likely that the SNP, through close linkage, has been inherited along with the change which contributes to the trait ( Figure 28 ). Once a locus has been identified by GWAS the next step is to look at the genomic region to see which genes in that region are likely to be relevant to the observed phenotype, and to see if the association can be confirmed by other studies, which will need to include functional studies in cells and/or animal models. Over 120 genetic loci have been identified by GWAS for T2D; some of these are shown in Table 9 .

GWAS can be an effective way of linking common variants with associated diseases, but rare variants may also play a significant role within some families and subpopulations, for example the p.Glu508Lys allele of HNF1A in Native Americans ( Table 9 ). Identification of additional rare variants is likely to come from approaches involving genome sequencing. It should be noted that variants might either increase or decrease disease risk, depending upon their functional effect (see KCNJ11 and SLC30A8 in Table 9 ). The mechanism by which variants might contribute to complex disorders is often not obvious; for some loci implicated in T2D, there is a clear link to pancreatic function/glucose homoeostasis or obesity, but the significance of other loci identified by GWAS is less clear. At first glance, the function of the CDKAL1 product (tRNA modification) has no relationship to diabetes, but a potential impact emerges when the effect of lysine mistranslation on proinsulin cleavage is considered. Another locus, CDKN2A/2B , encodes products involved in cell cycle/cell proliferation, and it is feasible that there might be a link to the overall number of islet cells in the mature pancreas (having more islet cells may equate to better ability to sustain insulin production).

Despite the large number of T2D-associated loci that have been identified by GWAS, these are not able to explain all of the heritability of T2D. However, it is becoming increasingly clear that epigenetics also plays a significant role in complex diseases like T2D. Imprinting may be involved: the risk that offspring will be affected by T2D is greater when the mother is affected than when the father is affected. Interestingly, this is the reverse of the situation for T1D, for which the risks for a child are higher if the father is affected, than if the mother is affected. A parent-of-origin effect has been observed for some alleles of KCNQ1 which only increase T2D risk when transmitted maternally.

The impact of epigenetics appears to begin preconceptionally: mouse experiments have demonstrated effects on health and also in DNA methylation patterns for offspring following paternal exposure to high-fat diet or low nutrition. Early foetal life is also a critical time. Key observations have come from the study of individuals who were exposed to an adverse intrauterine environment, particularly during first trimester, as a consequence of severe famine during the ‘Dutch hunger winter’ of 1944/45. These individuals had normal birth weight (since the famine had ended by the later stages of the pregnancy), but had significantly increased rates of obesity and T2D as adults, suggesting that a form of foetal programming had occurred. This is supported by the observation of altered methylation patterns 60 years later when comparing the DNA of these individuals with that of their siblings.

Lifestyle choices and environmental exposures also lead to epigenetic change. Clearly, sedentary lifestyles combined with high calorie obesogenic diets contribute directly to T2D risk, but there are also many studies that demonstrate epigenetic changes associated with different foods. Tobacco smoking leads to decreased methylation in several genes associated with T2D, including KCNQ1 , and exercise has been shown to promote methylation changes in T2D-associated genes as well as altering histone deacetylase expression. Many epigenetic marks in the genome can change throughout the life of an individual as a result of changing lifestyle ( Figure 30 ), and may provide a useful target for management of T2D risk. The epigenetic marks present in the DNA of monozygotic twins have been shown to diverge as they age, and, when comparing individuals with/without particular complex disorders, differential epigenetic marks can be demonstrated in key genes. Epigenome-wide association studies (EWAS), which operate on similar principles to GWAS, may help to elucidate the epigenetic basis of complex diseases.

Many factors, environmental, genetic and epigenetic interact together in the overall risk for T2D

Epigenetic factors can alter throughout the life of an individual, and may be affected by parental environment preconception, and maternal environment during pregnancy. A multitude of inherited variants (some of which may be protective) combine with epigenetic status to generate an overall genetic risk for T2D, but the disease state will generally only be manifested in the presence of environmental triggers. Although inherited genetic variants are hard to change, it is apparent that environmental change (improved diet and more exercise) may impact on disease severity not only directly, but also indirectly by epigenetic changes. Pictograms from PictArts.

There is still a long way to go in understanding genetic contributions in complex diseases. T2D has only reached epidemic proportions over the last few decades, but the majority of genetic variants implicated as risk factors for T2D have been around for much longer in the human gene pool. Therefore, it is the environmental context of high calorie intake plus sedentary lifestyle which potentiates the effect of the genetic risk variants in T2D. Furthermore, it is important to recognise that variants which appear to be ‘bad’ as risk factors for one disease may in fact be protective against another (see HNF1B in Table 9 ), which underlines the fact that there is no such thing as a ‘perfect’ human genome!

Cancer affects approximately 1 in 4 people worldwide, with an estimated 14.1 million new cases in 2012 and a prediction that there will be 23.6 million new cases per year by 2030. In the U.K. there are nearly 990 new cases diagnosed every day, which equates to a new diagnosis approximately every 2 min. In the U.S.A., there are over 4600 new cases every day (a new case every 19 s). These rates are rising, due both to the increase in population size and increasing longevity. More than one-third of cancer cases in the U.K. are diagnosed in people aged 75 and older.

There are many different types of cancer and these types reflect the tissue and cell type from which the cancer originated. The most common types in the U.K. are cancer of the breast, prostate, lung and bowel, which together comprise over 53% of all cancer cases. Overall, half of the people diagnosed with cancer survive their disease for more than 10 years and this is improving, from only 24%, 40 years ago. However, each type of cancer shows a very different mortality rate, for example 98% of people diagnosed with testicular cancer survive for more than 10 years after diagnosis, while the figure is only 1% for pancreatic cancer.

Although the different types of cancer show different disease patterns and survival rates, the commonality of all cancers is that the cells have lost the normal controls over growth and movement. Cancer cells proliferate in an uncontrolled way and this can lead to the formation of a lump, or tumour. When the growth of the cells within the mass is limited and the cells retain certain normal features, do not invade adjacent tissues, nor spread to other parts of the body, the tumour is called ‘benign’. However, if the growth becomes more uncontrolled, such that the cells divide indefinitely and spread to other parts of the body, the cancer is termed malignant and the tumours that form at secondary sites are called metastases and it is metastatic disease that is the primary cause of cancer mortality.

There are several contributing factors that enable cancer cells to grow in this uncontrolled way and Hanahan and Weinberg described these in a seminal review in 2011 as the ‘hallmarks of cancer’. These features of cancer cells can be summarised as follows: (i) they have an inherent ability to divide; (ii) the cells do not respond to factors in the body that might inhibit their growth; (iii) they develop ways to avoid being destroyed by the immune system; (iv) they overcome the in-built clock that limits normal somatic cell division; (v) the cells release factors that in turn promote the surrounding normal cells to release other factors that will support the growth of the cancer cells, in other words, cancer cells can promote a permissive environment for their growth; (vi) they acquire the ability to move and invade other tissues; (vii) they promote the growth of a blood supply to the tumours to provide the oxygen and nutrients the cancer cells need to grow; (viii) the cancer cell genome becomes more prone to mutation; (ix) they become resistant to the normal mechanisms of cell death and (x) the cells adjust their metabolic pathways to better support rapid cell proliferation. All these changes from a normal cell are brought about by different somatic mutations in the cancer cell genome, and/or by epigenetic modifications. As such, cancer is essentially a disease of mutation.

The genome of a cancer cell is full of somatic mutations. Indeed, in some cancers, such as lung cancer and melanoma, there may be hundreds of thousands of mutations ( Figure 31 ). Many such mutations are observable at the level of the karyotype, including whole and part chromosome duplications, deletions, inversions and translocations. In addition, cancer cells typically carry large numbers of point and micromutations.

Different cancer types typically display different numbers of mutations in the cell genome

These can range from less than one hundred observed in some retinoblastomas to hundreds of thousands in lung cancer.

Many of these mutations will have been involved in the disease process to some degree (called causative or driver mutations), however, the cell also accumulates mutations that are not causative, i.e. ‘passenger’ mutations (as many as 99.9% of the mutations present) and one challenge is to distinguish between the two (see next section on ‘Genomics’). While there are a number of genes known to be powerful oncogenes when mutated or critical tumour suppressor genes, cancer cells never have only one causative mutation. This is because for the cancer cell to acquire all of the changes (as described above), mutations in numerous genes are needed to overcome normal growth regulatory processes. This is also reflected by the incidence of cancer. The statistics show that the biggest risk factor for cancer is age. The older an individual is, the more likely they are to develop cancer, indeed most cancer types are quite rare in young people ( Figure 32 ). The very shape of the incidence curve reveals that cancer is caused by multiple changes to the cellular genome. Mutations occur and accumulate in the cells of the body throughout life. The vast majority of these will be harmless and may not affect the phenotype of the cell at all. However, over time, as mutations accrue, there is a risk, a statistical chance, that eventually a cell undergoes enough causative mutations that it begins to develop cancerous properties and with time, this may progress to a cancerous state. Agents that speed up the mutation rate in cells will also increase the risk of cancer, so for example, overexposure to sunlight (a component of which is mutagenic UV rays), will increase the risk of melanoma, a type of skin cancer. Similarly, cigarette smoke contains multiple mutagens and smoking tobacco increases the risk of lung cancer.

Cancer increases with age

Theoretical cancer incidence curves are shown reflecting a set mutation rate. If only one mutation could cause a normal cell to become cancerous, the cancer incidence rate would be linear (blue line). The actual incidence increase with age (red curve) reflecting the accumulation of cancer causing changes that act together over time.

Oncogenes are genes whose activation contributes to the development of cancer. Oncogenes are usually mutated versions or pathogenic variants of normal cellular genes (the unmutated genes are often called proto-oncogenes for this reason), and this reflects that the normal function of the gene is involved in the control of cell growth in some way. Thus genes that promote or are involved in cell division (mitosis) or inhibit programmed cell death (apoptosis), differentiation, quiescence or senescence are genes that when mutated, could become oncogenic. In addition, some pathogens carry oncogenes, for example a small number of viruses can lead to a higher risk of specific cancers, because they encode genes that promote cell proliferation or survival. It is estimated that approximately 15% of cancers have developed with the involvement of an infectious agent, for example some human papillomaviruses can increase the risk of developing cervical cancer.

Many proteins expressed by potential oncogenes act in a process called signal transduction, or are transcription factors that are activated by this mechanism. Signal transduction is the method by which a cell converts a signal, typically received from the outside of the cell, into a change in gene expression which will lead to a response ( Figure 33 ). For example, if a growth factor acts upon a cell, this triggers a signal that passes through the cytoplasm, to induce the expression of genes required to initiate cell division. This is usually (but not exclusively) achieved by the growth factor interacting with a receptor at the cell surface. The interaction activates the receptor, which leads to a cascade of changes in the state of other factors that are located in the cytoplasm. Transcription factors are often activated by this process through phosphorylation upon specific serine or threonine residues, resulting in their translocation to the nucleus to regulate gene expression ( Figure 34 ). Importantly, once the signal has concluded, all components are deactivated. Mutations in genes involved in this process that lead to overactivation of the protein, or just too much of it, can result in excess signalling, instructing the cell to divide continuously.

Signal transduction

The cell receives signals from contact with other cells, from the extracellular matrix and from soluble molecules, including secreted proteins. The information received is integrated and transduced to the nucleus. The cytoplasmic signalling pathways and networks that are activated will depend upon the cell’s status and which genes are currently expressed. The combined signalling input can result in an altered programme of gene expression to achieve one of several possible responses.

A simplified, typical signal transduction pathway

Many growth factors (secreted proteins) interact with a receptor at the cell surface and both ligand and receptor can act in the form of a monomer or in a complex. The interaction causes the receptor to become active, and this will lead to a signalling cascade (depicted by the dashed red lines), passed from one molecule to the next. The signal may culminate in the activation of a transcription factor with a consequent change in gene expression, or influence mitochondrial membrane integrity and cell survival, or have an alternative destination to elicit a cellular response. The activation signal may be transmitted in several ways, the most common method is through the action of kinases, enzymes which phosphorylate their substrates (depicted by P), thereby activating the substrate for the next step. While a simple pathway is depicted, the reality is that a vast network of complex interactions occur, integrating numerous signals allowing for an extensive array of subtly different responses.

Essentially all types of mutation have been observed in the conversion of a proto-oncogene into an oncogene, including gene duplication, point mutation, partial deletion or rearrangement and chromosomal translocation. Oncogenic mutations tend to be gain-of-function and thus are usually dominant. Such mutations generally lead to overexpression of the gene or overactivation.

Oncogene activation by overexpression

There are three main mutational mechanisms by which gene overexpression is achieved ( Figure 35 ). These are: amplification of the gene, with increased expression due to the increased copy number, novel juxtaposition of sequences that enhance expression (for example, through chromosomal translocation) and mutations in the gene expression control sequences that either prevent gene silencing or directly enhance expression. In addition, epigenetic modification of the gene promoter sequences can act to increase or suppress expression.

Oncogenic mutations

Examples of oncogene activating mutations are depicted. ( A ) Gene amplification leading to increased expression of the product. ( B ) Reciprocal chromosomal translocation leading to enhanced expression of a gene at the breakpoint, as observed in follicular lymphoma and the 18:14 translocation involving the BCL2 gene and the IGH locus (above); or as observed in chronic myeloid leukaemia and the 9:22 translocation leading to a BCR-ABL fusion protein (fused in frame with respect to the ORF). ( C ) Loss of a protein regulatory region by small deletion. ( D ) Activating change in the coding sequence brought about by a point mutation (exemplified by RAS genes). In each case, the gene region is depicted by a coloured box and expression indicated by a bent arrow.

An example of mutation leading to overexpression is seen with the gene encoding the receptor protein HER2 (aka ERBB2, a member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases), which is frequently mutated in breast cancer. One type of HER2 mutation found in cancer cells is amplification. The whole gene is duplicated resulting in more than one copy, sometimes several copies. This leads to excess production of the protein within the cell. As a consequence, the cell sends more signals to the nucleus to initiate mitosis, which contributes to the cancerous state by increasing cell proliferation. This knowledge led to the development of a drug called Herceptin, which blocks the action of HER2 and is an effective co-treatment for those breast cancers that overexpress HER2.

Another example of mutation causing gene overexpression is exemplified by the BCL2 gene in follicular lymphoma, a type of B-cell cancer. The BCL2 protein sits at the surface of the mitochondria and inhibits a form of programmed cell death called apoptosis. If a cell is destined to die (and there are several instances where this is normal), overexpression of BCL2 can inhibit cell death. Follicular lymphoma cells display a typical chromosomal translocation, juxtaposing part of chromosome 18, the location of the BCL2 gene, to chromosome 14, the location of an antibody gene (the immunoglobulin heavy chain ( IGH ) gene) ( Figure 35 ). The result is that BCL2 comes under the control of an enhancer sequence which would normally drive the expression of the IGH gene in B cells, but in the mutant cells, leads to overexpression of BCL2 . Thus the B cells are resistant to apoptosis and this contributes to the development of B-cell lymphoma.

Oncogene activation through increased activity

There are several mutational mechanisms by which the activity of an encoded protein can be increased or rendered constitutive. These include point (or small) mutations at critical regulatory residues, for example loss of negative regulatory phosphorylation sites, deletion of negative regulatory domains (which can occur by simple deletion or result from larger rearrangements such as chromosomal translocation), or activating mutations in catalytic domains or interaction domains.

Proteins that relay growth signals in cells have to be exquisitely regulated. These proteins generally exist in an inactive state, are briefly activated by signal transduction and then return to an inactive state, thereby tightly controlling cell proliferation. Mutations that lead to increased or constitutive activity can be oncogenic. A classic example of this occurs with the RAS genes ( H-RAS, N-RAS and K-RAS ). These three related genes encode small proteins that are pivotal in multiple cell signalling pathways and in the development of numerous cancers, and therefore RAS has been referred to as a ‘molecular switch’. The RAS proteins bind to either GDP or GTP (guanosine di- or tri-phosphate). When bound to GDP, the protein is inactive. As a consequence of signalling from receptors, RAS switches to bind to GTP and in doing so, changes conformation and becomes active and thereby can interact with the next protein in the chain to pass on the activation signal ( Figure 36 ). In the absence of an activating signal, RAS proteins are rapidly deactivated via an intrinsic GTPase activity (which hydrolyses the bound GTP to GDP). At just a few key points along the gene, mutation changing a single amino acid (typically codons 12, 13 or 61), can prevent GTP hydrolysis, thus locking RAS into the active, GTP-bound state and lead to constitutive signalling.

RAS activation

( A ) RAS is bound to GDP in the inactive state. Signal transduction can lead to the activation of RAS, via a GEF (GDP/GTP exchange factor), which displaces GDP from RAS, allowing the binding of GTP. This causes a change in conformation of RAS that enables interaction with effector proteins, thereby passing the activation signal onwards. Deactivation of RAS occurs by hydrolysis of GTP to GDP, assisted by GTPase-activating proteins (GAP). ( B ) Proteins of the RAF family are among several effectors of RAS. RAF proteins are serine/threonine kinases. Activated RAS binds to RAF, leading to a change in conformation of the latter and activating its kinase activity. RAF then phosphorylates its substrate MEK (which is also a kinase) thus activating it, and so the signal proceeds. This describes part of well-known signal transduction pathway, the mitogen activated protein kinase (MAPK) pathway.

Another example of protein activation is observed with the C-SRC gene, which encodes a tyrosine protein kinase. The C-SRC protein locates to the inside surface of the plasma membrane and passes on the mitogenic signals from several growth factor receptors. The kinase activity of the protein is controlled by a regulatory site at the C-terminal end, the location of a critical tyrosine residue (Tyr 527 ). The phosphorylation status of Tyr 527 is determined by other protein tyrosine kinases and phosphatases and when Tyr 527 is phosphorylated, this inhibits the kinase activity of C-SRC. Mutations that delete this residue result in a protein that is constitutively active and constantly relaying growth signals to the nucleus. The mutation can be as small as a point mutation, such that the tyrosine residue is lost or replaced by an alternative amino acid. Such mutations are frequently found in cancer of the colon, lung, liver, breast and pancreas. A further example of mutation leading to loss of a regulatory domain is seen with a chromosomal translocation that leads to the expression of a fusion protein (derived from two genes), called the BCR-ABL fusion. This particular chromosomal translocation (between chromosomes 9 and 22), called the Philadelphia chromosome, is a characteristic of chronic myeloid leukaemia and leads to the loss of a regulatory domain from the ABL1 gene, which encodes a tyrosine kinase. The fusion protein has constitutive kinase activity which promotes cell division.

Tumour suppressor genes

Tumour suppressor genes (TSG) are genes whose action inhibits the growth of tumour cells, therefore their inactivation is advantageous to a cancer cell. Consequently, the function of several TSGs is lost from all forms of cancer. The loss of function can be achieved by mutation affecting a critical region of the protein or by loss of expression, the latter is frequently brought about by deletion mutations (deleting part or all of the gene) or alternatively, by epigenetic modification of the gene regulatory sequences to suppress expression. Several TSGs function to inhibit the progression of the cell cycle, each acting at different points of the cycle, or in different tissues, or under different circumstances. The cell cycle is directed by a complex of proteins, including cyclins and their partners, the cyclin-dependent kinases (CDK). The CDKs, in turn through the cycle, phosphorylate and activate a plethora of proteins that orchestrate the cycle moving forward, from the initial growth phase (G 1 ), through DNA synthesis (S), the completion of DNA synthesis and continued growth (G 2 ) and mitosis (M) ( Figure 37 ). One of the central players in the cell cycle is a TSG called the retinoblastoma ( RB ) gene. In the unphosphorylated state, the RB protein inhibits both entry into S phase and the progress of the cell cycle by obstructing crucial cell cycle progression factors. When a cell receives signals to undergo division, this activates the cyclin/CDK complexes and one of the substrates is RB. As RB becomes phosphorylated, it releases the cell cycle progression factors to allow the cell cycle to move forward. If RB is lost from the cell, this critical inhibitory mechanism is lost, rendering the cell subject to uncontrolled proliferation. Many cancer cells show complete loss of RB expression. This means that both alleles must be affected, either by mutation (typically deletion) or epigenetic suppression. At the level of the cell phenotype, loss of RB is recessive, with one functional copy sufficient to control the cell cycle, however, as discussed below under heritable cancers, the dominant/recessive issue is more complex.

The cell cycle and RB

The cell cycle is depicted, showing the phases (divided by chevrons): growth or gap 1 (G 1 ), DNA synthesis (S), growth or gap 2 (G 2 ) and mitosis (M) in a circle, with exit from cycle represented as G 0 . Cell cycle check points are depicted as bars, G 1 /S check point (red: a DNA damage check), S-phase check point (blue: a DNA damage and replication fork check), G 2 /M check point (green: a DNA damage and completion of replication check) and spindle check point (yellow: ensuring correct alignment of the chromosomes upon the spindle, ready for division). The cyclin and CDK complexes relevant to each phase are shown. Central to cell cycle control is the TSG RB. RB becomes increasingly phosphorylated by the activated CDKs through G 1 (as depicted by increasing P). As the cycle progresses, it becomes hyperphosphorylated and this allows entry into S phase and further progression. Un-phosphorylated RB blocks cell cycle progression. During G 1 , the cycle can be initiated via mitogenic signalling (purple arrows). Once past ‘start’ the cell is committed to cycle.

Several other TSG products also act to inhibit cell cycle components to tightly control proliferation, such that this proceeds only when required and when all conditions are optimal, acting directly to inhibit the kinase activity of CDKs. A number of these (when first characterised), were given the unimaginative name that simply refers to the apparent size of the protein (in kiloDaltons), including p21, p16, p27 etc., with a superscript to distinguish between it and other proteins of the same size. The TSG encoded protein p21 Waf1 (expressed from the CDKN1A gene), inhibits CDK2 and therefore blocks entry into S phase and progression through G 2 , while p16 Ink4a (expressed from the CDKN2A gene) inactivates the CDK4 or CDK6 complex bound to cyclin D and therefore plays a key role in the passage of cells into G 0 (exiting cell cycle) and entering quiescence (reversible) or senescence (irreversible).

Numerous other TSG products function in processes that are not directly related to the cell cycle, instead affecting the growth conditions of the tumour and its environment. For example, if a solid tumour does not acquire a blood supply to provide sufficient oxygen and glucose to the dividing cells, it can grow little more than a few millimetres in diameter. The TSG termed von Hippel–Lindau ( VHL ) encodes an enzyme required in the processes of protein degradation; a ubiquitin ligase, its primary target, HIF (hypoxia-inducible factor), is a key protein that controls the growth of blood vessels from existing vessels (angiogenesis). Normally angiogenesis occurs when metabolic activity is high and oxygen availability low (like in a growing muscle in response to exercise), but otherwise is kept repressed. Mutations in VHL that result in the loss of the ability to cause HIF degradation, permit the persistent activation of HIF, thence the unrestrained angiogenesis necessary for tumour growth.

Genome integrity

As somatic mutation is a driving force in cancer, loss or aberrant function of genes involved in the processes of repair of damaged DNA can be tumorigenic. DNA damage can be caused by exogenous mutagenic agents, but the vast majority of mutations that are present in a cancer cell have occurred as a result of errors during DNA replication or have been caused by endogenous biochemical processes. As such, replication proofreading and repair proteins work continuously to maintain the integrity of the genome. Not all DNA repair genes are TSGs or proto-oncogenes, many are essential and therefore their mutation or loss will lead to cell death. However, if mutation of such a gene permits cell survival, but increases the chance of incorrect repair (i.e. mutation), this will increase the cancer risk.

The most commonly mutated TSG in human cancer is a gene termed TP53 . The encoded TP53 (or simply p53) protein is a DNA-binding transcription factor. Normally present at low levels in the cell, it becomes stabilised and activated when the cellular genome is at risk, particularly following DNA damage ( Figure 38 ). When DNA damage is detected by a complex of proteins, the information is transduced by either the ATM kinase or the ATR kinase to activate effectors, CHK1, CHK2 and p53 ( Figure 38 ). P53 then acts to induce the expression of other genes that will halt the cell cycle, including p21 Waf1 . As such, there is an effective ‘check point’ at the G 1 /S boundary of the cell cycle ( Figure 37 ). If DNA is damaged, activated p53 induces p21 Waf1 expression, CDK2 is then inhibited and the cycle does not proceed. P53 is also involved in DNA repair processes, therefore, following DNA damage, the repair machinery can work while the cell cycle is delayed. Additionally, p53 can induce the expression of genes that will lead to cell death (counteracting the survival function of BCL2) if the cell is beyond repair, thus the cell can be neatly removed. The most common mutations in TP53 in cancer cells occur in the DNA-binding region of the protein and prevent p53 from binding to DNA and therefore disable its function as a transcription factor. As a consequence, cells with damaged DNA can progress through the cell cycle check points with a high risk of mutation. For this reason, p53 has been referred to as ‘the guardian of the genome’.

Sensing and responding to damaged DNA

The proteins that initiate DNA repair after damage or replication blockage can be divided into sensors, transducers and effectors. The sensors: a complex of proteins recognise the broken ends of DNA double strand breaks (DSB) and complexes of different composition recognise stalled DNA replication forks (pink and yellow bubbles). These complexes attract two key kinases, ATM and ATR, the transducers, which function to phosphorylate, and thereby activate, two further kinases, CHK1 and CHK2. TP53 is stabilised both directly via phosphorylation by ATM and by phosphorylation by CHK1 and CHK2. Following on, the effectors lead to one of several responses, as indicated.

BRCA1 and BRCA2 (breast cancer 1 and 2) are also TSGs involved in DNA repair. The encoded proteins act in a complex to repair DNA double strand breaks (DSB). Mutations that lead to loss of function of the proteins or loss of expression result in a high chance of inaccurate repair of DNA DSB and thereby markedly increase the mutation rate of the cells and therefore also the cancer risk.

Some oncogene products act to down-regulate DNA repair, either as one of several functions, or in some cases, their primary function. The mitogenic protein HER2 (described above), when activated, down-regulates several DNA repair factors and this contributes to its oncogenic properties. In the last few decades, the importance of small non-coding RNAs in controlling gene expression has become apparent. Numerous tiny RNAs (called miRNAs) are expressed by cells and these function by down-regulating the expression of specific target genes. The miRNA-182 (miR-182) specifically down-regulates the expression of BRCA1 and a few other TSGs and miR-182 has been found overexpressed in several cancer cells (including breast cancer), often as a result of gene duplication. It can therefore be viewed as a distinct type of oncogene.

Cancer types show characteristic mutation profiles

Multiple powerful oncogenes have been known for several decades and historically, many were identified by virtue of the action of retroviruses in animal tumour model systems. Many of these are mutated in particular types of cancer and with different frequencies, for example RAS gene mutations are found in roughly 60% of pancreatic cancers, 50% of colon cancers, 20% of lung cancers, but rarely (1%) in kidney cancer. Several critical TSGs were discovered as a result of determining the pathogenic variant in familial cancer syndromes, such as heritable retinoblastoma. Furthermore, it has long been known that certain types of mutations are typical of particular cancer types, for example follicular lymphoma cells carry a chromosomal translocation involving the BCL2 locus and Burkitt’s lymphoma cells always harbour a translocation involving the C-MYC gene. However, the vast majority of oncogenes and TSGs make just a small contribution to the development of disease and are therefore harder to discern. Tackling this problem has been revolutionised by the huge advances in genome sequencing technologies over the last few decades. As will be described in the next section on ‘Genomics’, large sequencing projects comparing the mutated genome of a tumour with that derived from the normal tissue of the same individual has enabled the identification of causative mutations in that cancer. Taking this approach, not only have many more mutations (and therefore genes) which contribute to the cancer process been identified, but it has also been found that cancer types (and even subtypes) show characteristic somatic mutation profiles and this can then inform treatment options.

Epigenetic modifiers

In addition to mutation, overexpression of oncogenes and loss or reduced expression of TSGs are found in cancer cells through epigenetic modification of the expression control sequences. The genes whose products are epigenetic modifiers, are themselves frequently mutated in cancer cells. The mutation of these genes, (or their abnormal expression as a consequence of epigenetic modification of their control sequences) leads to aberrant chromatin modelling and the misexpression (under or over) of multiple genes. Epigenetic silencing of TSGs has been found to play a significant role in the genesis of cancer. Moreover, mutation in epigenetic modifier genes can have widespread effects and in some cases, they can be viewed as TSGs. For example, loss-of-function mutation in the DNA methyltransferase 3A ( DNMT3A ) gene is frequently found in blood cell tumours (lymphoid and myeloid malignancies). The loss of DNMT3A appears to increase the proliferative capacity of the cells and inhibit differentiation. Conversely, other genetic modifier genes have gain-of-function mutations in cancer cells. The histone-methyltransferase encoding gene EZH2 has been found to be activated by point mutation or is overexpressed through gene amplification in a variety of tumours. However, this gene cannot be simply classified as an oncogene, as its loss is observed in other tumours indicative of a TSG role in some cell types. Thus, altered epigenetic modification of genes is widespread in cancer cells, however its control is highly complex.

Heritable cancer and predisposition

Three factors essentially determine whether a cell becomes cancerous: the environment (including lifestyle), chance and the genotype. As described above, environmental mutagens (such as sunlight and tobacco smoke) clearly increase the risk of cancer and, although some are highly controversial, dietary factors (such as alcohol) may also influence risk. Statistical chance reflects that only a tiny proportion of all possible somatic mutations will be causative in cancer processes and this is why carcinogens are described as increasing the ‘risk’ of cancer. The genotype is all-important. Heritable loss-of-function variants in some TSGs increase the risk of cancer so substantially, that these present as dominant pathogenic variants, however, they contribute to a relatively small proportion of cancers overall ( Table 10 ). This is exemplified by heritable loss of function variants in TP53, RB, BRCA1 and BRCA2 . Breast cancer is a common cancer, and approximately 1 in 8 women in the U.K. will develop it during their lifetime, while only 3% of these cases are caused by inherited pathogenic variants in BRCA1, BRCA2 or TP53 . Conversely, retinoblastoma is a very rare childhood cancer, with approximately 45 children diagnosed per year in the U.K. Of these, approximately 40% carry inherited pathogenic variants in the RB gene. Germline loss of function variants in TP53 cause Li–Fraumeni syndrome (affecting approximately 1–4 individuals per 20000), which is characterised by early-onset cancer of several different types. The risk of developing cancer in such an individual is approximately 50% by the age of 30, rising to 90% by the age 70. The apparent paradox, that loss of function of these TSGs is recessive in the cellular phenotype, yet dominant in the individual, is explained by Knudson’s ‘two hit hypothesis’, first put forward to account for this phenomenon with respect to the RB gene and familial retinoblastoma (from which the gene was discovered). The function of one allele is heritably inactivated and the other allele is inactivated through somatic mutation or epigenetic silencing, such that tumours arising in these individuals show loss of function of both RB alleles. The same applies to other TSGs and tumour types, including heritable loss of TP53 function and the development of Li–Fraumeni syndrome tumours and heritable loss-of-function variants of BRCA1 and BRCA2 in breast cancer.

The population frequency % given under organ affected, indicates the proportion of individuals in the U.K. that are likely to develop this cancer at some point in their life. Numbers indicate new cases diagnosed in the U.K. Statistics were derived from the Cancer Research UK website.

Some heritable pathogenic allele variants increase the cancer risk by a small but significant degree, for example patients with a hyperactivated variant of the PIK3CD gene (a proto-oncogene which functions in signal transduction) suffer from the dominant disorder activated PI3Kδ syndrome (APDS) but also have an increased risk of B-cell lymphoma.

Aside from the clear cancer-associated, high risk, inherited gene variants, the genetic profile of an individual has a profound effect upon the predisposition to cancer. Thousands of allele polymorphisms or variants may increase or decrease the cancer risk (relative to each other) by a tiny degree, or under specific circumstances. Combinations of many such medium or low risk alleles together may have a compound effect upon risk. These low, medium and condition-specific risk alleles are being identified and explored using GWAS approaches and mass sequencing endeavours like the 100,000 Genomes Project (see next section). As such, although the statistics currently give this impression, there is really no clear distinction between ‘heritable’ and ‘spontaneous’ cancers, it is better described as a sliding scale of inherited risk. The large proportion of cancers currently not classified as heritable, nevertheless arose against a genomic background with a certain risk value. The massive GWAS and sequencing studies currently underway hold enormous promise for the future; there will come a time when the genotype of an individual can be used to determine the lifetime risk of certain diseases, particularly cancer and this can then be used to suggest preventative lifestyle measures or treatments.

Whereas genetic studies have traditionally focused on the effects of variants in individual genes, there is a shift towards consideration of the impact of the whole genome in health and medicine. Many conditions with a strong genetic basis, like T2D, epilepsy, hypertrophic cardiomyopathy and intellectual disability are associated, not with pathogenic variants in single genes, but rather, with variants in any one of a growing number of genes. There are (in 2018) 84 genes in which variants are reported to be associated with epilepsy as a core symptom, and several hundred other genes in which variants lead to conditions with epilepsy appearing as part of a wider spectrum of symptoms. There are over 600 genes in which pathogenic variants have been reported to be associated with intellectual disability, and the list is expanding. This diversity underlies the fact that for many individuals and families affected by genetic disease, there has been a ‘diagnostic odyssey’, with a series of misdiagnoses over many years, and perhaps a series of genetic tests, which may or may not have culminated in a definitive outcome.

As explained earlier, cancer results from an accumulation of somatic mutations which lead to disruption of the pathways which normally regulate processes including cell proliferation, cell death and cell motility. These pathways collectively involve input from the products of hundreds of genes (over 1% of our genome), and it is a challenge to identify all the genes in which mutation can contribute to cancer (the causative mutations). In addition to this, the inherited genome of all individuals influences the risk of developing certain types of cancers, upon which the somatic mutation profile builds.

Whole genome approaches, both GWAS and full sequencing are now being used by collaborative groups of scientists and consortiums to investigate the genetic predisposition to disease and the contribution of somatic mutation. To help address the gaps in our understanding of genes involved in rare diseases and complex disorders and genes associated with cancer, as well as to enhance understanding of our genome as a whole, the 100,000 Genomes Project was initiated in 2012 by Genomics England (owned and funded by the U.K. Department of Health).

The 100,000 Genomes Project and Scottish Genomes Partnership

The 100,000 Genomes Project set out with two targets. Firstly, to fully sequence entire ‘normal’ and ‘tumour’ genomes from approximately 50000 cancer patients, in order to be able to identify all the alterations in the cancer genomes; and secondly to fully sequence the genomes of approximately 17000 rare disease patients together with two very close relatives (ideally mother and father) ( Table 11 ). Analysis of parent-child trios facilitates identification of de novo mutations that may contribute to disease, as well as recognition of variants that may be benign (present in a healthy parent). The Scottish Genomes Partnership (SGP) plans to sequence genomes of at least 3000 individuals, with goals that are similar to those of the 100,000 Genomes Project.

In a few cases, it may be another close relative.

Each genome sequenced generates roughly 200 GB of data, which represents huge challenges for data storage and analysis, as well as data security. Nevertheless, the benefits should include not only a molecular diagnosis for thousands of rare disease patients, but also a huge amount of data that will contribute to our understanding of the role of genomic variations and mutations in disease, and to the development of better diagnostic approaches and improved therapies that are targeted to key alterations.

Genetic modifiers

The complexity of, and interactions between, biochemical pathways and physiological processes within the body mean that it is important to consider not only pathogenic variants in a single gene, but to also take into account the potential effects of other genetic variants elsewhere in the genome. This is exemplified by long QT syndrome (LQTS; named for an alteration seen on electrocardiogram traces of the heart’s rhythm, where the ‘QT interval’ is very prolonged) which presents as a defect in the electrical activity of the heart affecting approximately 1 in 2000 individuals, and can result in sudden death. The commonest cause of autosomal dominant LQTS is a loss-of-function variant in one copy of the KCNQ1 gene. Some common variants in another gene, NOS1AP , have been demonstrated to have a small but significant effect on QT interval, even in healthy individuals. These variants in NOS1AP can cause further prolongation of the QT interval that is associated with an increased risk of sudden cardiac death in carriers of a pathogenic KCNQ1 variant.

Variants in several genes have been identified as potential modifiers of lung disease phenotypes in CF, and it is likely that multiple genetic modifiers exist for a major proportion of genetic diseases. Identification and understanding of genetic modifiers and the mechanisms by which they operate will extend the range of potential therapeutic targets, and also allow better prognostic information and risk stratification. It is hoped that initiatives like the 100,000 Genomes Project and SGP will contribute to the identification of such genetic modifiers.

Investigating cancer predisposition

There are many examples in which the identical pathogenic variant leads to different severity of disease in different individuals. For many variants the penetrance (the proportion of individuals with the variant who exhibit the phenotype) is less than 100%, and the expression (pattern of effects observed in individuals with the variant) can also vary. For example, inherited pathogenic BRCA1 variants are associated with predisposition to breast and ovarian cancer. However, some women inherit a clearly pathogenic BRCA1 variant but are not affected during their lifetime. Women who inherited the same pathogenic BRCA1 variant may be affected by breast cancer only (unilateral or bilateral), by ovarian cancer, or by both breast and ovarian cancer, and in fact other cancer types may also be seen as a consequence of the inherited BRCA1 variant. Differences in penetrance and expression are likely to depend to a great extent upon a combination of environmental and genetic modifiers. Thus, while such individuals carry a high risk pathogenic variant, multiple other genes contribute to the overall risk of disease.

The majority of cancers arise in individuals who do not carry a high risk pathogenic variant (such as the BRCA1/2 variants). Nevertheless, the genetic make-up of the individual influences the chance of cancer occurring, affording protection against risk, or increasing the predisposition. By comparing the genotypes of individuals who have suffered from one type of cancer with those who have not, it is possible to begin to build information about the relative risk that certain gene variants might hold, also, to relate the risk to particular conditions. Such studies typically involve GWAS approaches (see Figures 28 and  29 ), but can also be revealed by full genome sequence analysis. For example, a specific SNP might be linked with some protection for the individual from the damaging effects of cigarette smoke in the lung, but might have little effect on lung cancer incidence in a non-smoker. Similarly, another variant might increase the cancer risk, but only in a smoker. Risk of lung cancer attributed to such variants therefore would be conditional upon the smoking status. Similarly, risk alleles might reflect diet or other environmental factors, or may show a disease association that is not dependent upon any known environmental condition. In relation to cancer, such studies hold great promise for future cancer prevention, as building a risk profile for individuals would facilitate informed lifestyle choices and preventative treatment measures (as is currently the case with prophylactic surgery for BRCA1 and BRCA2 pathogenic variant carriers).

Identifying causative or driver mutations in cancer

Cancer cells harbour hundreds, even thousands of somatic mutations, but only a small proportion of these are causative in the cancer process; the vast majority are generally ‘passenger’ mutations. By comparing the genomic sequence of the cancer cells with that of the unaffected genome from the same individual (from non-cancer tissue, usually the blood), all of the somatic mutations that have occurred in the cancer cell can be identified. Then by comparing the genes that have been subject to mutation, between cancers arising in hundreds of different people, it is possible to establish which genes are commonly mutated in a given cancer type. On the basis that mutation occurs largely at random, the chance that a passenger mutation in a given gene will be observed in multiple cancer samples is low. Conversely, if a causative mutation occurs, this will give the cell a growth advantage and it will be selected during the ‘evolution’ of the cancer. Therefore, genes that are found to be mutated in multiple different cancer samples constitute candidate driver mutations. The gene’s properties and function can then be researched to assess if it can indeed contribute to cancerous processes.

Understanding the contribution of risk alleles and the role of all the cancer-associated mutations is crucial to enable the design and successful delivery of novel therapies which target particular mutations present in a given cancer. Furthermore, it appears likely that future genetic diagnostics will be aiming to identify not only the primary causative variants in rare and complex diseases, but also the genetic modifier variants that may influence disease severity and progression: a genomic rather than genetic approach.

Advances in technology, particularly in DNA sequencing technologies, have led to identification of even more genes for which loss or changes in function can lead to disease. This in turn increases the need for genetic testing, to confirm potential diagnoses, to provide information on recurrence risk (for example, in future pregnancies) and to facilitate testing in relatives where appropriate. The range of tests available in genetic diagnostic laboratories has changed dramatically in recent years, with time-consuming tests like Southern blot being replaced by approaches with much faster turn-around times.

Karyotyping

Genetic testing has its roots in being able to visualise whole chromosomes in a process known as karyotyping (see Figure 2 ). This process usually requires culture of cells (can take 1–2 weeks) and arrests cells in metaphase, the stage of the cell cycle in which the chromosomes are in their most condensed form and thus easiest to visualise. In early karyotyping analyses, the imaged chromosomes were simply arranged, in order of their size and position of the centromere. Advances in this procedure came in the 1970s when various banding techniques were developed, including G-banding, currently the most widely used technique in the U.K. and U.S.A. Following trypsin digestion, Giemsa dye is used to stain the chromosomes, with AT-rich, gene-poor regions staining more readily than the gene-rich regions. The resultant pattern allows the chromosomes to be distinguished and thus permits the presence of large abnormalities such as deletions, duplications, inversions and translocations to be assessed. One drawback of karyotyping is the lack of resolution; in general changes of less than 3–4 Mb are virtually impossible to detect.

Fluorescence in situ hybridisation

A later development, in the 1980s, was fluorescence in situ hybridisation (FISH), which uses labelled DNA probes to assess the presence, copy number and location of the complementary sequence of DNA in an individual’s genome by hybridisation. The sample under investigation can comprise interphase cells or cultured cells arrested in metaphase, and is immobilised on a surface, usually a glass slide. After incubation with the fluorescently tagged probe followed by washing to remove unbound probe, binding of the probe is viewed using a fluorescence microscope ( Figure 39 ). An example of a condition where FISH might be useful is DiGeorge syndrome (DGS), a genetic condition usually caused by microdeletions of 3 kb or less, including the TBX1 gene, at 22q11.2. Conventional karyotyping does not have sufficient resolution to identify such deletions. However, using FISH probes for the TBX1 gene, the deletion can be easily identified. Various types of FISH probes can be used, including single locus probes (like the TBX1 probe), centromeric probes (which recognise centromeres of specific chromosomes), subtelomeric probes (which target unique sequences close to the telomere) and chromosome paints (which can target the non-repetitive content of an entire chromosome). Chromosome paints can facilitate the identification of the chromosomal origin of constituent parts of rearranged chromosomes. A drawback of FISH is the cost of the probes (£ 50–100) plus the time taken for the analysis, so that there is a limit to the number of loci that it would be economically feasible to test for in one patient. Thus the subsequent development of microarrays has superseded the use of FISH, particularly where the clinical features do not narrow the region of the genome that is likely involved.

( A ) One or more fluorescently labelled probes are required for the targets that are to be detected. The patient sample containing chromosomal DNA (which may be cultured cells for metaphase FISH or uncultured cells for interphase FISH) is immobilised on a microscope slide. Probes and chromosomes are denatured and allowed to hybridise together, thus localising the fluorescent probes to the regions where complementary chromosomal DNA is present. ( B ) Probes for detection of DiGeorge syndrome. One probe (red) targets the DiGeorge locus at 22q11.2 (including the TBX1 gene), and a control probe (green) targeting genes at 22q13 ( ARSA and SHANK3 ) helps to identify both copies of chromosome 22. Note that FISH probes are very long, typically hundreds of kb, in order to render the target detectable; this means that a small deletion may be missed. ( C ) A fluorescence microscope is used to visualise the results; the image here includes an interphase nucleus as well as a metaphase spread. The chromosomal material has been counterstained blue by DAPI. The normal chromosome 22 is indicated by ‘ n ’ in the metaphase spread and in the inset; both red and green probes hybridise (the presence of two separate spots for each probe is due to the presence of sister chromatids each possessing a copy of the relevant locus). The chromosome 22 with deletion of the DiGeorge locus (indicated by ‘d’ in the metaphase and inset) shows hybridisation only to the control probe. Note that the interphase nucleus shows only the number of loci present (two green control loci and one red DiGeorge locus), not their location with respect to each other. Note also that in interphase nuclei the chromosomes are very extended so that even loci on the same chromosome become widely separated. FISH image courtesy of West of Scotland Genetics Service. Chromosome ideogram from NCBI Genome Decoration Page.

Mutation specific assays

Although karyotyping and FISH offer a large scale view of chromosomes, there are often times where resolution at the nucleotide level is required. Conditions where the underlying genetic change is known allows the design of specific assays which can be used in a clinical context. Using CF as an example, it is known that by testing for a defined set of 31 pathogenic variants, it is possible to detect almost 90% of CF cases in a Caucasian population. One of the approaches used is known as allele-specific PCR (or amplification refractory mutation system, ARMS).

This allele-specific PCR is based on the principle that complementarity at the 3′ binding site of the primer is crucial for amplification to occur. Although base mismatches at other points in the primer may be tolerated, mismatches at the 3′ end prevent amplification in the extension phase of the PCR. Thus it is possible to design two sets of primers – one which matches the ‘normal’ allele and one set where the 3′ end of one primer is complementary to the pathogenic allele ( Figure 40 ). By determining which set of primers generate a PCR product, it can be determined whether normal, pathogenic or both alleles are present in the individual. This process is repeated for multiple variants, often carried out simultaneously in the same reaction.

Allele-specific PCR by positioning the variant at the 3′ end of one primer

( A ) As with all PCRs, both forward and reverse primers are required, one of which will be a common primer (here the forward primer) and one of which will have specific versions for each allele (here the reverse primer). The specificity is generated by the sequence at the 3′ end of the primer. For assay of a SNP with two alleles, two PCR amplifications are set up, both containing the common primer, but containing the alternate versions of the allele-specific primer. ( B ) An assay for a T/C SNP. ( 1 ) One version of the reverse primer has an A at the 3′ end; this matches the T allele, and extension can occur from the primer when the T allele is present, so PCR products are obtained from homozygotes or heterozygotes for T (TT or TC). ( 2 ) The reverse primer with A at the 3′ end does not allow extension, so PCR would fail if only the C allele were present (CC homozygotes). ( 3 ) Reverse primer ending in G does not allow PCR amplification when the template contains only the T allele (TT homozygotes). ( 4 ) Reverse primer ending in G allows extension if the C allele is present (CC or TC).

Several other techniques, including reverse dot blot and the oligonucleotide ligation assay are alternatives to consider when detecting pathogenic variants that affect one or a few nucleotides. For conditions where pathogenic change is more likely to be a deletion or duplication, for example DGS or Duchenne muscular dystrophy (DMD), a technique such as multiplex ligation-dependent probe amplification (MLPA) may be used ( Figure 41 ). Although FISH ( Figure 39 ) can also detect deletions such as those found in DGS, MLPA, utilising multiple smaller probes across a larger genomic region, can provide a higher resolution view of the extent of any deletion. However FISH is able to provide information on chromosomal position of the target sequence(s), whereas MLPA only informs on copy number.

The MLPA assay and application to diagnosis of DGS

( A ) Short regions of DNA, roughly 50–70 bp, are selected as targets, indicated by S and T ( 1 ). Single-stranded oligonucleotide probe pairs are designed for each target ( 2 ), with half of the target sequence present in the ‘left’ probe and the other half in the ‘right’ probe. Each left probe contains an additional sequence ‘F’ and each right probe contains an additional sequence ‘R’. The right probes also contain a ‘stuffer’ sequence which is a different length for each target to be detected. Genomic DNA is denatured and probes allowed to anneal ( 3 ). Annealed probe pairs will lie precisely adjacent to each other on the target DNA ( 4 ) allowing DNA ligase to join left and right probes together into a single molecule ( 5 ). The ligated probes are denatured away from the target ( 6 ), and then PCR amplification is carried out ( 7 ) using the same primer pair for all ligated probes (fluorescently-labelled F and the complement of R). The final quantity of each amplified product is dependent upon the copy number of that target sequence within the sample genome. ( B ) For each target the amount of fluorescent product from the test sample is compared with the amount of product from a control genome, and the ratio is plotted. This plot depicts typical MLPA results for 29 target sequences across the 22q11 region for a patient suspected of having DGS. The gene targeted by each probe is indicated below the plot; distance along the X-axis indicates distance along the chromosome. A ratio of approximately 1.0 indicates normal copy number (blue squares). However the results for 14 targets (including two for the TBX1 gene) give a ratio of only 0.5, indicating a halving of the copy number (one copy instead of the two expected from two complete copies of chromosome 22). This result confirms a diagnosis of DGS. ( C ) The region of chromosome 22 which is targeted by MLPA probes from the ‘P250-B2 DiGeorge’ kit from MRC-Holland. Cat eye syndrome (CES) is caused by duplication of the region indicated by the green bar; duplications can be identified by amplification ratios of 1.5 compared with control. Roughly 90% of DGS cases result from a 3-Mb deletion, indicated by the blue bar, and including approximately 60 genes, while approximately 8% of cases have a 1.5-Mb deletion, indicated by the purple bar, involving 28 genes. A small number of cases have atypical deletions which may be larger than 3 Mb. While FISH using the TBX1 probe (red) can identify a deletion in the region, MLPA can provide a more accurate picture of the extent of any imbalance due to the greater number of probes used. The P250-B2 DiGeorge kit also contains probes that target relevant regions on chromosomes 4q, 8p, 9q, 10p and 17p, in which copy imbalance generates phenotypes which overlap with DGS; thus a single MLPA assay can assess multiple target regions. Chromosome ideogram from NCBI Genome Decoration Page.

Sanger sequencing

The techniques described above are useful in detecting conditions where there is already some knowledge of where in the gene the pathogenic variant is likely to be, for example it is known that p.Phe508del accounts for approximately 70% of CF alleles worldwide, which can be easily detected using allele-specific PCR. However, many conditions do not have a subset of common mutations, a good example being the inherited predisposition to breast cancer, where pathogenic variants are spread throughout the relevant genes, which include BRCA1 and BRCA2 . In order to detect these types of changes it is often necessary to determine the sequence of the whole gene(s) in a patient and to then compare this with a reference genome to identify changes in the patient. For many years this has been done using Sanger sequencing, a technique which was first developed in the 1970s, but which has undergone many developments to generate the currently used automated method ( Figure 42 ).

Automated Sanger sequencing

( A ) PCR products ( 1 ) are generated from the region to be sequenced so that there are billions of template molecules for the sequencing reaction. A sequencing primer is annealed to the denatured PCR products ( 2 ). A mixture of deoxynucleotide triphosphates (dNTPs) and dideoxynucleotide triphosphates (ddNTPs) is added ( 3 ), which are used by DNA polymerase ( 4 ) to synthesise a new strand. The four ddNTPs are each labelled with a different fluorescent dye: ddATP green, ddCTP blue, ddGTP yellow and ddTTP red. When a dNTP has been added, DNA synthesis can continue in the normal way. However, ddNTPs are chain terminators, so that once a ddNTP is added, synthesis will terminate; the colour of fluorescence of the terminated chain will indicate which nucleotide is present at that position (here the red fluorescence indicates a T). Because there are billions of templates, and because ddNTPs are added randomly, terminating different chains at different positions, billions of terminated chains are generated, with many chains terminated at each nucleotide position. ( B ) The products of the sequencing reaction are denatured away from the template and electrophoresed to separate them by size; the shortest chains will move fastest. A laser-based detector registers the colours of fluorescence emitted as each of the sequencing products travels past. ( C ) The data from the detector is processed to generate an ‘electropherogram’, in which successive peaks represent products which are each one nucleotide longer than the previous one, allowing the sequence to be read by using the fluorescent colour to identify the nucleotide(s) at that position in the DNA. Here the control sequence is TTACAGC, while the patient sample shows a heterozygous substitution of T in the middle of this sequence: since two different alleles are present in the patient, both are represented in the sequence trace at this position, indicated by the pink star.

Aneuploidy testing by quantificative fluorescence PCR

Karyotyping was the traditional approach to diagnose aneuploidy, but the complete process took approximately 1–2 weeks due to the time taken to culture cells. To provide a rapid result, for example for testing during pregnancy, interphase FISH has also been used, but more recently quantitative fluorescence PCR (QF-PCR) has become the technique of choice for initial aneuploidy testing. This involves the analysis of microsatellites with high variability in the population. The copy number of each chromosome tested is deduced from a combination of the number of different microsatellite alleles present, and their ratios ( Figure 43 ). For each chromosome to be tested (usually 13, 18, 21 and sometimes including sex chromosomes) four or five loci are analysed along the length of the chromosome. This approach is generally effective in rapidly (next day) identifying trisomy, and a positive finding can be confirmed by karyotyping or another test if desired. Sometimes one or more of the loci used are homozygous and therefore non-informative, but results from the other loci on that chromosome are generally informative, allowing a result to be reported. Consanguinity is likely to lead to multiple uninformative microsatellites, in which case it is possible to use additional loci, or if that also fails, to use FISH/karyotyping.

Several microsatellite loci (here R, S and T) on the relevant chromosome(s) are analysed by PCR using an appropriate pair of flanking primers, one of which is fluorescently labelled, so that all products will be fluorescent, and quantity of product is measurable by amount of fluorescent product generated. The particular loci are selected on the basis of high variability (many different alleles) in the population. ( A ) Where there are two copies of the chromosome, there should be two copies of each microsatellite, which ideally have different repeat numbers. Thus at locus R one chromosome has 12 repeats, whilst the other has 14 repeats. Following PCR and electrophoretic analysis (see Figure 42 ), two product peaks are generated, one for each allele, at a 1:1 ratio. The same pattern is observed for loci S and T. ( B ) Trisomy should result in three copies of each microsatellite. Where there are three different alleles present (as for locus R) three peaks, at a ratio of 1:1:1, will be generated by the analysis. If two of the chromosomes share the same allele while te other is different (as for loci S and T) there will be two peaks with a ratio of 1:2 or 2:1. Thus disomy can be differentiated from trisomy by number of peaks generated and the ratios between them. Note that if all chromosomes present share the same allele at a particular locus, then only one peak is generated and that locus is therefore uninformative.

New approaches to diagnostics

Where there is clear suspicion relating to a particular gene or group of genes, it may be that specific assays, as discussed above, are the most cost-effective diagnostic approach ( Figure 44 ). But it is not always possible to pinpoint the relevant genes or genomic region from the patient symptoms. In such circumstances whole genome approaches are frequently used as the first-line strategy. Developmental delay and learning difficulties, for example can be associated with not only full aneuploidy, but also with gains and/or losses involving large segments of DNA which might be the consequence of microdeletions, microduplications or unbalanced rearrangements of parental translocations/inversions or specific gene variants.

Selecting an appropriate test

Where the pathogenic variant in a family is known then testing will generally use a specific assay for that variant. For new diagnoses the most appropriate and cost-effective test must be selected according to technology and expertise available to the laboratory as well as the clinical features of the patient. Definitive findings (blue, underlined) can be reported in cases where a specific family variant was being tested for, or where a clearly pathogenic variant that is causative of the patient phenotype is detected. Note that use of some techniques, such as karyotyping, is declining with the advent of NGS- and array-based approaches. *It is possible NGS gene panels may be used in future even where the disease gene is known. Abbreviations: ASP, allele-specific PCR; NGS, next generation sequencing; SS, Sanger sequencing; WES, whole exome sequencing; WGS, whole genome sequencing.

Microarrays

Microarrays allow simultaneous analysis of hundreds of thousands of individual targets across the genome. For whole genome analysis, SNP genotyping by array has largely replaced the earlier array comparative genomic hybridisation (aCGH) approach, so only SNP arrays will be described here. There are several different approaches (or ‘platforms’) for SNP array, but all are based on oligonucleotide ‘probes’ for each of the targets to be assayed, that are immobilised on a solid surface ( Figure 45 ).

Basic microarray

The microarray ( 1 ) is a grid of hundreds of thousands of microscopic ‘spots’; each spot ( 2 ) contains billions of copies of an oligonucleotide ‘probe’ that represents a specific target. These single-stranded probes will be able to hybridise to, and therefore capture ( 3 ), complementary ssDNA from a denatured sample – for example DNA from a patient (purple strands). Fluorescent label (yellow starbursts) can be attached to the patient DNA prior to hybridisation to facilitate detection – the presence and amount of label at each spot on the array is determined by scanning of the entire array.

DNA from patient samples can be fragmented, denatured and hybridised to the microarray; each spot on the microarray will capture its complementary sequence from the patient sample, provided that the particular sequence is present in the patient’s genome. The quantity of patient DNA that is captured on each spot will be proportional to the amount of that sequence present in the sample. The hybridisation process is optimised such that only perfectly complementary matches can occur. Thus the hybridisation can be sensitive to a single nucleotide difference, allowing genotyping to determine which allele of a particular SNP is present, for example by having one spot on the array for each of the two alleles. A typical SNP array can be used to genotype hundreds of thousands of SNPs from across the genome of a patient, and the interpretation of allele ratios plus total fluorescence ( Figure 46 ) can reveal multiple chromosomal imbalances ( Figure 47 ).

SNP array data can reveal copy number imbalance and homozygosity associated with consanguinity and UPD

For ease of display and interpretation in SNP arrays the two alleles of each SNP are conventionally designated A and B, thus, for a T/C SNP, T would become the ‘A’ allele and C would become the ‘B’ allele. Each SNP is genotyped and the result plotted (as a green spot) according to position along the chromosome in terms of ‘B allele ratio’, which will be 0% for AA, 50% for AB and 100% for BB. Trisomy is revealed by B allele frequencies of 33 and 66%, and by an overall gain in fluorescence. In monosomy there is only one allele for each SNP so there will be no heterozygosity, and the total fluorescence will be only half the expected value. Long runs of homozygosity resulting from UPD or consanguinity will generate normal fluorescence levels. Other states can also be diagnosed, for example mosaicism (mixtures of two or more cell lines) will lead to skewed B allele ratios.

SNP array demonstrates areas of loss and gain across the genome at high resolution

( A ) ‘LogR’ plot for all 22 autosomes and the sex chromosomes demonstrates balanced copy number for most chromosomes. The pink star indicates a duplication (upward shift of LogR) affecting the chromosome 2p terminus, which is expanded in ( i ). The blue star indicates a deletion affecting the 15q terminus, which is expanded in ( ii ). The green star indicates apparent loss affecting the X chromosome but this reflects the presence of only one X chromosome in a male. ( B ) The B allele frequency plot confirms the 2p duplication ( i ) and 15q deletion ( ii ); each spot represents the result for a single SNP – there are 843551 SNPs represented in this array. ( C , D ) The sample in this case came from the child of a balanced reciprocal translocation carrier. The chromosomes 2 and 15 of the parent are depicted in (C), with arrows indicating the breakpoints. The array result indicates that the child received an unbalanced arrangement from this parent: a normal chromosome 2 together with the translocation 15 (D). Note that the array result (A,B) also demonstrates a duplication of chromosome 15 material (yellow arrow) associated with the translocation breakpoint. This would have been below the resolution of a standard karyotype, but is clear from the array result. Small gains and losses can be seen in other chromosomes on close inspection; these may represent CNVs. Array images courtesy of West of Scotland Genetics Service using Illumina CytoSNP 850K Beadchip; chromosome images generated using CyDAS ( www.cydas.org ).

SNP arrays are more effective than karyotyping at revealing chromosomal abnormalities, since the resolution is higher: typically 50 kb, with a resolution of 10 kb in critical regions for diagnostic SNP arrays, compared with approximately 3–4 Mb for karyotyping.

Next-generation sequencing

While microarrays provide whole genome coverage at high resolution, many genetic conditions result from much smaller alterations, typically SNVs or small indels. Sanger sequencing provides accurate data but, even when automated, only one or two genes can generally be analysed at a time. A number of newer technologies, collectively referred to as next-generation sequencing (NGS), overcome the limitations of Sanger sequencing and can provide an entire human genome sequence by ‘massively parallel sequencing’. DNA from a patient sample can be fragmented and then the fragments can be sequenced as part of massive arrays generating millions or even billions of short sequence ‘reads’ per run. Bioinformatics is then used to map all these reads to the reference genome, which can then be assembled into a whole genome sequence for that individual ( Figure 48 ). Differences from the reference sequence are identified by the software, and this is where the limitations of whole genome approaches start to become apparent. Because of the sheer amount of variation present in each human genome, the task of filtering the information to identify relevant variants is enormous. In fact, in 2010 Elaine Mardis described the whole genome approach as ‘the $1,000 genome, the $100,000 analysis’ in recognition of the fact that while obtaining the full genome sequence is now relatively cheap, the subsequent analysis requires huge input of time and effort. Development of improved bioinformatics approaches will undoubtedly decrease the cost of analysis, however whole-genome sequencing (WGS) is currently beyond the scope of routine diagnostics in a healthcare context.

NGS data analysis

The screenshots cover one exon from the analysis of a patient sample with an epilepsy gene panel that examines exon sequences and flanking regions from 104 genes. ( A ) The top of the screenshot provides chromosomal context (in this case 14q32). The ‘read depth’ window provides an indication of the number of times each nucleotide was represented among all the reads. Individual reads are shown as blue (forward strand read) or green (reverse strand read) bars in the ‘pile-up’. Each read is approximately 100 nucleotides in length, and represents the output from one of the millions of massively parallel sequencing reactions. The reads are aligned to the matching segment of the genome reference sequence, to generate the ‘pile-up’ view. Where the sequence of a read differs from the reference sequence that nucleotide is highlighted in a different colour. Differences seen in only one or two of the reads are likely sequencing errors (for example, those indicated by orange arrows), while the pink arrow indicates a position at which approximately 50% of the reads differ from the reference, which indicates a heterozygous variant. At the bottom is shown the intron/exon structure: the data are for exon 65 plus flanking sequence of the DYNC1N1 gene. ( B ) The view is zoomed in to the heterozygous variant detected in the first nucleotide of exon 65 (the second base of a codon); this is a characterised variant known as rs138428684, present in 1 per 1000 European alleles, changing the coded amino acid from threonine to arginine at position 3981 in the encoded protein. Readers can explore this variant in databases like Ensembl genome browser ( www.ensembl.org ) by inserting the variant name (rs138428684) into the search box. Images courtesy of West of Scotland Genetics Service using SeqVar software.

An alternative to WGS is whole-exome sequencing (WES), in which either exon sequences are specifically captured/amplified from the sample for sequencing, or bioinformatics tools remove non-coding sequences from the subsequent analysis. A typical WGS will generate 3–4 million variants per genome, whereas WES will generate only 30000–60000. In cases where a particular variant leads to loss-of-function (e.g. nonsense, frameshift) in a gene that has been previously associated with the patient’s condition, or where the particular variant has been reported as causative for that condition, then an unambiguous diagnosis can be provided. However, large numbers of VUS are identified during NGS, in particular missense variants, or variants that might affect splicing. These can be analysed in silico , for example based on properties of the new amino acid compared with the original, or conservation of that amino acid between species, or potential to create or destroy a splice recognition site in the RNA.

The scale and difficulties associated with variant analysis mean that a preferred approach for many genetic conditions is to use a gene panel representing the specific set of genes that are known to be associated with the particular condition, for example epilepsy, cardiomyopathy, inherited cancer predisposition or even broader panels, such as for recessive paediatric-onset conditions. Even with a reduced sequencing target the problem of VUS is still significant, and many patients will still not receive a diagnosis. As knowledge improves, for example with functional studies by research laboratories, some VUS will be reclassified as either benign or pathogenic. However, the current position is that NGS technology surpasses our ability to effectively utilise the information generated for the benefit of patients.

Variants which are expected to have a severe effect on an encoded protein (for example nonsense or frameshift) are easy to classify as pathogenic. However, variants which might affect the quantity or sequence of the mRNA (for example, variants affecting splicing or promoter activity) are harder to interpret using the DNA sequence alone. Although in silico analysis can help, the optimal approach is to investigate the transcripts generated, by isolating RNA from a patient sample and conversion into complementary DNA (cDNA) for analysis. Of course, transcription and splicing patterns of many genes are tissue-specific, so there may be a requirement to use a tissue biopsy rather than a blood sample. RNA-based analysis is currently uncommon in diagnostic laboratories, with the notable exception of cancer diagnostics (see below). Nevertheless, NGS technology can also be applied to the analysis of cDNA, and this ‘RNA-seq’ approach, currently used extensively in research, has enormous potential in clinical diagnostics.

The role of molecular pathology in cancer diagnostics and management

Cancer cells accumulate large numbers of mutations, many of which are passengers, but some of which are drivers of the cancer phenotype. Identification of the driver mutations present in the cancer of a particular patient can help direct therapy. A relatively new application of genetic diagnostics is in molecular pathology, which is fast becoming a core discipline within cancer management. Immunohistochemistry is frequently used to detect levels of particular proteins in tissue sections from cancers, for example the detection of HER2 overexpression to inform decisions about use of the drug Herceptin. However, many of the genetic diagnostic approaches used for inherited disorders can also be applied to investigation of cancers. The presence of genome rearrangements that are associated with particular diagnoses and/or success of a particular therapy ( Figure 35 ) can be identified by use of specific combinations of FISH probes applied to interphase cells or tissue sections. Likewise, techniques including allele-specific PCR and DNA sequencing can be used to identify mutations of diagnostic or therapeutic significance, and MLPA can be used to identify gene copy number changes. The presence of cancer-associated transcripts, particularly fusion transcripts such as those from BCR-ABL gene fusions, can be assessed by PCR amplification of cDNA. Such PCR-based approaches have much higher sensitivity than FISH; for example interphase FISH can detect one leukaemia cell per 200 normal cells, whereas PCR using cDNA can detect one leukaemia cell per million cells. This level of sensitivity is critical in monitoring response to therapy, and in early detection of relapse (by reappearance of fusion transcripts in blood samples). In fact, the sensitivity of PCR is being harnessed in the development of ‘liquid biopsy’, which targets circulating cancer DNA present in the blood, and has the potential to replace invasive tissue biopsies.

As with all genetic diagnostics, NGS-based approaches are starting to play a role in molecular pathology, which is not surprising, given the large numbers of mutations in each individual cancer. Gene panels can be applied to the analysis of hundreds of targets within cancer DNA for alterations that provide information relevant to diagnosis, prognosis and response to therapy. Whereas the PCR-based approaches mentioned above are effective in identifying fusion transcripts, the number of targets that can be assessed in one assay is very limited, and therefore some fusions will be missed. RNA-seq represents a powerful approach to screen for hundreds of potential fusion targets in a single assay, and will be particularly useful in initial identification of relevant gene fusions in individual patients. Following identification of the fusion, standard PCR-based approaches can be used to monitor that patient in relation to the identified fusion.

Clearly health service genetics laboratories have many different approaches available for the detection of pathogenic variants, either inherited or in relation to cancer tissue. One of the key roles of a clinical scientist is therefore to ensure that the most appropriate and most cost-effective approach is used for each patient sample. This can also require that the clinician who is referring the patient for genetic analysis provides a sufficiently clear and thorough view of the clinical features, to guide appropriate genetic analysis. However, the increasing use of NGS-based approaches will facilitate a more comprehensive genetic analysis that will improve diagnostic success rates.

When considering genetic diseases, it is always vital to remember the impact they can have on the life of an individual, family and society. Diagnosis, management and therapy are all important aspects of genetic disease and these issues are discussed briefly in this section. Obtaining a clear diagnosis is often important for several reasons, potentially directing therapeutic intervention, management or informing reproductive decisions. A diagnosis can also be useful in terms of gaining access to relevant support, whether this be financial, social or practical. In addition, many individuals for whom obtaining a diagnosis has been problematic, report great relief when a diagnosis is finally made. Genetic testing can be carried out at any time during the life of an individual who is symptomatic or has a high risk. However, in some situations it is desirable to be proactive in testing whole populations in order for timely intervention to occur. This is typified by genetic screening programmes.

Newborn screening

Newborn screening for genetic conditions has been used for several decades in order to detect and treat genetic conditions and potentially avert serious outcomes. Diagnosis and treatment of the autosomal recessive condition phenylketonuria (PKU) (see Table 6 ), is one such success story. In this situation both parents are carriers and phenotypically unaffected but with a one-fourth chance of having an affected child. Affected individuals lack the enzyme phenylalanine hydroxylase which converts phenylalanine into tyrosine and this results in the toxic build-up of phenylalanine in the body. This has a devastating effect on the developing brain in particular, and causes irreversible damage.

Newborn screening for PKU in the U.K. began in 1969 and identifies affected babies by measuring the phenylalanine levels in a bloodspot taken from the heel between 5 and 8 days after birth. Once PKU is diagnosed, a strict phenylalanine-free diet is implemented which ideally should be continued throughout life (although adherence is less essential during adulthood with the exception of pregnancy). If this diet is implemented prior to day 23 of life, the individual will not suffer from brain damage and is likely to lead a normal life. Testing for other conditions such as CF and sickle cell disease is now also routinely offered and new conditions are added to the programme as part of regular review processes. Mass Spectrometry with its ability to give insight into the metabolome has already proven significant in these developments and will likely contribute to further expansion.

Pre-marital genetic testing for thalassemia

While newborn screening attempts to identify affected infants very early in life, other strategies are aimed at preventing the conception of affected individuals. Specifically, pre-marital or pre-conception testing identifies couples where both are carriers of the same condition so that they can make informed choices. Examples of conditions in which pre-marital testing has been successfully used are the thalassemias and sickle cell anaemia as well as Tay–Sachs disease. The widely reported pre-marital screening programme for thalassaemia in Cyprus began in 1973, with couples being required to produce a certificate confirming they had been tested for thalassemia carrier status before marriage could legally take place. In the majority of countries where this is practiced, marriage between two carrier individuals is not forbidden, however the social structure in many communities means that it is discouraged. In other settings, religious leaders, for example in some Jewish communities, have used the genetic information (with full consent from the individuals) as part of their marriage arrangement considerations. This was deemed to be both acceptable and indeed welcomed by the community, who for many years had suffered the effects of a high incidence of Tay–Sachs disease, a fatal inborn error of metabolism.

Prenatal diagnosis

Prenatal diagnosis (PND), the testing of an unborn foetus for a specific condition, is also offered by genetics services. An initial requirement of any PND is that the sample is obtained from the foetus. This can be achieved in a number of ways, primarily chorionic villus sampling (CVS) between 10 and 14 weeks of gestation, and amniotic fluid sampling, usually between 14 and 20 weeks of gestation ( Figure 49 ). As both have an intrinsic risk of miscarriage (1–2% and 0.5–1% respectively), they tend to only be offered where there is a substantial risk of disease. Later in pregnancy, taking a cord blood sample is also a possibility, with a similar risk of miscarriage to CVS. Amniocentesis and cordocentesis have the advantage that they represent foetal rather than placental tissue – although both are derived from the embryo, the possibility exists that mosaicism may be present, resulting in the placenta and the foetus having different genotypes and thus a small risk of misdiagnosis using a CVS.

Amniocentesis procedure

Under ultrasound guidance, a thin needle is passed through the abdominal wall into the amniotic sac. A small amount of amniotic fluid is then removed and subjected to analysis. The amniotic fluid contains a mixture of cells, a proportion of which will be foetal. By BruceBlaus, CC BY-SA 4.0, from Wikimedia Commons.

Once a sample has been obtained through CVS or amniocentesis, testing can be carried out. The genetic test used depends upon the reason for the PND; QF-PCR ( Figure 43 ) for aneuploidies is currently a routine step, and additional testing can be either directed (for a particular condition or chromosomal imbalance that the foetus is at-risk for) or a whole genome approach like SNP array ( Figure 47 ), where abnormalities of unknown aetiology have been detected on ultrasound. Individuals undergoing these procedures most often opt for termination of pregnancy if a genetic problem is found, while others use the knowledge to enable them to prepare for the birth of an affected child.

Pregnancy screening and non-invasive prenatal diagnosis

Traditionally, women have been offered maternal blood screening tests in early pregnancy, the results of which place them in either high or low risk categories for DS other trisomies. In the maternal blood sample, the level of a number of proteins is quantified and these results are combined with ultrasound measurements and factors such as age to assess risk. Women in the high risk category are then offered PND using CVS or amniocentesis to obtain a sample.

However, the relatively low sensitivity and specificity of the traditional maternal blood screening tests result in both false positives (unaffected pregnancies placed in the high risk category and therefore undergoing invasive diagnostic tests, with inherent miscarriage risk) as well as false negatives (affected pregnancies where the mother is falsely reassured by being placed in the low risk category).

Therefore, more recently, non-invasive prenatal diagnosis (NIPD) has been offered in pilot schemes in the U.K., in an attempt to reduce the number of healthy pregnancies lost due to diagnostic testing and to offer women greater choice. In NIPD, a sample of maternal blood is taken from approximately 7 weeks of gestation onwards and analysed directly, using cell-free foetal DNA in the maternal circulation ( Figure 50 ). The amount of DNA present can be quantified and a risk for aneuploidies given with a very high sensitivity and specificity (approximately 99% for DS). This screening can be followed up by diagnostic testing if a high risk result is obtained. NIPD can also be applied to some inherited disorders, for example by testing for foetal sex by presence of Y chromosome (for X-linked recessive disorders) or looking for paternal pathogenic variants.

NIPD for trisomy 21

( A ) Foetal cell-free DNA (cfDNA) from the foetal circulation crosses the placenta into the maternal circulation, which thus contains both maternal and foetal cfDNA. ( B ) cfDNA is collected from maternal blood samples. The maternal cfDNA tends to be longer fragments than foetal cfDNA so that separation is possible but not straightforward. In general, however, there is no separation stage. In cases where the foetus is affected by trisomy 21, there will be more foetal cfDNA fragments derived from chromosome 21 (coloured red and indicated by asterisks) in comparison with a case where the foetus is unaffected. ( C ) The total cfDNA is analysed by DNA sequencing using NGS, allowing a count of how many reads have been obtained from each chromosome. If there was an over-representation of chromosome 21 fragments in the cfDNA sample then there will be increased representation of NGS sequence reads that match chromosome 21 (asterisked). The analysis is often quantified by calculating ratios of (for example) chromosome 21 reads to chromosome 1 reads. If only foetal cfDNA was present the chr 21:chr 1ratio would be expected to be 1:1 from an unaffected foetus, and 1.5:1 from an affected foetus, but the additional presence of disomic maternal cfDNA in the sample means that the ratio will be lower.

Preimplantation genetic diagnosis and three parent babies

As an alternative to prenatal diagnosis and possible termination of an affected pregnancy, some couples prefer to prevent the implantation of an affected embryo. Pre-implantation genetic diagnosis (PGD) is an approach which combines IVF and genetic technology to ensure only embryos unaffected by a specific genetic condition are implanted in the uterus ( Figure 51 ). After IVF, and growth to approximately the 8-cell stage, 1 or 2 cells are removed from the developing blastocyst and, depending on the condition being tested for, undergo FISH or PCR-based analysis, looking for specific variants or imbalances. Only unaffected embryos are then implanted. Follow-up PND is recommended during the pregnancy as occasionally technical limitations may lead to false results at the genetic analysis stage. PGD has been successfully used for a number of conditions, including both single gene disorders and chromosomal disorders.

Pre-implantation genetic diagnosis by biopsy of early embryos

Traditional IVF procedures ( 1 ) are used to generate fertilised embryos ( 2 ), which are allowed to develop to the 8-celled stage ( 3 ). One or two cells are then removed for genetic analysis ( 4 ) and only embryos without the condition tested for are implanted into the mother’s uterus ( 5 ).

Furthermore, as discussed earlier, in a family with a mitochondrial disorder, transmission to the next generation can be prevented using the new approach known as mitochondrial replacement therapy in which a maternal and donor egg are combined, either prior or subsequent to fertilisation.

Personalised medicine

In addition to provision of diagnostic information for genetic disease, treatment is also an important area to address. While, general therapies have been used for centuries, the concept of personalised medicine has long been seen as the ‘holy grail’ of genetics. Encompassed in the idea of giving the right treatment to the right patient at the right time, personalised medicine relies on the ability to specifically diagnose the underlying molecular and genetic aspects of the condition.

With some cancers, a personalised approach is, to some extent, mainstream. In the treatment of breast cancer, only patients whose cancer expresses specific hormone receptors on their cell surface will be offered hormonal treatments such as tamoxifen for those whose tumours overexpress the oestrogen receptor. Similar approaches in leukaemia (using the drug imatinib to target cancer cells with BCR-ABL translocations) have been used for several years and are now beginning to be used in lung cancers (using erlotonib to target cancer cells which have EGFR mutations) and a variety of others ( Figures 52 and  53 ).

EGFR mutation status determines the outcome of erlotinib as a therapy

( A ) EGFR is a transmembrane receptor that has a tyrosine kinase (TK) domain. In the absence of EGF the normal receptor is in an inactive state. ( B ) When EGF binds, the TK domain undergoes a conformational change and becomes activated, generating signals for cell proliferation. ( C ) Cancer associated mutations in EGFR lead to hyperactivation of EGFR that represents a key driver of tumorigenesis. ( D ) The TK inhibitor erlotinib binds to EGFR and prevents downstream signalling. Therefore in cases where EGFR mutations are driving tumorigenesis, erlotinib can block this process. ( E ) The acquisition of a second mutation that prevents erlotinib binding leads to resistance to this inhibitor.

EGFR mutation status must be determined in order to ensure that erlotinib is only used in those cases where it will provide benefit

The EGFR activating and TKI resistance mutations are clustered in the tyrosine kinase domain (see Figure 52 ) between amino acids 688 and 875 of the EGFR protein, so that mutation analysis can be focussed on the coding sequences for this region. Abbreviation: NSCLC, non-small cell lung cancer.

More recently, personalised approaches to single gene disorders, for example CF are beginning to be used. For CF, drugs have been developed which target the specific protein defects caused by particular mutations, for example some mutations which cause the protein to form channels that cannot open and close properly. A drug called KALYDECO (ivacaftor) can be used in these patients to help the channel to stay open allowing normal passage of ions through the open channel.

Gene therapy/gene editing

While personalised treatments in cancer and in CF target the affected protein, therapies which address the underlying genetic aspects, to ensure that a functional protein can be generated, also hold great appeal. Broadly speaking, gene therapy aims to replace the defective gene by delivering a new working copy to the cell, while gene editing aims to correct the defective gene.

One condition in which these approaches have been studied is DMD, an X-linked recessive disorder which causes progressive muscle degeneration and weakness. DMD is mainly caused by large deletions and duplications (and less commonly nonsense mutations) in the dystrophin gene and affected individuals produce virtually no dystrophin, with resultant muscle cell damage. Males with the condition commonly use a wheelchair by 12 years old and the average lifespan for an affected individual is approximately 30 years.

In a condition such as DMD, where the underlying mutation is known, a variety of approaches have been trialled ( Figure 54 ). It is hoped that to induce exon skipping, whereby the RNA processing machinery excludes the affected exon, can result in a milder form of the condition, similar to Becker muscular dstrophy (BMD). Replacing the dystrophin gene through delivery by adenovirus particles has also been attempted, although not without difficulty due to both the size of the gene and the immune reaction to the viral particles.

Potential therapeutic approaches for DMD

( A ) In healthy muscle the dystrophin protein functions as a link between the actin fibres in the cell and the dystroglycan complex (DGC) in the cell membrane, preventing damage to the cell during muscle contraction. ( B ) In the absence of dystrophin, the muscle cell sustains damage during contractions, eventually leading to muscle cell death. A number of therapeutic approaches are possible (those in pink boxes have been trialled in DMD patients, with some success reported; the relevant drug names are in green font). ( 1 ) Stem cell therapy, by injecting either healthy, tissue matched muscle stem cells from a donor, or stem cells from the patient which have been isolated, cultured in vitro , and then subjected to genome modification (see 6 , 7 ) to correct the defect prior to injection back into the patient. ( 2 ) The utrophin protein has a similar structure and function to dystrophin, but is not normally expressed in sufficient quantity to substitute for dystrophin; by up-regulating utrophin gene expression the function of dystrophin can be replaced ( C ); this approach has been effective in mouse models. ( 3 ) A significant proportion (approximately 15%) of DMD is due to nonsense mutations which lead to premature translation termination, and would therefore generate non-functional protein fragments. By use of a nonsense suppressor drug, which influences the ribosome to read through nonsense codons by incorporating an amino acid and continuing translation, full length dystrophin protein can be generated ( D ). ( 4 ) Roughly 70% of DMD is due to deletion or duplication of exons, leading to frameshift; a proportion of microlesions also lead to frameshift. By use of molecules that target the splicing process, and cause selected exons to be skipped (removed during splicing), the reading frame can be restored, generating a shorter version of the dystrophin protein, which is, nevertheless, still able to form a link between actin and DGC ( E ). Although not the same as normal dystrophin, these shorter dystrophin proteins are associated with much milder symptoms, i.e. Becker muscular dystrophy (BMD). Exon skipping could also be used to skip exons harbouring nonsense mutations. ( 5 ) The full-length dystrophin gene is too large to be accommodated in current gene therapy vectors, but because shorter versions of dystrophin are effective in restoring function, gene therapy with minigenes is a possibility. (6) Genome editing using strategies like CRISPR-Cas may be utilised to correct the pathogenic change within the genome, either by in vitro targeting of stem cells removed from the patient prior to injection back into the patient, or by delivering the CRISPR-Cas system directly to the muscle cells. (7) Genome editing (exon snipping) to remove particular exons from the genome is an alternative approach to generating an in-frame gene that is free of pathogenic variants.

Clinical trials using gene therapy have had a notoriously difficult path, with death of a patient affected by ornithine transcarbamoylase (OTC) deficiency (Jesse Gelsinger) in one trial and development of leukaemia in others. Even in conditions which seem naturally amenable to gene therapy (e.g. CF with its well-understood pathophysiology and relative ease of access to affected tissues), achieving stable and sustained expression of replacement genes has proven difficult.

Recent success in treating the neuromuscular disorder spinal muscular atrophy (SMA) using a treatment known as antisense oligonucleotide therapy has aroused much interest. With the condition being caused by loss of a gene called SMN1 , research has focused on attempting to restore the function of a homologue, the SMN2 gene. Under normal conditions SMN2 is largely non-functional due to a point mutation which results in exon 7 being spliced out. Antisense oligonucleotide therapy employs an oligonucleotide which binds to the SMN2 mRNA and changes how it is spliced, allowing the SMN2 protein to substitute for the absent SMN1. Trials have so far been very successful, with every indication that this is a remarkable breakthrough in treating this severe and life-limiting condition.

Great excitement has also surrounded the advent of gene editing technology, in particular the use of the CRISPR Cas9 (clustered regularly interspaced short palindromic repeats (CRISPR) associated nuclease 9) system, a genome editing tool which acts as a pair of ‘molecular scissors’ to cut a specific piece of DNA. Made from two components and originating as part of bacterial immune defences, Cas9 is a nuclease, guided to its target by a single guide RNA which binds to its cDNA sequence. The Cas9–RNA complex creates specific DSB non-homologous end joining or by homology directed repair if a suitable donor DNA is present. This allows precise sequence modification to edit out the genetic defect and replace it with a desired sequence. Recent studies, for example in DMD mouse models show promise and there are hopes that the technique may also be applicable in humans ( Figure 55 ), although difficulties such as specificity and efficiency of the repair still have to be fully addressed, as does the issue of immunogenicity. Nevertheless this is an exciting area, holding great promise for the future.

The use of CRISPR/Cas9 in DMD

In stem cells from the patient CRISPR/Cas9 can be used to remove the section of the dystrophin gene which harbours the mutation. The cells will then repair the DNA, creating a gene which, when expressed, will result in a shorter but functional form of the protein. When the cells are then grown and caused to differentiate into skeletal and heart muscle cells which can then be transplanted into the patient resulting in a milder phenotype. This has already been achieved in mice and the same treatment could potentially be applicable to humans.

As options available to patients, healthcare workers and scientists continue to expand, we face an array of issues and dilemmas in genetics.

The first full human genome was sequenced at a cost of $1 billion over a period of 13 years. Today, a full genome can be sequenced in 1 h costing approximately $ 1000 ( Figure 56 ). As we understand the genetic basis of increasing numbers of conditions, and as full genome sequencing becomes ever more available, it seems inevitable that there will be a clash between cost effectiveness and the patient’s ‘right to know’. Additionally, although it is relatively straightforward to sequence the human genome, the interpretation of these data are an altogether more complex issue, highlighted by the issues surrounding VUS.

Cost per genome over time

As a comparison, expected fall in cost as predicted by Moore’s law, a commonly used model for tracking technological development, was surpassed beginning approximately 2008. Image courtesy of National Human Genome Research Institute https://www.genome.gov

VUS pose increasing dilemmas for the healthcare sector because, while the capability exists to detect virtually all variants in the human genome, the ability to understand this information has yet to catch up. Simply put, although it is possible to identify that there has been, for example a single base change in a particular gene, it is much more difficult to determine what the resultant effect of that change is at a protein or even cellular level. Variants are investigated using a range of computer algorithms, a lengthy process which examines aspects such as conservation across species, amino acid similarity, protein domain structure etc., but which will not always yield a definitive result (see Table 2 ). As explained earlier, each individual harbours approximately 3 million variations in their genome, the vast majority of which are harmless. Deciding which, if any, of all the variants found is responsible for, or may predispose to a specific condition is a potential minefield. Similarly challenging is the issue of which of these variants should be disclosed to patients, and with what explanation. As our ability to catalogue and share information on variants expands, their significance will likely become clearer. Ensuring that patients are kept abreast of significant discoveries relevant to their healthcare is likely to be challenging. Finally, if interpreting VUS in post-natal, child and adult genetic services is complex, the challenge is even greater in prenatal genetics, where the lack of phenotype information compounds uncertainty. Additionally, the issue of data storage is an increasingly important one, with the concern that health service systems may soon struggle to keep pace with the increasing quantity of data being generated.

Direct to consumer testing

While individuals affected with genetic conditions have typically been seen by genetics hospital services, in the past decade the availability of ‘Direct to Consumer’ (DTC) genetic testing has risen exponentially. DTC testing is ‘sold’ directly to the customer with no healthcare service/provider involvement and through companies such as ‘23andMe’ and ‘Living DNA’, individuals can be tested for both ancestry and health information. As an example, ‘23andMe’ (at the time of writing) offers to screen customers for their carrier status for 40 diseases and their susceptibility to an additional ten conditions (including Alzheimer’s, Parkinson’s and Celiac disease), as well as offering insights into ‘traits’ such as earlobe type, sweet taste preference and hair curliness. Samples, generally saliva or cheek swaps are sent through the post with results being communicated online after a period of approximately 3 months.

The testing carried out by these companies is generally SNP array-based and ranges from testing for established mutations (e.g. CF carrier screening tests for 29 mutations in the CFTR gene) to the highly controversial susceptibility testing. For example in the test used to determine an individual’s risk of developing Parkinson’s disease, two SNPs in the LRRK2 and GBA genes are used to provide an estimate of the individual’s risk of developing the condition. Evidence surrounding these SNPs is reasonably convincing, however they are only two of several such SNPs that have been reported. The U.S. Food and Drug Administration withdrew ‘23andMe’s’ licence to provide heath information in 2013 due to concerns regarding ‘medical guidance reasons and the accuracy of the data gathered’, however this has since been reinstated for a limited number of conditions. Uncoupling of genetic testing from professional genetic counselling has raised concerns and several studies have suggested that many consumers are not able to fully understand the implications of their test results. This in turn may lead to increased pressure on GPs, with whom patients are likely to consult for help interpreting this information.

Whose information is it?

As the amount of genetic information generated grows, the question of data ownership becomes increasingly pertinent. Both within and out-with individual families, it is often not clear who has a right to know certain genetic information. Consider the situation where a child has been diagnosed with DS, and more specifically with DS resulting from a translocation present in one of the parents (accounting for approximately 4% of cases). Other members of the family, (for instance, the carrier parent’s siblings) may well be at risk of having similarly affected children. The question of communicating the results to other family members is generally left to the discretion of the family themselves, however this may not be information they want to share. Emotions such as guilt and blame, as well as existing family dynamics all come into play when such personal information is disclosed. Thus at risk relatives may be left uninformed. Similarly, a young adult receiving an ‘affected’ predictive test result for a condition such as HD has simultaneously uncovered a parent’s result because it is almost certain that they inherited this affected allele from one of their parents. This is irrespective of whether the parent wished to be tested or not. In such cases, patients are advised during pre-test counselling that they may wish not to disclose to family members that they are considering testing, on the premise that once a result is known it is very difficult to conceal the news.

Perhaps arousing more debate is the question of who, if anyone, outside a family has the right to access genetic test results. Clearly such results may be of considerable use to certain public services, for example the police, however, the ethics of release of information remains unclear. Regulatory bodies such as the U.K. Driver and Vehicle Licensing Agency also have a vested interest in genetic test information – for example from patients whose genetic condition means they may not be safe to continue holding a driving licence.

Insurance is also an important issue with the moratorium on the use of genetic test results by insurers in the U.K. until 2019. Some would argue that the current health questionnaires required to gain insurance already screen for some of the information, e.g. a family history of HD, and that by including genetic testing results those not at risk would not be unfairly penalised. However, requiring genetic results to be disclosed on application could prevent some from having useful genetic testing carried out, or may prevent other vulnerable people from obtaining relevant insurance. Thus while the understanding and interpretation of genetic data are challenges for the scientific community and healthcare providers, the encompassing issues require considerable ethical debate and supporting legislation.

Concluding remarks

During recent decades the role of genetics in medicine has changed dramatically, beginning as a speciality dealing with conditions that were relatively rare in the population, and becoming a discipline that underpins developments in wider areas of patient care. Better understanding of the contributions of genetic predisposition and epigenetic changes to common diseases, and of the role of genetic alterations in response to therapy, means that genetics will be relevant to everyone in the population. Education, both for health professionals and for their patients, will play a key part in ensuring that new developments in genetics and genomics continue to be successfully translated and implemented into clinical practice. There will be an increasing need for clinical scientists, genetic technologists and bioinformaticians to provide the laboratory services, as well as an increasing need for clinicians, genetic counsellors and nurses who are conversant with the new genetic and genomic technologies. Additionally, there will be a great need for further generations of research scientists to address the huge remaining gaps in our understanding and to generate innovative approaches in the application of our knowledge to the delivery of cost-effective healthcare. For anyone exploring career options, genetics and genomics should provide many interesting and rewarding possibilities for the future!

We thank the West of Scotland Genetics Service for providing images of diagnostic results.

The authors declare that there are no competing interests associated with the manuscript.

The main sections of this article were authored as follows:

- The human genome and variation by Maria Jackson

- Chromosome structure and chromosomal disorders by Gerhard H.W. May

- Single‐gene disorders by Gerhard H.W. May

- The sex chromosomes, X and Y by Joanna B. Wilson

- Mitochondrial disorders by Leah Marks

- Epigenetics by Maria Jackson

- Complex disorders by Maria Jackson and Leah Marks

- Cancer: mutation and epigenetics by Joanna B. Wilson

- Genomics by Maria Jackson and Joanna B. Wilson

- Genetic testing in the diagnostic laboratory by Maria Jackson and Leah Marks

- Diagnosis, Management and therapy of genetic disease by Leah Marks

- Challenges in delivering a genetics service by Leah Marks

Acetylation/acetyltransferase  The process of acetylation involves the addition of acetyl group (O=C–CH 3 ) to the target molecule, for example proteins, by the action of the appropriate acetyltransferase enzymes.

Allele A particular form of a given gene, usually one of several versions that differ in sequence and may differ in phenotype. Multiple different alleles (gene versions that differ in sequence) can exist within a population (some quite common), giving rise to phenotypic variation. Germ line differences from the sequence database for the human reference genome are called polymorphisms, or those that are more rare, called variants. Polymorphisms and variants arose in the germ line gene pool by mutation. Therefore the distinction between what is called a polymorphic or variant allele and what is called a mutant allele by research geneticists, can be blurred. In general, the frequency of the allele in the population and the extent to which it is disease causing or not, determines what it is called. Thus, the currently accepted definitions used by medical geneticists, in relation to the human reference genome are: pathogenic variant, likely pathogenic variant, VUS, likely benign variant and benign variant.

Allele-specific PCR  A PCR-based method in which particular allele(s) are amplified, facilitating genotyping of the locus, typically by placing the variant nucleotide at the 3′ end of either the forward or the reverse PCR primer.

Aneuploidy  An abnormal number of chromosomes in a cell, with one or more extra chromosomes or chromosomes missing.

Angiogenesis  The process of ‘growing’ new blood vessels from pre-existing vessels.

Anticipation  Anticipation can occur in some genetic conditions as a pathogenic variant is passed from one generation to the next. In those cases, the age of onset of the symptoms decreases from one generation to the next, and often the severity of symptoms increases as well.

Antisense oligonucleotide Short deoxynucleotide which is complementary to a ‘sense’ sequence of DNA.

Apoptosis  This is a form of ‘programmed cell death’. The phenomenon results when a cell is genetically determined to die or receives internal and/or external signals to self-destruct. The cell dismantles into component parts that are neatly disposed of or recycled and this does not cause inflammation. A classic example of normal apoptosis occurs during the formation of the fingers and toes in development. During mammalian embryogenesis, as an ‘evolutionary throwback’, the digits form, linked by webbing. The cells that make up the webbing are programmed to die and as development proceeds, they die by apoptosis, separating the digits.

Association The occurrence of a specific polymorphism together with a particular trait more often than would be expected by change.

Autosome  A chromosome that is not a sex chromosome.

Benign growth/tumour  This results from limited new growth of a cell such that a small (occasionally large) lump forms within a tissue, but does not progress on to become invasive. A classic example of this is a mole or nevus on the skin. Benign tumours are mostly harmless, but some may acquire further mutations to become cancerous.

Benign variant  A variant allele which is believed to have no effect on health either in the heterozygous or homozygous state.

Biallelic  Relating to both alleles of a gene; for example biallelic expression means that products are generated from both copies of the gene.

Carcinogen  Any agent that acts to increase the risk of cancer. Not all carcinogens are mutagens, but many are.

Candidate gene  A gene thought to have a high chance of being involved in a particular phenotype, often due to pathways it is known to be involved in.

Cell cycle  The process by which a cell divides into two cells. The cycle usually follows the four stages: G 1 (gap or growth 1), S (synthesis of DNA), G 2 (gap or growth 2), finally mitosis (note in meiosis, the cell cycle follows a different pattern, as described below). G 1 , S and G 2 together make up ‘interphase’.

Cell-free DNA (cfDNA) DNA which is not contained within a cell and is found in small amounts in the circulation or other fluids, e.g. urine.

Cell proliferation  The term used when cells divide by mitosis, resulting in an increase in cell number.

Chromatin  Describes the way the human genome is organised/packaged within a cell. Usually, DNA is wrapped around a core of histone proteins, forming nucleosomes.

Centromere  The waist-like constriction of a chromosome which separates the short from the long arm. During cell division, spindle fibres attach at the centromere to pull replicated chromatids apart.

Chimera  An organism consisting of cells which are genetically different, which can be generated by fusion of early embryos.

Codon  Three consecutive nucleotides which instruct a ribosome to incorporate a specific amino acid into a growing polypeptide, or to stop translation. Note that strictly it makes only sense to speak of codons in mRNA sequences, but codons are also usually referred to when describing nucleotide triplets in the coding sequences of genomic DNA.

Complementary DNA ( cDNA ) This is generated by use of the enzyme reverse transcriptase to make a DNA copy (a ‘complementary’ copy) from RNA that has been isolated from a sample (for example, blood or tissue). This cDNA can be used to analyse splicing patterns and relative transcription levels.

Compound heterozygote  An individual with (usually) pathogenic variants in both copies of a gene, where the variants are different from each other, for example a CF patient with p.Phe508del in one copy of the CFTR gene and p.Gly542X affecting the other copy.

Consanguineous  Refers to families where both parents share at least one recent common ancestor.

Copy number variant (CNV)/copy number polymorphism (CNP) Segments of our genome that range in size from 1000 to millions of bp, and which, in healthy individuals, may vary in copy number from zero to several copies. Where the population frequency reaches 1% or more it may be referred to as a copy number polymorphism.

Cytogenetics  The study of chromosomes.

De novo  Latin for ‘anew; starting from the beginning’. Used to describe newly arisen mutations, as opposed to variants which have been inherited from a parent.

Dideoxynucleotide Used in Sanger DNA sequencing, the deoxyribose moiety of these nucleotides lacks the 3′ hydroxy group so that, while dideoxynucleotides can be incorporated into a growing DNA chain, they do not allow the addition of further nucleotides, so that the chain is terminated.

Differentiation  The process by which cells and tissues acquire specialized characteristics, for example during embryonic development.

Diploid  Having two copies of each autosome, and two sex chromosomes. This is the normal state of most human somatic cells.

Disorders of sex development (DSD)  A diverse group of conditions that affect the development of the gonads and/or sexual differentiation and include partial or complete sex reversal in relation to the XX or XY genotype.

Dominant  An allele or mutant gene version that leads to a phenotype when in a heterozygous state (for example the other allele is wild-type) is referred to as dominant, is also often used to describe a condition.

Dosage compensation  The mechanism by which an imbalance in gene dose (gene copy number) is compensated for by differential gene expression. This is particularly relevant to genes residing on the X chromosome that have no Y chromosome homologue. In mammals, the process of X chromosome inactivation results in only one copy of the two alleles in female cells being available for expression, balancing with the fact that male cells only have one allele.

Dysgenesis  Defective or abnormal development of an organ, for example of the gonads.

Electropherogram  This is a visualisation of the results of electrophoretic separation of molecules; in the case of genetic analysis, DNA molecules can be separated based on size, and detected by the use of fluorescent labels previously attached to the DNA.

Enhancer A specific DNA sequence often adjacent to the coding region of a gene, which functions in gene regulation, for example by binding transcription factors.

Epigenetic modification This refers to modification marks that do not change a DNA sequence, but can effect gene expression and includes methylation of DNA bases (usually cytosine in mammals), and methylation, phosphorylation and acetylation of the proteins that DNA is wrapped around, the histones.

Epigenetics  The study of changes in gene function that are heritable mitotically and/or meiotically and that are not a consequence of change in the DNA sequence.

Exome  The portion of the genome that codes for proteins – the complete collection of all the exons.

Exon  A section of a protein-coding gene that encodes part of the protein sequence; within the gene exons are separated by intervening sequences (introns) and in order to generate a functional mRNA the relevant exons must be spliced together to generate an uninterrupted coding sequence.

Gene expression represents the processes including transcription and translation which lead to the production of products (for example, proteins) from genes

Expression is also used to describe physical traits (or phenotypes) generated as a consequence of variants; the term expressivity is the degree to which the traits observed differ between individuals who have the same genotype.

Frameshift  Ribosomes translate mRNA molecules one triplet codon at a time, in a continuous ‘reading frame’. Any mutation that leads to the insertion or deletion of a number of nucleotides into the mRNA, which is not a multiple of three, leads to a shift in this reading frame. This usually leads to premature truncation of the resulting polypeptide.

Gametologue  A gene that has homologues on both X and Y chromosomes that are not subject to crossover in meiosis. These are not termed alleles due to the fact that they do not recombine and therefore evolve independently on the two chromosomes.

Gene amplification  The duplication of a gene, often at the site of the original gene, leading to multiple copies. The duplicated gene may be wild-type or mutant and duplication usually results in its overexpression.

Genome  The complete set of genetic information (usually DNA) of an organism, including all genes plus all other sequences, and in humans includes both nuclear and mtDNA.

Genomics  In contrast with genetics, which often focuses on single genes, genomics represents the study of large groups of genes, often the entire genome of one or more organisms.

Genotype  The genetic make-up of a cell or organism, relating to the sequence of the genes and genome as a whole. Often the genotype(s) at one or a few loci only are considered. Genotyping is the process of determining which alleles are present at one or more loci.

Germ cells  Cells that will form the gametes, to become the haploid oocytes or sperm cells upon differentiation.

Gonadal mosaic  Having cells of different genotypes within one or both gonads, often as a consequence of somatic mutation, with the consequence that an apparently de novo mutation, not present in the parent, may be transmitted to more than one child.

Haploid  Having only a single copy of each autosome, and one sex chromosome. The usual state of gametes.

Haploinsufficiency This occurs when one allele of the homologous pair of genes in a diploid organism is lost or not expressed and this results in an abnormal phenotype. The remaining allele is expressed, but can only provide half the normal level of gene product and this is not sufficient to fully conduct the required function. Such loss-of-function mutations are dominant, as they give rise to a phenotype.

Hemizygous  Having only one locus/allele within the cell.

Heteroplasmy The presence of differing mitochondrial genomes within a cell.

Heterozygous  Having two different alleles at one locus.

Histone acetyl transferase (HAT)/histone deacetylase (HDAC)  These enzymes add or remove acetyl groups (O=C–CH 3 ) from histone proteins leading to changes in chromatin structure that affect function of the DNA.

This is a genetical term referring to genes that are related by evolutionary descent, that is, homologues have evolved from the same gene in an ancient organism. There are also subdivisions of the term homologue. Paralogue: indicating descent within a single species, for example the human RAS genes ( HRAS, NRAS and KRAS ) are paralogues of each other. In the ancestral organism, the RAS gene underwent duplications and three of these remain in humans (and many other mammals) today that have evolved to take on slightly different roles. Orthologue: indicating the same gene in different species, for example human HRAS and mouse HRas are orthologues.

In a diploid organism, each autosome and the X chromosome in females (and therefore also each gene on these chromosomes), has a homologue, thus comprising the homologous pairs of chromosomes present in the nucleus of the diploid cell.

Homoplasmy  The presence of only identical mitochondrial genomes within a cell.

Homozygous  Having two identical alleles at one locus.

Ideogram  A graphical representation of a cell’s or organism’s karyogram.

Imprinting (chromosomal or genomic)  The process by which epigenetic marks are attached to particular loci in a parent-of-origin specific manner, leading to differential expression of maternally and paternally derived genes.

Indel  A term describing any variant which represents the insertion or deletion (or a combination of both) of nucleotides at a specific position, compared with a reference genome.

Inflammation  This describes an immune response, usually wounding or infection, but can be of unknown cause. Immune cells enter the damaged or infected tissue and release factors that are designed to repair the wound and combat infection. Short-lived inflammation, for example in response to a small wound, is called acute inflammation. Prolonged inflammation, sometimes of unknown cause, is called chronic inflammation and can be damaging to tissues if it continues unabated.

In silico  Performed using a computer; for example the application of software or algorithms that use existing information to predict the effect of DNA variants.

Intron  A segment of a gene, between two coding segments (exons), in other words an intervening sequence, which is transcribed into RNA and then removed by splicing during generation of the final mRNA.

Karyogram  A (usually photographic) representation of the chromosomes of a cell, arranged in pairs.

Karyotype  The number and appearance of the chromosomes in the nucleus.

Kinase Kinases are enzymes that add a phosphate group onto their substrates. Protein kinases phosphorylate (by transfer of the phosphate group onto the oxygen atom of the amino acid side chain) their protein substrates upon serine, threonine or tyrosine residues.

Locus  Genetical term referring to a specific location in a genome, usually defining the position of a gene or DNA sequence of interest. Plural: loci.

Metaphase  One of the phases of the mitotic cell division cycle, during which chromosomes become condensed and visible under a light microscope.

Metastasis (plural metastases)/metastatic disease  Cancer cells that are dividing out of control and have spread (from the primary tumour site) to other tissues or organ sites around the body.

Meiosis  The final stages of germ cell division to produce four haploid gametes, each of which is genetically distinct. A germ cell undergoes DNA replication and then, before separation of the replicated ‘sister chromatids’, homologous chromosomes pair and undergo recombination, such that DNA is swapped or ‘crossed over’. Then two rounds of cell division occur: Meiosis I and Meiosis II. In Meiosis I, the chromosome pairs separate into daughter cells, in Meiosis II, the sister chromatids separate into daughter cells. In some organisms and in the production of mammalian sperm, all four meiotic products form gametes. In female mammals, only one cell develops into the ovum or oocyte, with asymmetric division of the cytoplasm, the other three meiotic nuclei are extruded as polar bodies.

Methylation/methyltransferase  The process of methylation involves the addition of methyl (CH 3 ) groups to target molecules, for example DNA or proteins, by the action of the appropriate methyltransferase enzymes.

Microarray  A set of targets, most often DNA probes, arranged in a grid to facilitate testing. DNA microarrays, including SNP arrays, usually contain hundreds of thousands of probes to which sample DNA or RNA can be hybridised.

Microdeletion/microduplication  A deletion/duplication that is generally defined as below the resolution of karyotyping and therefore less than 4–5 Mb, but larger than 1 kb. However, precise definitions may vary between authors.

Microsatellite  A variable number tandem repeat in which the repeating unit is generally between 2 and 6 bp in length, and under some definitions includes mononucleotide repeats.

Minisatellite  A variable number tandem repeat in which the repeating unit is generally between 10 and 100 bp in length.

Minor allele frequency (MAF)  The frequency at which the second most common allele occurs in a population.

Missense  An alteration (mutation), often affecting a single nucleotide, which leads to the change of a codon for one specific amino acid into one for a different amino acid.

Mitosis  The process of somatic cell division, as part of the cell cycle after DNA replication, whereby a diploid cell goes through the stages: prophase, metaphase, anaphase and telophase; to separate the chromosomes into two nuclei. This is followed by cytokinesis, dividing the cytoplasm and organelles to produce two diploid daughter cells.

Mitochondrial replacement therapy A modification of IVF in which the mitochondria of the embryo are obtained from someone other than the mother or father of the child.

Modifier gene  A gene in which variation can alter the severity or phenotype of disease caused by a pathogenic variant at another locus.

Molecular pathology  The study and diagnosis of disease by analysis of molecules such as nucleic acids and proteins within tissues or body fluids.

Mosaic  A condition in which cells of distinct genotypes or distinct karyotypes are present in one individual, often as a consequence of somatic mutation or mitotic non-disjunction.

Mutagen  Any agent that can lead to DNA mutation. Therefore, by definition, all mutagens are potential carcinogens.

Mutant  see Wild-type.

Mutation  Any heritable (through somatic cell division or germline) change in the DNA sequence. It does not have to result in a phenotypic change or a change to an encoded protein sequence (which would be a silent mutation). See also the definition of wild-type (and polymorphic, variant and mutant alleles).

Non-invasive prenatal diagnosis (NIPD) A form of PND in which foetal DNA is obtained from the maternal blood rather than from a CVS or amniotic fluid sample.

Nonsense  An alteration (mutation) affecting a single nucleotide which leads to the change of a codon for one specific amino acid into one of the three stop codons.

Oncogene  A gene whose product can positively contribute to the cancerous process. Often an oncogene is a mutated form of a normal cellular gene.

Pathogenic variant  A variant which is associated with disease.

Penetrance  The extent to which a pathogenic variant leads to observable clinical symptoms, that is, the proportion of individuals with the variant who exhibit the disease phenotype. A variant with 100% penetrance would affect all carriers, whereas for a variant with 80% penetrance the particular phenotype would not be seen in 20% of carriers.

Phenotype  The appearance, properties and behaviour of a cell or organism that are a direct consequence of its genotype.

Point mutation:  The mutational change of one base pair, either to any of the other three possibilities, or deletion of the base pair, or addition of a new base pair in the sequence.

Polygenic  The situation where a trait or phenotype is controlled by multiple genes.

Polymorphism  Any variant allele that is present in the population at a frequency of at least 1% of all alleles.

Polyploidy  State of a cell or organism which contains more than two complete sets of all chromosomes. Triploidy indicates the presence of three sets of chromosomes, tetraploidy of four.

Primer A short sequence of DNA or RNA which can act as a starting place for a new DNA strand to be synthesised.

Programmed cell death  see Apoptosis.

Pronuclear transfer  A technique in which the mother’s egg as well as a donor egg are both fertilised with the father’s sperm. Subsequently the nucleus from each fertilised egg is removed and the donor egg’s nucleus is then replaced with that of the mother.

Pseudogene  A locus that resembles a protein-coding gene, and likely arose via an ancient gene-duplication event, but which, as a consequence of mutation, is not able to generate the original protein. Pseudogenes may, however, have regulatory roles in expression of other genes.

Quiescence  Describes the state when cells are not in cell cycle (reversible G 0 ).

Recessive  An allele or mutant gene version that leads only to a phenotype when in a homozygous state (or heterozygous with another pathogenic allele) is referred to as recessive. Also used to describe a condition.

Reference sequence  A genomic sequence that represents a baseline from which to compare individual human sequences; the reference sequence is intended not as a ‘norm’, but only as a reference point for describing human variation.

Senescence  Describes the state when cells can no longer divide, they are irreversibly in G 0 . They may still be able to function.

Sex chromosome  Chromosomes determining the genetic gender of an organism. Human sex chromosomes are X and Y, male somatic cells carry one of each, female somatic cells carry two X chromosomes.

Signal transduction The process by which a cell converts an external signal into a responding action. For example, when a growth factor binds to its receptor on the cell surface, this sends a cascade of signals inside the cell, to the nucleus (or other target, such as mitochondria), which can result in a change in gene expression resulting in the cell following a new action (such as initiating the cell cycle).

Silent mutation  A mutation that results in no observable phenotypic effect.

Somatic cells  Comprise all cells of the body, other than those that contribute to the germ line.

Spindle transfer  A technique in which the nucleus is removed from an unfertilised mother’s egg and this is then inserted into a donor egg which has had its nucleus removed. Fertilisation with the father’s sperm then takes place.

Synonymous mutation  A mutation in a coding region which, despite changing the DNA sequence does not change the sequence of the resulting polypeptide (due to the redundancy of the genetic code).

Tetraploidy  Having four complete sets of chromosomes – i.e. four times the haploid number.

Telomere  Specific, repetitive, sequences present at the ends of linear chromosomes that protect the chromosome ends and play a key role in chromosome maintenance and stability.

Translocation  This describes a large rearrangement, often visible by karyotypic analysis, where a large chunk of one chromosome has moved and joined another chromosome. Reciprocal translocation is when two chromosomes have effectively exchanged large portions. In a Robertsonian translocation, two acrocentric chromosomes lose their short arms and fuse at the centromere.

Transcription factor A protein that, typically, binds to DNA (often as part of a complex of proteins) and regulates (up or down) the expression of a gene that is usually located at, or near, the site of binding.

Triploidy  Having three complete sets of chromosomes – i.e. three times the haploid number.

Trisomy  Three copies of a specific chromosome, e.g. three copies of chromosome 21 in Down syndrome.

Tumour suppressor gene (TSG)  A gene whose product can inhibit tumour cell growth, often through inhibiting cell cycle progression. One or more TSGs are frequently silenced in cancer cells.

Ubiquitin  A small protein of 76 amino acids, that can be covalently attached to other proteins, by ubiquitin ligases, resulting in a variety of potential regulatory effects that include targeting for degradation, and changes in localisation or activity of the ubiquitinated protein.

Uniparental disomy (UPD)  A situation in which both homologues of a chromosome are from the same parent.

Variant  Any DNA sequence that differs from the reference genome sequence.

Variant of uncertain significance (VUS)  A classification applied to variants for which the effect on the phenotype is not clear, and there is insufficient evidence to support either benign or pathogenic classification.

Wild-type allele  A term used by research geneticists to indicate the allele that is most commonly found in the population. Different alleles commonly found in the population are referred to as polymorphisms, or more rare alleles, variants. Medical geneticists tend not to use the term wild-type and instead refer to the human reference genome (see also Allele). Mutant alleles are those that have undergone a sequence change as a result of somatic mutation. Constitutional pathogenic variants are often referred to by research geneticists as ‘mutant’ alleles (and this term will be found in the scientific literature), but this terminology is out of favour with medical geneticists.

X chromosome inactivation  The almost complete expressional silencing of one of the two X chromosomes in every mammalian female cell, with the exception of the gametes. The process is initiated in early embryonic development and persists throughout adult life.

achondroplasia

Angelman syndrome

Becker muscular dystrophy

breast cancer susceptibility

cyclin-dependent kinase

complementary DNA

cystic fibrosis

cell-free DNA

CF transmembrane conductance regulator

copy number polymorphism

copy number variant

chorionic villus sampling

Duchenne muscular dystrophy

DNA methyl transferase

Down syndrome

double strand break

disorder of sex development

direct to consumer (genetic testing)

fluorescence in situ hybridisation

genome-wide association study

histone acetyl transferase

histone deacetylase

hypoxia-inducible factor

Immunodeficiency, centromeric instability, and facial anomalies syndrome

International System for Human Cytogenetic Nomenclature

in vitro fertilisation

kilobase pair (1000 bp)

Leber hereditary optic neuropathy

long QT syndrome

minor allele frequency

multiplex ligation dependent probe amplification

next-generation sequencing

non-invasive prenatal diagnosis

nucleolar organiser region

pseudoautosomal region

programmed cell death

pre-implantation genetic diagnosis

pre-natal diagnosis

Prader–Willi syndrome

quantificative fluorescence PCR

ribosomal DNA

Scottish Genomes Partnership

spinal muscular atrophy

single nucleotide polymorphism

single nucleotide variant

sex-determining region Y

simple sequence repeat

short tandem repeat

type 1 diabetes

type 2 diabetes

testis determining factor

tyrosine kinase

tyrosine kinase inhibitor

tumour suppressor gene

uniparental disomy

variable number tandem repeat

variant of unknown significance

whole exome sequencing

whole genome sequencing

active X chromosome

inactive X chromosome

X inactivation centre

Author notes

Authors in alphabetical order.

This article is a reviewed, revised and updated version of the 1999 Biochemistry Across the School Curriculum (BASC) booklet The Genetic Basis of Human Disease by G. Wallis. For further information or to provide feedback on this or other Biochemical Society education resources, contact [email protected] .

Get Email Alerts

• Online ISSN 1744-1358
• Print ISSN 0071-1365
• Submit Your Work
• Language-editing services
• Recommend to Your Librarian
• Request a free trial
• Accessibility
• Sign up for alerts
• Sign up to our mailing list
• The Biochemist Blog
• Biochemical Society Membership
• Publishing Life Cycle
• Biochemical Society Events
• About Portland Press
• Portland Press Tel
• +44 (0)20 3880 2795
• Portland Press Company no. 02453983
• Biochemical Society Tel
• +44 (0)20 3880 2793
• Email: [email protected]
• Biochemical Society Company no. 00892796
• Registered Charity no. 253894
• VAT no. GB 523 2392 69
• Privacy and cookies
• © Copyright 2024 Portland Press

This Feature Is Available To Subscribers Only

Sign In or Create an Account